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Meniscus background
The knee joint is an important joint in the human body. It joins the upper and lower leg, 
and allows movements that are essential for everyday activities while supporting the 
body’s weight. The knee joint consists of four bones (femur, patella, tibia, and fibula) and 
two articulations (tibio-femoral and patello-femoral). The patella is embedded in the 
quadriceps tendon, articulates in the trochlear groove of the femur, and acts mechanically 
by increasing the leverage of the quadriceps. The tibiofemoral articulation is formed by 
the incongruent joint surfaces of the convex femoral condyles and the relatively flat tibial 
plateaus, and allows flexion and extension of the knee joint (as well as slight internal and 
external rotation). The incongruence between the femoral condyles and the tibial plateaus 
is turned into a tight articulation by the interposition of crescent shaped fibrocartilaginous 
tissues; the menisci. 
Each knee has two menisci, one laterally and one medially, both having their own distinct 
anatomy, meeting the anatomic constraints of the femoral condyles and tibial plateaus. 
In general, the lateral meniscus is more circular whereas the medial meniscus has a more 
elongated “C”- shape. Both menisci are firmly attached to the tibial plateau via the anterior 
and posterior horns (meniscotibial ligaments).1 (Figure 1) Besides, the medial meniscus 
is also firmly attached to the joint capsule and medial collateral ligament. The lateral 
meniscus is not as rigidly attached to its circumference, in part due to the popliteal hiatus.2, 3 
The popliteal hiatus is the opening defined by the fascicles of the lateral meniscus, giving 
room to the popliteal tendon.4 Although subject to anatomic variation, the anterior 
margins of the medial and lateral menisci are connected via the anterior intermeniscal 
ligament (transverse ligament), and two meniscofemoral ligaments connect the posterior 
margin of the lateral meniscus to the lateral side of the medial femoral condyle (ligaments 
of Humphrey and Wrisberg).2, 3 (Figure 1) The menisci have the limited ability to move, 
accommodating to the relative movements of the tibia and femur during knee flexion. 
Due to the differences in anatomy and attachments, the lateral meniscus is more mobile 
compared to the relative less mobile medial meniscus.5, 6 
Blood supply to the menisci originates from branches of the geniculate arteries, and is 
limited to the peripheral zones of the menisci. The central zone of the menisci receives 
nutrition from synovial fluid by passive diffusion and active diffusion through fluid flow 
mediated by repeated compressions upon weight bearing.7 Un-myelinated nerve fibers 
and free nerve endings have been localized in the meniscus, with perivascular nerves 
containing substance P and calcitonin gene-related peptide (CGRP).8-13 In conjunction 
with blood vessels, nerve fibers penetrate the outer portion of the meniscus, reaching as 
far as its middle third, with the innermost portion remaining both avascular and aneural.
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 Additionally, the menisci have roles in joint lubrication, nutrient distribution, sensory 
function and proprioception.24, 25
Meniscus injuries and treatment
Menisci are injured quite commonly, and meniscus tears are one of the most frequent 
diagnoses made by orthopedic surgeons.26-28 In the Netherlands, orthopedic surgeons 
establish a diagnose of meniscus lesions about 70.000 to 80.000 times annually (annual 
incidence of 417 to 477 per 100,000 subjects).27 Based on the underlying etiology and 
their clinical presentation it is possible to distinguish two types of meniscal tears, traumatic 
or degenerative tears.29 Since traumatic and degenerative tears are two different entities, 
they will be discussed separately.
The meniscus is highly hydrated, with the remaining comprised of organic matter, mostly 
cells and extra cellular matrix.14 A meshwork of collagen fibers make up the vast majority of 
this extra cellular matrix, followed by proteoglycans and glycoproteins.14 Different collagen 
types exist in varying quantities, of which collagen type I (main constituent of tendon tissue) 
and II (main constituent of cartilage tissue) are most abundant. The orientation of these 
collagen fibers is highly functionalized in order to provide the meniscus’ biomechanical 
properties.15-17 (Figure 2)
The key function of the menisci is to transfer load over the incongruent articular surfaces 
of the knee joint during weight bearing. By distributing this load evenly over the two 
incongruent surfaces, the menisci prevent accumulation of pathological peak stresses.
(Figure 3) Indeed, an increased understanding of the damaging effects on the knee joint 
that occur after removal of the meniscus has led to the awareness of the true biomechanical 
importance of the menisci.18, 19 The menisci transfer forces between the femoral and 
tibial joint surfaces by the development of ‘hoop stresses’ within meniscal tissue.20 Hoop 
stresses are tensile stresses which are transferred along the circumferential collagen fibers 
of the meniscus, opposing the tendency of the menisci to be displaced peripherally 
during compressive loading.20, 21 The result is an even load distribution over the two the 
incongruent surfaces, preventing the accumulation of peak stresses.21-23 (Figure 3)
Figure 1  An overview of the tibial articular surface showing both menisci and ligaments.
MM = medial meniscus; LM = lateral meniscus; MFL = meniscofemoral ligament; TL = tranverse (intermeniscal) 
ligament; ACL = anterior cruciate ligament; PCL = posterior cruciate ligament; [illustration adapted from (100)]
Figure 2  A synoptic drawing of the functionalized organization of the collagen bundles.
Superficially, the surfaces of the meniscus are covered by a meshwork of thin fibrils. Beneath this superficial 
network there is a layer of lamellae of collagen fibrils. Towards the periphery the bundles of collagen fibrils are 
arranged in a radial direction. In all other parts the collagen fibril bundles intersect at various angles.
The main portion of the meniscus collagen fibrils is located in the central region, where the bundles of collagen 
fibrils are orientated in a circular manner. From the periphery inwards, connective tissue from the joint capsule 
penetrates radially between the circular fibril bundles. [reprinted with permission from (17)]
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repair is only suited for a limited number of tears, the majority of traumatic meniscus tears 
are treated with partial meniscectomy.31, 32 
Degenerative tears
Degenerative meniscus tears are typically seen in middle aged and older patients, in 
knees that already demonstrate signs of knee osteoarthritis, and are caused by chronic 
degenerative processes.29, 33 Clinical symptoms routinely attributed to the degenerative 
meniscus commonly have a gradual onset and may encompass pain and mechanical 
obstructions (occasional catching of locking of the knee).34, 35 Compared to traumatic tears, 
degenerative tears are more often complex, horizontal and/or have a flap like appearance 
and occur in a degenerative meniscus in a knee with osteoarthritic changes.30, 36-40 
(Figure 4) Disruption of collagen bundles, proteoglycan loss, perimeniscal synovitis and 
calcification are described degenerative changes of the meniscus.13, 41-47
The guidelines by the Netherlands Orthopaedic Association indicate that non surgical 
treatment is preferred in the management of degenerative meniscus tears without 
symptoms of mechanical obstruction.30 On the other hand, surgical treatment with 
(partial) meniscectomy is indicated for degenerative meniscus tears accompanied by 
mechanical obstructions, and/or after insufficient benefit from non surgical treatment.30 
Traumatic tears
Traumatic meniscal tears occur in younger active patients and are caused by a serious 
traumatic (twisting) injury, often during sports. Traumatic tears are typically orientated 
vertically longitudinal or radially in the otherwise healthy knee.30 (Figure 4) Meniscus tears 
are more common in the medial meniscus compared to the lateral meniscus, which may 
in part be explained by the relative immobility of the medial meniscus. Depending on 
the location and extent of the tear symptoms encompass pain, joint effusions, and 
mechanically obstructed motion. A vertical longitudinal meniscus tear can produce the 
classic ‘locked’ knee, which refers to the inability to straighten out the knee. This locking 
is caused by the displacement of the inner portion of the torn meniscus towards 
the intercondylar space (referred to as a bucket handle tear). (Figure 4) A radial tear can 
progress to a so called parrot beak tear. (Figure 4)
 The management of meniscal tears depends upon the extent of the clinical symptoms. 
Although conservative, non surgical, treatment should routinely be considered, tears 
associated with persistent joint effusions and/or tears that frequently cause disabling 
mechanical symptoms (such as locking of the knee) are generally treated surgically. 
Surgical treatments encompass arthroscopic knee surgery with resection of the damaged 
tissue (partial meniscectomy) or repair of the meniscus tear (e.g. by suturing).30 Since meniscus 
Figure 3   A graphical representation of the biomechanical function of the meniscus, load 
distribution over two incongruent surfaces.
The menisci provide an increase in the joint contact area. At a similar load (during weight bearing) this increased 
joint contact area leads to a lower peak contact pressure on the articular cartilage. [illustration adapted from (21)]
Figure 4   A graphical representation of different types of meniscus tears.
A vertical longitudinal meniscus tear can progress to a bucket handle tear, and produce the classic ‘locked’ knee, 
which refers to the inability to straighten out the knee. In the bucket handle tear, the inner portion of the torn 
meniscus is displaced towards the intercondylar space. A (untreated) radial tear can progress to a so called parrot 
beak tear. Degenerative tears are more often complex, horizontal and/or have a flap like appearance
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Degenerative tears
Arthroscopic knee surgery with meniscectomy is an established procedure to treat pain 
and mechanical symptoms attributed to degenerative meniscus tears in the osteoarthritic 
knee.26, 30, 32, 35, 72, 73 The prevailing understanding regarding symptoms of degenerative 
tears is that they are attributable to a mechanical problem.35 In this argumentation, 
symptoms such as locking, clicking and knee pain are assumed as arising from the 
meniscus tear that causes a mechanical obstruction. However, this rationalization falls 
short. The sensitivity and specificity of the symptoms routinely attributed to the injured 
meniscus in the osteoarthritic knee are low74-77, and asymptomatic meniscal tears are highly 
prevalent among people with knee osteoarthritis.73 These factors make it challenging to 
determine whether localized symptoms are attributable to a degenerative meniscus tear 
or to other factors in the osteoarthritic knee (e.g. cartilage damage, synovitis, ligamentous 
abnormalities).73, 74, 78, 79 
 Next to the concerns about the rationalization for surgery, evidence has accumulated 
that questions the efficacy of arthroscopic surgery for degenerative meniscus tears.80, 81
 Despite emerging evidence questioning the indication of arthroscopic surgery for 
degenerative meniscal tears80, 81, orthopedic surgeons remain convinced that it is an 
effective treatment82-86, and the procedure is still, unaffectedly, performed on large 
scale.32, 33, 37, 38 Apparently, surgeons assume that the short term benefits of the procedure 
outweigh the associated surgical harms and other consequences of the treatment.
 With respect to a, sustainable and evidence based health care system, it is important 
that the surgical treatment of degenerative meniscus tears is based on unbiased, reliable 
types of evidence, and that additional surgical and financial consequences are taken into 
account while interpreting the potential short term benefits of the treatment.
Thesis objective and outline
Traditionally, orthopedic research is focused on retrospective cohort studies, and 
orthopedic surgeons (like other surgeons) have often been blamed for not adhering to 
scientific standards and for ignoring randomized controlled trials as the best methodology 
for evaluating effectiveness of existing and new treatment procedures.87-91 
 The formal assessment of surgical procedures is complex, in part due to the types of 
patients in surgery, the disposition of surgeons, and the constant innovation of the 
procedures.91 Nevertheless it is crucial to adequately assess the potential added value of 
the new treatments so that introduction and adoption can derive from evidence-based 
principles rather than trial and error.88, 91-93 
 The overall objective of this thesis was to provide an evidence based evaluation of 
the (potential) added value of treatment strategies for meniscus tears. The treatment of 
traumatic meniscus tears, with emphasis on the use of meniscus implants, will be discussed 
Thesis rationale
Traumatic tears
Formerly, the treatment of a lesion as obvious as a torn meniscus embraced total excision 
of the meniscus, and a good recovery was expected for the patient afterwards.48 
However, acknowledging the development of degenerative changes in the knee joint 
after total meniscectomy made clear that it is paramount to save as much meniscus tissue 
as possible and to preserve the peripheral rim wherever possible (thus only removing 
the damaged part of the meniscus, i.e. partial meniscectomy).19, 49-52 Still, although 
providing adequate short term improvement in symptoms, the disadvantage of partial 
meniscectomy still remains in the subsequent development of degenerative changes of 
the knee joint.53
 Currently, much effort is put into the development of new innovative treatments for 
traumatic meniscus tears that do not give rise to the degenerative changes in the knee 
joint.54 
 Already in the late 1980s meniscus allograft transplantation procedures were developed, 
to offer a solution for the many patients who had underwent a total meniscectomy.55-60 
The initial goal of meniscus allograft transplantations was to treat, prevent, and possibly 
even reverse, the progressive joint degeneration that followed total meniscectomy.58 
However, problems such as limited graft availability, the risk of disease transmission, and 
challenges in tissue processing prevented uptake on a larger scale.61, 62 The feasibility and 
initial promising results of meniscus allograft transplantation encouraged the development 
of meniscus implants, intended for the treatment of meniscus tears that would otherwise 
be treated by partial meniscectomy.63 Meniscus implants can broadly be categorized into 
permanent implants and degradable implants. Degradable meniscus implants are 
scaffolds designed to promote the formation of new meniscus tissue in a self-healing 
process, and as such, assume the meniscus’ native form and function, hypothetically 
preventing degenerative changes in the knee joint.64-66 Permanent meniscus implants 
are designed to replace and to take over the function of the lost meniscus’ tissue, 
subsequently preventing the degenerative changes in the knee joint.67, 68 Although 
promising in concept, the effectiveness and added value of these implants should be 
demonstrated and outweigh additional therapeutic and financial consequences. This 
does not become naturally because short term results after partial meniscectomy are 
satisfactory50, and not all patients who undergo partial meniscectomy will develop 
symptomatic knee osteoarthritis despite degenerative changes of the knee joint.69-71 
With respect to a sustainable and evidence based health care system, it is important that 
the promotion of these innovative treatments is based on unbiased, reliable types of 
evidence, and that the additional therapeutic and financial consequences are taken into 
account while evaluating the potential effectiveness.
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 The fourth objective of this thesis was to evaluate the incidence of arthroscopic 
procedures for meniscus tears in the Netherlands and whether these incidences changed 
over the past decade. (Chapter 5)
 The weighing of both beneficial and harmful effects is paramount in the choice of 
treatment, and informing the patient of both beneficial and harmful effects is vital in order 
to obtain valid informed consent. Surgery related risks of knee arthroscopy include 
thrombosis, infection, and anesthesia-related complications.81 Moreover, retrospective 
studies have raised concerns that people who undergo arthroscopic meniscectomy may 
have an increased risk of progression of osteoarthritis.53, 79, 95
 The fifth objective of this thesis was to assess whether patients with degenerative 
meniscus tears and whom undergo arthroscopic meniscectomy have an increased risk for 
future knee replacement surgery. (Chapter 6)
 Despite the accumulation of evidence questioning its efficacy32, 35, 96-99 orthopedic 
surgeons remain convinced that arthroscopic knee surgery with meniscectomy is an 
effective treatment for degenerative meniscal tears in selected patients in a normal health 
setting.82-86 In order to offer added value for the health care system the possible health 
benefits should outweigh the incremental costs and additional consequences.
 The sixth objective of this thesis was to assess the cost-effectiveness of arthroscopic 
meniscectomy in subjects with knee osteoarthritis in a normal health care setting, while 
taking into account the increased risk for future knee replacement surgery after the 
procedure. (Chapter 7)
A general discussion and a summary of the results of this thesis will be provided in chapter 8 
and chapter 9 respectively. 
in part 1 of this thesis. The treatment of degenerative meniscus tears, with emphasis on 
arthroscopic meniscectomy, will be addressed in part 2 of this thesis. 
PART 1: Traumatic tears
In the treatment of traumatic tears much effort is put in the development of treatments 
that treat traumatic meniscus tears but do not give rise to the development of degenerative 
changes in the knee joint. Encouraged by the results of meniscus allograft transplantation, 
meniscus implants are developed for the treatment of meniscus tears that would 
otherwise be treated by partial meniscectomy. For these implants, the meniscus allograft 
can be considered to be the reference standard. However, despite widespread reporting 
on its clinical implementation it is still unknown whether it is possible to prevent 
degenerative changes in the knee joint by means of meniscus allograft transplantation.94
 The first objective of this thesis was to systematically evaluate the literature on the 
effect of meniscus allograft transplantation on the articular cartilage, and to assess whether it 
is possible to prevent cartilage damage with meniscus allograft transplantation. (Chapter 2)
 Compared with arthroscopic partial meniscectomy, meniscus implant procedures 
come with additional therapeutic consequences and increased costs accrued to society. 
For a sustainable health care system, costs related to meniscus implant procedures and 
their therapeutic consequences should be taken into consideration simultaneously while 
evaluating their potential to prevent degenerative changes of the knee joint.
 The second objective of this thesis was to examine, by means of an early health 
technology assessment, the socioeconomic effect and potential added value of treating 
meniscal tears with a meniscus implant. (Chapter 3)
 With the development of new medical devices, such as meniscus implants, conflicting 
(i.e. commercial) interests may result in biased presentation of results. These biased results 
have the potential to misguide decision making by means of incorrect or incomplete 
information. One of such biases is the selective reporting of a subset of study outcomes 
(i.e. only reporting on favorable outcomes, or omitting non favorable outcomes). 
 The third objective was to evaluate outcome reporting bias for orthopedic surgical 
trials and evaluate how this problem should be addressed in order to guide unbiased 
evaluation of innovative treatments for meniscus tears. (Chapter 4)
PART 2: Degenerative meniscus tears
Despite accumulating evidence questioning its efficacy, arthroscopic procedures with 
meniscectomy are still widely performed to treat degenerative meniscal tears. However, it 
is not clear to what extent this also applies to the Netherlands.
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Abstract 
Objective: Despite widespread reporting on clinical results, the effect of meniscus 
allograft transplantation on the development of osteoarthritis is still unclear. The aim of 
this study was to systematically review all studies on the effect of meniscus allograft trans-
plantation on articular cartilage in animals.
Design: Systematic review and meta-analysis. 
Methods: Pubmed and Embase were searched for original articles concerning the effect 
of meniscus allograft transplantation on articular cartilage compared with both its positive 
(meniscectomy) and negative (either sham or non-operated) control in healthy animals. 
Outcome measures related to assessment of damage to articular cartilage were divided in 
five principal outcome categories. Standardized mean differences (SMD) were calculated 
and pooled to obtain an overall SMD and 95% confidence interval. 
Results: 17 articles were identified, representing 14 original animal cohorts with an average 
timing of data collection of 24 weeks [range 4 weeks; 30 months]. Compared to a negative 
control, meniscus allograft transplantation caused gross macroscopic (1.45 [0.95; 1.95]), 
histological (3.43 [2.25; 4.61]) damage to articular cartilage, and osteoarthritic changes on 
radiographs (3.12 [1.42; 4.82]). Moreover, results on histomorphometrics and cartilage 
biomechanics are supportive of this detrimental effect on cartilage. On the other hand, 
meniscus allograft transplantation caused significantly less gross macroscopic (-1.19 [-1.84; 
-0.54]) and histological (-1.70 [-2.67; -0.74]) damage to articular cartilage when compared 
to meniscectomy. However, there was no difference in osteoarthritic changes on plain 
radiographs (0.04 [-0.48; 0.57]), and results on histomorphometrics and biomechanics did 
neither show a difference in effect between meniscus allograft transplantation and 
meniscectomy. 
Conclusion:  Although meniscus allograft transplantation does not protect articular cartilage 
from damage, it reduces the extent of it when compared with meniscectomy. 
Introduction
The menisci fulfill key biomechanical functions in the knee joint.1 Unfortunately, meniscal 
injuries are quite common, accompanied by acute clinical symptoms such as knee pain, 
locking, and joint effusions. First documented treatments embraced swift and total 
meniscectomy to ameliorate acute symptoms.2 However, an increased understanding of 
the osteoarthritic changes that occur after meniscectomy made clear that it is beneficial 
to save as much meniscal tissue as possible.3-5 Meniscus allograft transplantation has been 
proposed as a promising treatment strategy for total meniscectomy already in the mid 
1980s.6 The initial goal of this treatment was to prevent, and possibly even reverse, the 
development of osteoarthritic changes in the knee joint.6-11 Encouraged by the results of 
few animal studies clinical implantation was experimented upon.12 However, a limited 
availability of donor menisci, and inconclusive results from meniscus allograft transplantation 
on development of osteoarthritis in humans, shifted its indication to treat localized pain 
after meniscectomy in a pre-selected patient population.9, 13 Rosso et al. recently published 
a systematic review on the clinical and radiographic outcomes of meniscus allograft 
 transplantation and its possible role in preventing osteoarthritis in humans.14 Despite 
the inclusion of 55 articles a meta-analysis could not be performed, mainly because of the 
lack of standardized evaluation methods to evaluate joint changes. The authors concluded 
that any chondroprotective effect in humans is still unclear. This result is not in accordance 
with their expectations based on the single animal study they refer to.15 Although it is not 
uncommon for animal studies not to correspond (well) to results from clinical studies it 
does raise the question what the actual effect is of meniscus allograft transplantation on 
the articular cartilage in animals.16 Therefore, we performed a systematic review and 
meta-analysis of all available preclinical studies we identified for this review, on the effect 
of meniscus allograft transplantation on the articular cartilage in animals. In addition, 
we discussed to what extent results from animals in meniscus related research can be 
translated to humans. 
Methods
This systematic review investigates the effect of meniscus allograft transplantation on 
articular cartilage in animals. The inclusion criteria and method of analysis were specified 
in advance and documented in a protocol.17
Search strategy and selection of studies 
Pubmed and Embase were searched (last search performed July 29th, 2014) for original 
articles concerning the effect of meniscus allograft transplantation on articular cartilage 
compared with both its positive (meniscectomy) and negative (either sham or non- 
operated) controls in healthy animals. The search strategy, composed of three elements 
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(meniscus, allograft, and animals), was developed in collaboration with information 
specialists from the medical library of the Radboud university medical center Nijmegen, 
the Netherlands.18 To detect all animal studies search filters for Pubmed and Embase were 
used.19, 20 The detailed search strategy is provided in supplementary file 1.
 Reference lists of the selected relevant (review-) papers were screened for potentially 
missed papers, and no restrictions (e.g. language or publication date) were imposed. 
Search results were imported in EROS (Early Review Organizing Software, developed by 
Institute of Clinical Effectiveness and Health Policy, Buenos Aires, Argentina) to remove 
duplicates, and randomly allocate references to two independent reviewers responsible 
for screening and selection (JR, GH). Discrepancies were resolved by discussion and if 
necessary a third reviewer was consulted (CH). 
 Initially, during the screening phase, primary studies evaluating meniscus allograft 
transplantation in healthy animals were selected based on their title and abstract only. In 
the event that there was insufficient information to make a valid judgment, the whole 
publication was evaluated
 Full-text copies of all publications eligible for inclusion were subsequently assessed 
and included when they met our pre-specified inclusion criteria: 1) a controlled interventional 
design (meniscectomy as a positive control and/or either sham or non-operated as a negative 
control); 2) description of (semi-) quantitative outcome measures related to articular 
cartilage damage (radiographic assessment, gross macroscopic assessment, histological/
histochemical based grading, immunohistochemistry based grading, histomorphometry, 
magnetic resonance imaging (MRI), and/or biomechanical characterization). 
Data extraction
Next to bibliographic details, information was extracted related to: study design; animal 
model; intervention; outcome measures; and information related to exclusion of animals 
from analysis. Outcome measures related to assessment of damage to articular cartilage 
were divided in five principal outcome categories1) Gross macroscopic assessment of 
damage (Grading or determining the area of articular cartilage with gross morphological 
changes , ICRS scores, Outerbridge scores, either with or without staining methods); 2) 
Medical imaging of changes related to osteoarthritis (plain radiographical (Kellgren & 
Lawrence) and MRI based classifications of morphological changes); 3) Histological 
histochemical grading of changes in articular cartilage (Mankin Grading method); 4) Histo-
morphometrics (any kind of quantitative study on microscopic images of articular 
cartilage); and 5) Biomechanical characterization of articular cartilage (tensile and 
compressive measures of stiffness). Raw data or group averages (mean, median), standard 
deviation (SD), standard error (SE) or ranges and number of animals per group (n) were 
extracted for all (semi-) continuous and ordinal outcome measures respectively. Attempts 
were made to obtain original data by contacting authors if results were presented 
incomplete or graphically only. If not otherwise possible, graphically presented data was 
converted to numerical data using digital ruler software (Plot Digitizer, University of South 
Alabama, USA).21, 22
Risk of bias assessment
The internal validity of the included studies was assessed, by two reviewers independently 
(JR, GH), using SYRCLE’s risk of bias tool.23 This tool is based on the Cochrane risk of bias 
tool 24 and has been adjusted for particular aspects of bias that play a role in animal 
intervention studies. It contains 10 entries related to 6 types of bias (selection, performance, 
detection, attrition, reporting and ‘other’ bias). The score ‘yes’ indicates a low risk of bias, 
‘no’ indicates high risk of bias, and ‘?’ indicates an unclear risk of bias. We used the provided 
signaling questions wherever possible.
 Reporting of experimental details on animals, methods and materials was expected 
to be poor.25 To overcome the problem of judging too many items as unclear risk of bias 
two entries were added: 1) reporting of any measure of randomization, and 2) reporting of 
any measure of blinding. 23 For these two items, a ‘yes’ indicates reported, and a ‘no’ 
indicates unreported.
Data analysis
A meta-analysis was performed whenever three or more independent comparisons per 
outcome category could be included (provided that outcome measure assessments were 
sufficiently comparable in terms of entity), and standardized mean differences (SMD) were 
calculated (SMD = the mean of the experimental group minus the mean of the control 
group divided by the pooled SDs of the two groups). Despite anticipated heterogeneity, 
the individual effect sizes were subsequently pooled to obtain an overall SMD and 95% 
confidence interval. We used a random effects model26 which takes into account the 
precision of individual studies and the variation between studies and weights each study 
accordingly. Heterogeneity was addressed by I2 which is the proportion of total variance 
explained by heterogeneity. With respect to the different time points of data collection 
across several studies, only results obtained equal or later than twelve weeks following 
index intervention were included in the meta-analysis. The latter is based on the 
assumption that, at least in sheep, damage to the articular cartilage is readily observed 3 
months after meniscal destabilization procedures.27 If multiple independent experimental 
groups were compared with the same control group within the same meta-analysis the 
number of animals in the control group was corrected by dividing it by the number of 
comparisons. In the case that more than one outcome measure corresponding to the 
same principal outcome category was presented, only one was included in the 
meta-analysis (continuous outcome measures were favored above semi quantitative and 
ordinal ones). For those outcome measures, of which results were presented separately for 
different anatomic regions in the knee joint, the tibia or its central weight bearing zone 
was used because this area is expected to demonstrate the highest degree of damage.28 
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If contralateral knees were presented as paired non-operated controls, we solely used the 
paired controls of the meniscus allograft transplantation as negative controls. Because 
several authors presented and/or analyzed their ordinal data as continuous, and it was not 
possible to obtain raw data for each data set, results of ordinal scales were meta-analyzed 
as continuous data. In case the SD of the control group was zero, we used the SD of the 
experimental group instead to be able to calculate a SMD.
 Subgroup analyses were performed only if the subgroups contained a minimum of 
3 independent comparisons. Subgroups were pre-specified in our protocol and analyses 
were planned for animal species (large/small), compartment of intervention (medial/lateral), 
and time of implantation after meniscectomy (delayed / immediate). Although not 
pre-specified, a subgroup analysis was additionally performed for timing of data collection 
as from meniscectomy (< 6 months (26weeks) / ≥ 6 months (26weeks)). Publication bias 
was addressed by means of a funnel plot, but only if at least ten studies could be included. 
 In order to assess the robustness of our findings and in an attempt to further explain 
observed study heterogeneity, we performed a sensitivity analysis and investigated the 
effect of study quality and changing the time point of data collection from 3 to at least 
6 months follow-up. 
Results
Study descriptives
The search strategy retrieved 377 unique records; subsequent selection procedure 
resulted in 17 eligible articles, representing 14 original animal cohorts (figure 1).15, 29-44 Both 
Aagaard et al.36, 37 and Rijk et al.32-34 confirmed that results of one single animal cohort were 
presented in more than one article. Overall, characteristics varied considerably between 
studies: Sheep (n=7), rabbits (n=7), goat (n=1), dogs (n=1), and rats (n=1), either males or 
females were used as animal models; they were operated upon uni- and bilaterally on the 
medial and lateral tibiofemoral compartment; and the follow up times ranged from 
4 weeks to 30 months (Table 1).
Risk of bias and quality of reporting
The risk of bias assessment, summarized in Figure 2, shows that many items were scored 
unclear risk of bias which can be regarded as an indicator for poor reporting of the 
included animal studies.45 For example, 9 of the 17 studies mentioned randomization at 
any level. However, none of these studies mentioned neither their methods of 
randomization nor sufficient details to judge its adequacy, and were therefore judged as 
unclear risk of bias. Twelve of the 17 studies stated that their experiment was blinded at 
any level, in all cases this implied that the outcome assessor was blinded. The individual 
scores of each study are presented in supplementary file 2.
Effect of meniscus allograft on articular cartilage
Out of the 14 original animal cohorts, 20 independent experimental groups could be 
identified which underwent meniscus allograft transplantation and had a follow up longer 
than or equal to 12 weeks. Only Yamasaki et al. provided results prior to 3 months (4 or 
8 weeks) and was therefore not included in any analysis.44 Aagaard et al.36, 37, Jiang et al.40, 
Rijk et al.32-34 and McNickle et al.39 provided additional data by request, although the latter 
two were not able to retrieve all the requested information. 
Figure 1   Flow diagram of the systematic review and meta-analysis literature search results.
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Table 1   Study characteristics of the included studies.
Study ID Animal characteristics Study characteristics Study characteristics Allograft characteristics
Reference Species 
(strain)
sex Age ʊ Weight 
(kg) ʊ
Experimental  
groups 
(n per time of  
data collection)
Control Groups 
(n per time of  
data collection)
Paired 
controls¤
Med  
or Lat§
Surgery 
uni/biǂ
Timing data 
collection from 
meniscectomy
Early 
Postoperative 
rehabilitationɸ 
Preservation Graft 
Sterilization
Graft Sizing Graft fixation
Mora 
2003
sheep 
(*)
* * 30-32 All(8) C(8);M(8) no med uni 6 Mo closed 
confinement
deep frozen * * transosseous  
+ direct sutures
Kelly 
2006
sheep 
(CXR)
F * 70-80 All(8+8+1) S(2+2+0); 
M(12+12+0)
yes lat uni 2, 4, 12 mo closed 
confinement
fresh * weight 
matching + 
morphometrics
transosseous  
+ direct sutures
Szomor 
2000
sheep 
(mblc)
* * 40-50 All(8) S(4); M(8); Au(8) no med uni 16 wk closed 
confinement
fresh * * Mitek GII 
suture anchors 
Jackson 
1992
goats 
(Spanish)
F * 35-40 All(10); cAll(10) S(6); Au(10) yes med uni 6 Mo no restriction fresh & 
cryopreserved  
* * anchoured 
bone plugs 
Rijk 
2002/2004/2006
rabbits 
(NZW)
F * 3-3.5 All(7+7); dAll(0+7) S(2+2); M(7+7) yes/no× med uni 6 wk,12 mo no restriction fresh * * direct suture
Elliott 
2002
dogs 
(mongrel)
* * 25–35 All(10) M(10) yes med uni 12 wk no restriction fresh * weight 
matching
direct suture
Aagaard 
1999/2003
sheep
(icelandic)
F  12-18 
mo
 40-55 S-M(6+5); S-All(0+5); S-dAll(0+5); 
M-All(0+5); M-dAll(0+5); All-dAll(0+5)¥
no med bi 3, 6 mo no restriction fresh * not transosseous 
suture
Cummins 
1997
rabbits
(NZW)
M * 4.0-4.5 All(8+0); dAll(0+8) M(8+8); yes med uni 3, 6 mo no restriction deep frozen * * direct suture
McNickle 
2009
sheep
(Dorset)
* ±1 
yr
50-60 All(3+6); sAll(3+6) M(2+2) yes med uni 2, 4 mo * deep frozen BioCleanse1 
protocol
* transosseous 
+ direct sutures
Jiang 
2012
rabbits
(NZW)
M * 2.0-2.5 All-M(8+8+8); XEN-S(8+8+8) ¥ no med bi 6, 12, 24 wk no restriction deep frozen gamma 
irradiation
* direct suture
Zwierzchowski 
2012
rabbits
(NZ)
M * 3.5-4.0 All†(8); AU(8) S(6) no med uni 6 mo no restriction culture 
medium 
* * transosseous 
+ direct sutures
Wada 
1997
rabbits
(NZ)
* 7-8  
mo 
3.5-4.0 All-M(0+16+16+15) ¥ C(12+0+0+0) no med bi 0, 9, 12, 26 wk no restriction fresh * Weight/age 
matching 
direct suture
Edwards 
1996
sheep 
(Merino)
F * 65-70 M-C(1); All-C(3); All-M(3); Au-M(5);  
M-M(1); M-All(1) ¥
no med bi mean 21.4 mo 
[range 13-30]
closed 
confinement
deep frozen * * bone plugs  
+ direct sutures
Yamasaki 
2008
rats
(SD)
* 14 
wks 
* All-M‡ (*+*); mscAll-M (*+*)‡ no med bi 4 or 8 wk * deep frozen * * *
Abbreviations: Mo = months; yr = years; wk = weeks; All = meniscus allograft; cAll = cryopreserved allograft; dAll 
= delayed allograft transplantation; S = sham procedure; C = unoperated control; M = meniscectomy; 
Xen = xenograft; Au = meniscus autograft; mscAll = meniscus allograft seeded with mesenchymal stromal cells 
derived from bone marrow; * = not mentioned / unknown; ? = unclear;   = age and weight at start of study; 
CXR = Columbian X Rambouillet; NW = New Zealand; NWZ = New zealand white; SD = Sprague–Dawley; 
MBLC = merino-border leister crossbred; ¤ = knee contralateral to intervention served as a paired unoperated 
control; § = procedures on either medial or lateral meniscus; ‡ = surgery procedures either uni- or bilaterally 
within one animal; ф = closed confinement (e.g. limited space to move around) for first time period after index 
surgery; † = meniscus allograft was implanted two weeks after removal of the meniscus and stored in culture 
medium containing both fetal calf serum and antibiotics;‡ = the meniscus allograft was treated with EDTA for 
the purpose of decalcification and freeze thawed three times to kill all the meniscal cells; ¥ = combinations of 
procedures performed on both legs are given and separated by – sign. × = In the 2002 study all nonoperated 
contralateral knees served as paired controls, whereas for the 2004 and 2006 studies only the nonoperated left 
knee joints of 6 rabbits were selected at random before surgery to serve as a control group.
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Gross macroscopic assessment
 Results of studies included in the meta-analysis. Nine and 10 comparisons could be 
included in the meta-analysis concerning gross macroscopic damage between meniscus 
allograft transplantation with either meniscectomy or a negative control, respectively. 
The average timing of data collection from meniscectomy was 21.3 weeks (range [12weeks; 
6 months]). Meniscus allograft transplantation demonstrated significantly less gross 
macroscopic damage when compared with meniscectomy (effect size -1.19 [-1.84; -0.54], I2 
= 63%, figure 3a), but demonstrated more damage compared with a negative control 
(effect size 1.45 [0.95; 1.95], I2 = 42%, figure 3b).
 Results of studies not included in the meta-analysis. Elliot et al.35 analyzed their results by 
using principal component analysis, providing factor loadings instead of descriptive 
results on gross macroscopic damage, and was therefore not included in the meta-analysis. 
Elliot et al.35 described significant more degenerative changes in the morphological 
appearance of the articular cartilage following meniscal allograft transplantation compared 
with the non-operated control (in line with the meta-analysis), but differences between 
meniscectomy and meniscal allograft transplantation were not observed (not in line with 
the meta-analysis). 
Medical imaging
 Results of studies included in the meta-analysis. Four comparisons could be included in 
the meta-analysis concerning osteoarthritic changes on plain radiographs between 
meniscus allograft transplantation with either meniscectomy or a negative control. The 
average timing of data collection from meniscectomy was 55.9 weeks (range [6 months; 
30 months]). There was no difference in osteoarthritic changes between meniscus 
allograft transplantation and meniscectomy (effect size 0.04 [-0.48; 0.57], I2 = 0%, figure 4a). 
Meniscus allograft transplantation demonstrated significantly more osteoarthritic changes 
compared to a negative control (effect size 3.12 [1.42; 4.82], I2 = 69%, figure 4b).
 Results of studies not included in the meta-analysis. Whereas the studies included in the 
meta-analysis assessed osteoarthritic changes on plain radiographs, Kelly et al.15 assessed 
morphologic changes in cartilage, bone, and bone marrow by using MRI. Because MRI 
and plain radiographs measure different entities of osteoarthritic changes the study of 
Kelly et al. 15 was not included in a meta-analysis. Kelly et al.15 demonstrated less MRI based 
morphologic degenerative changes for meniscus allograft transplantation when compared 
with meniscectomy (not in line with the meta-analysis). However, more degenerative 
changes were observed for meniscus allograft transplantation when compared with the 
non-operated controls (in line with the meta-analysis). Spin echo T2 quantitative relaxation 
maps demonstrated better results for the non-operated controls when compared with 
meniscus allograft transplantation (in line with the meta-analysis), but there was no 
difference between meniscus allograft transplantation and meniscectomy (in line with 
the meta-analysis). Fi
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Histological/histochemical grading
 Results of studies included in the meta-analysis. 11 comparisons could be included in 
the meta-analysis concerning histological histochemical grading of articular cartilage 
damage between meniscus allograft transplantation with either meniscectomy or a 
negative control. The average timing of data collection from meniscectomy was 26.5 
weeks (range [12 weeks; 12 months]). Notably, the Mankin score was used by all authors, 
but often modified and presented for various anatomical regions. Meniscus allograft 
transplantation demonstrated less histological damage to articular cartilage compared 
with meniscectomy (effect size -1.70 [-2.67; -0.74], I2 = 84%, figure 5a). However, meniscus 
allograft transplantation showed more histological damage to cartilage compared with a 
negative control (effect size 3.43 [2.25; 4.61], I2 = 82%, figure 5b). 
 Results of studies not included in the meta-analysis. Elliot et al.35 analyzed their results by 
using principal component analysis, providing factor loadings instead of descriptive 
results on gross macroscopic damage, and was therefore not included in the meta-analysis. 
Elliot et al.35 described more degenerative changes in the histological appearance of the 
articular cartilage following meniscal allograft transplantation compared with the 
non-operated control (in line with the meta-analysis). Differences in degenerative changes 
between meniscectomy and meniscal allograft transplantation were not observed (not in 
line with the meta-analysis). 
Histomorphometrics
There were five studies that used any kind of quantitative study on microscopic images of 
articular cartilage to assess the effect of meniscus allograft on articular cartilage. The nature 
of these measurements was so divers (e.g. measuring different entities) that pooling of 
the individual effect sizes was not suitable. Results of individual studies are summarized 
in figure 6. Three of the 9 comparisons, of which 2 were independent, demonstrated 
a significant difference in damage to articular cartilage between meniscus allograft 
 transplantation and meniscectomy, but in favor of different treatments. The remaining 
6 comparisons, of which 3 were independent, did not demonstrate any significant difference 
in damage (figure 6a). 
 Nine of the 13 comparisons, of which 5 were independent, demonstrated significant 
less damage to articular cartilage in favor for the negative control compared with meniscus 
allograft transplantation. The remaining 4 comparisons, of which 2 were independent, 
did not demonstrate any significant difference (figure 6b).
Biomechanics
Two studies used biomechanical characterization to address the effect of meniscus 
allograft transplantation on articular cartilage. Compared to meniscectomy, one comparison 
did, and one did not demonstrate a significant difference in stiffness in favor of meniscus 
allograft transplantation (figure 7a). Compared to a negative control, two comparisons Fi
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demonstrated a significant lower stiffness of articular cartilage after meniscus allograft 
transplantation (figure 7b). 
Subgroup analysis
Because of the relative low number of included studies it was not possible to perform 
statistical robust subgroup analyses for all planned subgroups. For those subgroups that 
included more than 3 studies, the effect estimates were described in table 2. None of 
those subgroup analyses showed significant differences between the groups.
Publication bias
Because of the low number of studies that were included in the meta-analyses, a funnel 
plot was not created.
Sensitivity analysis 
Changing the time point for data collection from 3 to at least 6 months follow-up did not 
change the outcome of results. Due to poor reporting of experimental details the results from 
the risk of bias could not be implemented as a screening part in the sensitivity analysis.
Table 2   Effect sizes of subgroup analysis.
Subgroups (n) Comparison Outcome measure Effect size [95%CI]
Animal species
   Middle (2) / Large (2) Allograft vs. meniscectomy Medical imaging n.e. /  n.e.
   Middle (3) / Large (6) Allograft vs. meniscectomy Gross macroscopic assessment -1.43 [-2.00; -0.86] /  -1.05 [-2.11, 0.01]
   Middle (6) / Large (5) Allograft vs. meniscectomy Histological-histochemical grading -2.06 [-3.64; -0.48] / -1.35 [-2.62; -0.09]
   Middle (2) / Large (2) Allograft vs. neg. control Medical imaging n.e. /  n.e.
   Middle (2) / Large (8) Allograft vs. neg. control Gross macroscopic assessment n.e. / 1.32 [0.78; 1.85]
   Middle (6) / Large (5) Allograft vs. neg. control Histological-histochemical grading 3.02 [1.60; 4.44] / 4.11 [1.91; 6.31]
Timing allograft transplantation
   Immediate (3) / delayed (1) Allograft vs. meniscectomy Medical imaging 0.13 [-0.47; 0.72] /  n.e.
   Immediate (8) / delayed (1) Allograft vs. meniscectomy Gross macroscopic assessment -1.51 [-1.92; -1.09] /  n.e.
   Immediate (8) / delayed (3) Allograft vs. meniscectomy Histological-histochemical grading -2.02 [-3.19; -0.85] / -0.98 [-3.17; 1.21]
   Immediate (3) / delayed (1) Allograft vs. neg. control Medical imaging 2.81 [0.82; 4.80] /  n.e.
   Immediate (9) / delayed (1) Allograft vs. neg. control Gross macroscopic assessment 1.30 [0.85; 1.75] /  n.e.
   Immediate (8) / delayed (3) Allograft vs. neg. control Histological-histochemical grading 3.58 [2.07; 5.10] / 3.26 [0.83; 5.68]
Compartment of intervention
   Medial (4) / Lateral (0) Allograft vs. meniscectomy Medical imaging 0.04 [-0.48; 0.57] /  n.e.
   Medial (9) / Lateral (1) Allograft vs. meniscectomy Gross macroscopic assessment -1.02 [-1.66; -0.38] /  n.e.
   Medial (10) / Lateral (1) Allograft vs. meniscectomy Histological-histochemical grading -1.26 [-2.08; -0.43] /  n.e.
   Medial (4) / Lateral (0) Allograft vs. neg. control Medical imaging 3.12 [1.42; 4.82] /  n.e.
   Medial (9) / Lateral (1) Allograft vs. neg. control Gross macroscopic assessment 1.37 [0.84; 1.89] /  n.e.
   Medial (10) / Lateral (1) Allograft vs. neg. control Histological-histochemical grading 2.94 [1.90; 3.98] /  n.e.
Timing of data collection
   Timing < 6mo (0) / Timing ≥ 6mo (4) Allograft vs. meniscectomy Medical imaging n.e. /  0.07 [-0.50; 0.64]
   Timing < 6mo (6) / Timing ≥ 6mo (4) Allograft vs. meniscectomy Gross macroscopic assessment -1.37 [-1.90; -0.84] /  -0.95 [-2.48; 0.58]
   Timing < 6mo (5) / Timing ≥ 6mo (6) Allograft vs. meniscectomy Histological-histochemical grading -3.10 [-5.22; -0.99] /  -0.93 [-1.84; -0.01]
   Timing < 6mo (0) / Timing ≥ 6mo (4) Allograft vs. neg. control Medical imaging n.e. /  3.12 [1.42; 4.82]
   Timing < 6mo (6) / Timing ≥ 6mo (4) Allograft vs. neg. control Gross macroscopic assessment 1.42 [0.73; 2.12] /  1.52 [0.74; 2.31]
   Timing < 6mo (5) / Timing ≥ 6mo (6) Allograft vs. neg. control Histological-histochemical grading 3.90 [1.85; 5.96] /  3.05 [1.52; 4.59]
The effect sizes and 95% confidence intervals (95%CI) for different subgroups are presented. The n reflects the 
number of independent comparisons. N.e. = not estimated. Timing < or ≥ 6mo = timing of data collection from 
meniscectomy earlier or equal/later than 6 months (26weeks). Large animals = sheep/goats; Middle animals = 
dogs/rabbits.
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Discussion
The concept of meniscus allograft transplantation was conceived to prevent degeneration 
of articular cartilage in the meniscectomized knee.6-11 So far, despite widespread reporting 
on clinical results, the effect of meniscus allograft transplantation on the development of 
osteoarthritis is still unclear.14 This is not in line with expectations from the animal study 
referred to by the recently published meta-analysis.14 We therefore conducted this study 
to systematically review all studies on the effect of meniscus allograft transplantation on 
articular cartilage in animals.
 From this systematic review and meta-analysis, which included studies with an 
average timing of data collection of 28 weeks (range [12 weeks; 30 months]), it becomes 
clear that compared to a negative control, meniscus allograft transplantation causes gross 
macroscopic and histological damage to articular cartilage, and osteoarthritic changes 
on plain radiographs. Moreover, results on histomorphometry and cartilage biomechanics 
support that meniscus allograft transplantation has a detrimental influence on articular 
cartilage. Although showing damage to articular cartilage, meniscus allograft transplantation 
causes significantly less gross macroscopic and histological damage to articular cartilage 
when compared to meniscectomy. However, this difference in favor of meniscus allograft 
transplantation is not observed for osteoarthritic changes on plain radiographs. Results 
on histomorphometrics and biomechanics do neither appear to show a clear difference 
in damage to articular cartilage between meniscus allograft transplantation and 
meniscectomy. Osteoarthritis is characterized by a molecular phase, a pre radiographic 
phase, and a recalcitrant radiographic phase with evident structural joint changes.46 In this 
continuum of osteoarthritic stages we interpret our results as such that, although both 
meniscus allograft transplantation and meniscectomy cause structural joint changes, 
damage to articular cartilage is less extensive after meniscus allograft transplantation.
Some methodological issues which might hamper the interpretation of the experimental 
animal data and the subsequent translation to the clinical setting have to be discussed.
 First, the heterogeneity among the various animal studies was substantial. Unfortunately, 
unraveling this heterogeneity by performing subgroup analyses was not feasible due to 
too low number of independent comparisons within subgroups. The soundness of pooling 
different animal species and models within a single meta-analysis could be questioned. 
However, consistent results across species and models do provide some reassurance 
that the observed effect is reliable. Moreover, subgroup analysis did not demonstrate 
differences in results between large (sheep/goats) and middle (dogs/rabbits) animals. 
In addition, from a biomechanical point of view, the meniscus has the same function 
across different species: load distribution over two incongruent moving articular surfaces. 
Removing it will inflict pathological (peak) stresses causing articular cartilage to be damaged. 
To what extent this damage occurs, at what rate, and with what clinical symptoms could 
well be species specific. For example, it has been demonstrated that sheep show changes 
in kinematics after meniscectomy comparable to humans.27 Rabbits only show little 
change in knee kinematics47, and rats show only minor changes in static weight-bearing 
after meniscectomy.48, 49 Unfortunately, due to too few comparisons, assessing differences in 
extent of damage between animal species could not be performed in this review. 
 The minimum of twelve weeks as a time point of data collection used in the present 
study was based on the assumption that, at least in sheep, damage to the articular 
cartilage is readily observed 3 months after meniscal destabilization procedures. It is 
possible that adequate duration would be different for different animals/species. 
 With the combination of consistent results across species and models, the theoretical 
background, and the results of the subgroup analysis in mind, we have no arguments that 
show that it might be better to only focus on large animals.
 We did not differentiate for time from meniscectomy to meniscus allograft trans-
plantation (e.g. delayed transplantation). It could well be that delayed meniscus allograft 
transplantation performs worse in comparison to immediate transplantation, because 
there is a time period in which the cartilage is overloaded. This seems as an important 
question to address, looking to the current clinical situation in which humans receive a 
meniscus allograft a substantial time period after the removal of their meniscus (Rosso et 
al. reported an overall weighted average time between meniscectomy and meniscus 
allograft transplantation of 15.16 years (range, 1.1-35.8 years)14). However, a fallacy here is 
that the current the indication of meniscus allograft transplantation is not the prevention 
of osteoarthritis but to treat localized pain post meniscectomy in a selected patient 
population. Not differentiating for time between meniscectomy and allograft trans-
plantation theoretically underestimates the protective effect on damage to articular 
cartilage when compared to meniscectomy.
 Second, poor reporting of crucial pieces of information in the included articles is of 
serious concern, and limited the application of the SYRCLE’s risk of bias tool. Regrettably, 
this is not uncommon practice in animal studies, limiting the ability to draw reliable 
conclusions. This concern is also shared and addressed by others.25, 45, 50-52 It is crucial that 
the poor reporting in animal studies is addressed and future studies should improve on 
this, allowing others to be able to replicate and build on previously published work. 
Ultimately, with better reporting, systematic reviews of high quality will become feasible. 
In recent years checklists have been developed to improve the quality of animal studies.45, 
50 Implementing such initiatives will improve the quality of individual scientific papers on 
animal experimentation. Moreover, as a consequence, numbers of animals used would be 
expected to fall, and will set in motion better translation to the clinic and increases patient 
safety.16, 45, 53, 54 
 Because of the poor reporting of experimental details it was not possible to assess 
how the results of this review might have been affected if studies with a high risk of bias 
were excluded from the analysis.
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 Third, results on long term effect of meniscus allograft transplantation on articular 
cartilage are not provided in the current systematic review. Our sensitivity analysis showed 
that results did not change if 6 instead of 3 months was used as a minimum time point of 
data collection. Damage to articular cartilage would be expected to be progressively 
more severe if even longer endpoints would have been used. Since both meniscus 
allograft transplantation and meniscectomy cause damage to articular cartilage it is 
imaginable that both interventions ultimately lead to end stages of osteoarthritis. To what 
extent meniscus allograft transplantation is able to postpone disabling end stages 
compared to meniscectomy, remains unknown. 
Regarding translation from pre clinical animal models to clinical practice, several aspects 
should be addressed. First, consistent results across species and models do provide some 
reassurance that the observed effect is reliable, and that humans might respond similarly. 
Moreover, the minimal invasive arthroscopic procedures used in humans may have less 
detrimental effect on cartilage compared to the extensive open procedures used in 
animal experiments, which could improve the outcome of meniscal allograft transplanta-
tion. Finally, whereas graft sizing was only scarcely mentioned in animal experiments it is 
common practice in humans. From a biomechanical point of view, proper graft sizing 
leads to better load distribution, which is an important factor for a successful outcome of 
meniscal transplantation.55 
 However, some aspects interfere with translation to clinical practice. First, in pre 
clinical animal models the meniscus allograft is transplanted in a “pristine” knee. Here, 
damage of articular cartilage is the result of both the surgical procedure and the meniscus 
allograft only. In contrast, clinically, a meniscus allograft is transplanted in a knee that has 
undergone a trauma large enough to cause considerable damage to the meniscus. This 
trauma may even well have damaged the cartilage directly, limiting the theoretical 
treatment effect of a meniscus allograft. 
 Second, we demonstrated that both meniscectomy as well as meniscus allograft 
transplantation will cause degeneration of articular cartilage. This raises the question as to 
what extent the theoretically lesser damage to articular cartilage after meniscus allograft 
transplantation gives rise to a clinical meaningful reduction or delay in clinical (disabling) 
osteoarthritis, and subsequent need for total knee arthroplasty. However it should be 
noted that, not all patients who develop damage to the articular cartilage, or even 
radiographical established osteoarthritis, will end up with clinical disabling osteoarthritis.56-
58 Subsequently, a next question would be what the cost per health unit gain would be of 
meniscus allograft transplantation. These questions can only be addressed with 
information obtained from a (randomized) controlled clinical trial. 
 Rosso et al. explain their inability to analyze the chondroprotective effect of meniscus 
allograft transplantation because of the lack of standardized evaluation methods (e.g. ra-
diographically different grading scores were used to evaluate joint changes). However, a 
more important limitation in human studies is the lack of control groups. To be able to 
demonstrate any positive effect of meniscus allograft transplantation in humans, a control 
group of patients undergoing meniscectomy is imperative. Only 1 out of the 55 articles on 
human meniscus allograft transplantation identified by Rosso et al. used a control cohort 
of meniscectomized patients. However, it concerned a historical cohort and comparisons 
were made on subjective assessment rather than evaluating the status of articular 
cartilage.59 This lack of control groups limits us to directly assess to what extent results 
from animal experiments in meniscus related research can be translated to humans. 
 In conclusion, this systematic review with an average follow up of included studies of 
28 weeks (range [12 weeks; 30 months]) demonstrates that, in animals, although meniscus 
allograft transplantation does not protect articular cartilage from damage, it reduces the 
extent of it when compared with meniscectomy. Consistent results across species and 
models do provide some reassurance that this observed effect is reliable, and that humans 
might respond in a similar manner.
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Supplementary Table 1   Search strategy.
Pubmed
Component 1: 
Meniscus
Menisci, Tibial [Mesh] OR (knee [mesh] AND fibrocartilage [mesh]) OR 
(knee joint [mesh] AND fibrocartilage [mesh]) OR meniscal [tiab]  OR 
meniscected [tiab]  OR meniscectomie [tiab]  OR meniscectomies [tiab]  OR 
meniscectomised [tiab]  OR meniscectomisized [tiab]  OR meniscectomized 
[tiab] OR meniscectomy [tiab]  OR menisceotomy [tiab]  OR meniscetomy 
[tiab]  OR menisci [tiab]  OR meniscial [tiab]  OR meniscopathies [tiab]  OR 
meniscopathy [tiab]  OR meniscopexia [tiab]  OR meniscopexies [tiab]  OR 
meniscopexy [tiab]  OR meniscoplasty [tiab]  OR meniscotomies [tiab]  OR 
meniscotomy [tiab] OR meniscus [tiab]  OR meniscusectomy [tiab]  OR 
meniscusectomy [tiab]  OR menisectomies [tiab]  OR menisectomized [tiab] 
OR menisectomy [tiab] OR (knee [tiab] AND fibrocartilage [tiab]) OR (knee 
[tiab] AND fibro-cartilage [tiab]) OR (knee [tiab] AND fibrocartilagenous 
[tiab]) OR (knee [tiab] AND fibro-cartilagenous [tiab]) OR (knee [tiab] AND 
fibrocartilageous [tiab]) OR (knee [tiab] AND fibrocartilages [tiab]) OR (knee 
[tiab] AND fibro-cartilages [tiab]) OR (knee [tiab] AND Semilunar [tiab]) OR 
(knees [tiab] AND fibrocartilage [tiab]) OR (knees [tiab] AND fibro-cartilage 
[tiab]) OR (knees [tiab] AND fibrocartilagenous [tiab]) OR (knees [tiab] AND 
fibro-cartilagenous [tiab]) OR (knees [tiab] AND fibrocartilageous [tiab]) OR 
(knees [tiab] AND fibrocartilages [tiab]) OR (knees [tiab] AND fibro-cartilages 
[tiab]) OR (knees [tiab] AND semilunar [tiab]) OR (tibiafemoral [tiab] AND 
fibrocartilage [tiab]) OR (tibia-femoral [tiab] AND fibrocartilage [tiab]) 
OR (tibiafemoral [tiab] AND fibro-cartilage [tiab]) OR (tibia-femoral [tiab] 
AND fibro-cartilage [tiab]) OR (tibiafemoral [tiab] AND fibrocartilagenous 
[tiab]) OR (tibiafemoral [tiab] AND fibrocartilagenous [tiab]) OR (tibia-
femoral [tiab] AND fibrocartilagenous [tiab]) OR (tibiafemoral [tiab] AND 
fibro-cartilagenous [tiab]) OR (tibiafemoral [tiab] AND fibro-cartilagenous 
[tiab]) OR (tibia-femoral [tiab] AND fibro-cartilagenous [tiab]) OR 
(tibiafemoral [tiab] AND fibrocartilageous [tiab]) OR (tibiafemoral [tiab] AND 
fibrocartilageous [tiab]) OR (tibia-femoral [tiab] AND fibrocartilageous [tiab]) 
OR (tibiafemoral [tiab] AND fibrocartilages [tiab]) OR (tibia-femoral [tiab] 
AND fibrocartilages [tiab]) OR (tibiafemoral [tiab] AND fibro-cartilages [tiab]) 
OR (tibiafemoral [tiab] AND fibro-cartilages [tiab]) OR (tibia-femoral [tiab] 
AND fibro-cartilages [tiab]) OR (tibiafemoral [tiab] AND semilunar [tiab]) 
OR (tibia-femoral [tiab] AND semilunar [tiab]) OR (tibiofemoral [tiab] AND 
fibrocartilage [tiab]) OR (tibio-femoral [tiab] AND fibrocartilage [tiab]) OR 
(tibiofemoral [tiab] AND fibro-cartilage [tiab]) OR (tibio-femoral [tiab] AND 
fibro-cartilage [tiab]) OR (tibiofemoral [tiab] AND fibrocartilagenous [tiab]) 
OR (tibio-femoral [tiab] AND fibrocartilagenous [tiab]) OR (tibiofemoral 
[tiab] AND fibro-cartilagenous [tiab]) OR (tibio-femoral [tiab] AND fibro-
cartilagenous [tiab]) OR (tibiofemoral [tiab] AND fibrocartilageous [tiab]) 
OR (tibio-femoral [tiab] AND fibrocartilageous [tiab]) OR (tibiofemoral [tiab] 
AND fibrocartilages [tiab]) OR (tibio-femoral [tiab] AND fibrocartilages [tiab]) 
OR (tibiofemoral [tiab] AND fibro-cartilages [tiab]) OR (tibio-femoral [tiab] 
AND fibro-cartilages [tiab]) OR (tibiofemoral [tiab] AND semilunar [tiab]) OR 
(tibio-femoral [tiab] AND semilunar [tiab]) OR Semilunar Cartilage [tiab] OR 
Semilunar Cartilages [tiab] OR Semilunar fibrocartilage [tiab]
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Supplementary Table 1  Continued.
Pubmed
Component 2: 
Allograft
Allografts [Mesh] OR Transplantation, Homologous [Mesh] OR Tissue 
Transplantation [mesh] OR Allogeneic implant [tiab] OR Allogeneic implants 
[tiab] OR Allogenic implants [tiab] OR Allograft [tiab] OR Allo-graft [tiab] 
OR Allografted [tiab] OR Allo-grafted [tiab] OR Allografting [tiab] OR Allo-
grafting [tiab] OR Allograftings [tiab] OR Allografts [tiab] OR Allo-grafts [tiab] 
OR Alloplastic implant [tiab] OR Alloplastic implants [tiab] OR Allotransplant 
[tiab] OR Allo-transplant [tiab] OR Allotransplantation [tiab] OR Allo-
transplantation [tiab] OR Allotransplantations [tiab] OR Allo-transplantations 
[tiab] OR Allotransplanted [tiab] OR Allo-transplanted [tiab] OR 
Allotransplanting [tiab] OR Allotransplants [tiab] OR Allo-transplants [tiab] 
OR Graft [tiab] OR Grafted [tiab] OR Grafting [tiab] OR Graftings [tiab] OR 
Grafts [tiab]  OR Homo-graft  [tiab]  OR Homograft [tiab]  OR Homografted 
[tiab] OR Homografting [tiab] OR Homo-grafting [tiab] OR Homograftings 
[tiab] OR Homografts [tiab] OR Homo-grafts [tiab] OR Homologous 
implants [tiab] OR Homotransplant [tiab]  OR Homotransplantation [tiab] 
OR Homo-transplantation [tiab] OR Homotransplantations [tiab] OR Homo-
transplantations [tiab] OR Homotransplanted [tiab]  OR Homo-transplanted 
[tiab]  OR Homotransplants [tiab] OR Homo-transplants [tiab] OR Transplant 
[tiab] OR Transplantation [tiab] OR Transplantations [tiab] OR Transplanted 
[tiab] OR Transplanting [tiab] OR Transplants [tiab]
Component 3: 
Animal
Search filter for animal studies [Hooijmans 2010]
Embase
Component 1: 
Meniscus
(exp knee / AND exp fibrocartilage/) OR (exp knee joint / AND  exp 
fibrocartilage/) OR exp knee meniscus/  OR exp knee meniscus rupture/  
OR exp meniscectomy/  OR exp meniscal surgery / OR meniscal .ti,ab.  
OR meniscected .ti,ab.  OR meniscectomie .ti,ab.  OR meniscectomies 
.ti,ab.  OR meniscectomised .ti,ab.  OR meniscectomisized .ti,ab.  OR 
meniscectomized .ti,ab. OR meniscectomy .ti,ab.  OR menisceotomy 
.ti,ab.  OR meniscetomy .ti,ab.  OR menisci .ti,ab.  OR meniscial .ti,ab.  OR 
meniscopathies .ti,ab.  OR meniscopathy .ti,ab.  OR meniscopexia .ti,ab.  
OR meniscopexies .ti,ab.  OR meniscopexy .ti,ab.  OR meniscoplasty .ti,ab.  
OR meniscotomies .ti,ab.  OR meniscotomy .ti,ab. OR meniscus .ti,ab.  OR 
meniscusectomy .ti,ab.  OR meniscusectomy .ti,ab.  OR menisectomies 
.ti,ab.  OR menisectomized .ti,ab.  OR menisectomy .ti,ab. OR (knee .ti,ab. 
AND fibrocartilage .ti,ab.) OR (knee .ti,ab. AND fibro-cartilage .ti,ab.) OR 
(knee .ti,ab. AND fibrocartilagenous .ti,ab.) OR (knee .ti,ab. AND fibro-
cartilagenous .ti,ab.) OR (knee .ti,ab. AND fibrocartilageous .ti,ab.) OR (knee 
.ti,ab. AND fibrocartilages .ti,ab.) OR (knee .ti,ab. AND fibro-cartilages .ti,ab.) 
OR (knee .ti,ab. AND Semilunar .ti,ab.) OR (knees .ti,ab. AND fibrocartilage 
.ti,ab.) OR (knees .ti,ab. AND fibro-cartilage .ti,ab.) OR (knees .ti,ab. AND 
fibrocartilagenous .ti,ab.) OR (knees .ti,ab. AND fibro-cartilagenous .ti,ab.) 
OR (knees .ti,ab. AND fibrocartilageous .ti,ab.) OR (knees .ti,ab. AND 
fibrocartilages .ti,ab.) OR (knees .ti,ab. AND fibro-cartilages .ti,ab.) OR (knees 
.ti,ab. AND semilunar .ti,ab.) OR (tibiafemoral .ti,ab. AND fibrocartilage .ti,ab.) 
OR (tibia-femoral .ti,ab. AND fibrocartilage .ti,ab.) OR (tibiafemoral .ti,ab.
Supplementary Table 1  Continued.
Embase
Component 1: 
Meniscus
AND fibro-cartilage .ti,ab.) OR (tibia-femoral .ti,ab. AND fibro-cartilage .ti,ab.) 
OR (tibiafemoral .ti,ab. AND fibrocartilagenous .ti,ab.) OR (tibiafemoral .ti,ab. 
AND fibrocartilagenous .ti,ab.) OR (tibia-femoral .ti,ab. AND fibrocartilagenous 
.ti,ab.) OR (tibiafemoral .ti,ab. AND fibro-cartilagenous .ti,ab.) OR (tibiafemoral 
.ti,ab. AND fibro-cartilagenous .ti,ab.) OR (tibia-femoral .ti,ab. AND fibro-
cartilagenous .ti,ab.) OR (tibiafemoral .ti,ab. AND fibrocartilageous .ti,ab.) 
OR (tibiafemoral .ti,ab. AND fibrocartilageous .ti,ab.) OR (tibia-femoral .ti,ab. 
AND fibrocartilageous .ti,ab.) OR (tibiafemoral .ti,ab. AND fibrocartilages 
.ti,ab.) OR (tibia-femoral .ti,ab. AND fibrocartilages .ti,ab.) OR (tibiafemoral 
.ti,ab. AND fibro-cartilages .ti,ab.) OR (tibiafemoral .ti,ab. AND fibro-cartilages 
.ti,ab.) OR (tibia-femoral .ti,ab. AND fibro-cartilages .ti,ab.) OR (tibiafemoral 
.ti,ab. AND semilunar .ti,ab.) OR (tibia-femoral .ti,ab. AND semilunar .ti,ab.) OR 
(tibiofemoral .ti,ab. AND fibrocartilage .ti,ab.) OR (tibio-femoral .ti,ab. AND 
fibrocartilage .ti,ab.) OR (tibiofemoral .ti,ab. AND fibro-cartilage .ti,ab.) OR 
(tibio-femoral .ti,ab. AND fibro-cartilage .ti,ab.) OR (tibiofemoral .ti,ab. AND 
fibrocartilagenous .ti,ab.) OR (tibio-femoral .ti,ab. AND fibrocartilagenous 
.ti,ab.) OR (tibiofemoral .ti,ab. AND fibro-cartilagenous .ti,ab.) OR (tibio-
femoral .ti,ab. AND fibro-cartilagenous .ti,ab.) OR (tibiofemoral .ti,ab. AND 
fibrocartilageous .ti,ab.) OR (tibio-femoral .ti,ab. AND fibrocartilageous .ti,ab.) 
OR (tibiofemoral .ti,ab. AND fibrocartilages .ti,ab.) OR (tibio-femoral .ti,ab. AND 
fibrocartilages .ti,ab.) OR (tibiofemoral .ti,ab. AND fibro-cartilages .ti,ab.) OR 
(tibio-femoral .ti,ab. AND fibro-cartilages .ti,ab.) OR (tibiofemoral .ti,ab. AND 
semilunar .ti,ab.) OR (tibio-femoral .ti,ab. AND semilunar .ti,ab.) OR Semilunar 
Cartilage .ti,ab. OR Semilunar Cartilages .ti,ab. OR Semilunar fibrocartilage 
.ti,ab. OR knee disk .ti,ab.
Component 2: 
Allograft
exp meniscal transplantation/  OR exp allograft/  OR exp allotransplantation/  
OR exp Tissue Transplantation / OR Allogeneic implant .ti,ab. OR Allogeneic 
implants .ti,ab. OR Allogenic implants .ti,ab. OR Allograft .ti,ab. OR Allo-
graft .ti,ab. OR Allografted .ti,ab. OR Allo-grafted .ti,ab. OR Allografting 
.ti,ab. OR Allo-grafting .ti,ab. OR Allograftings .ti,ab. OR Allografts .ti,ab. OR 
Allo-grafts .ti,ab. OR Alloplastic implant .ti,ab. OR Alloplastic implants .ti,ab. 
OR Allotransplant .ti,ab. OR Allo-transplant .ti,ab. OR Allotransplantation 
.ti,ab. OR Allo-transplantation .ti,ab. OR Allotransplantations .ti,ab. OR Allo-
transplantations .ti,ab. OR Allotransplanted .ti,ab. OR Allo-transplanted .ti,ab. 
OR Allotransplanting .ti,ab. OR Allotransplants .ti,ab. OR Allo-transplants .ti,ab. 
OR Graft .ti,ab. OR Grafted .ti,ab. OR Grafting .ti,ab. OR Graftings .ti,ab. OR 
Grafts .ti,ab.  OR Homo-graft  .ti,ab.  OR Homograft .ti,ab.  OR Homografted 
.ti,ab. OR Homografting .ti,ab. OR Homo-grafting .ti,ab. OR Homograftings 
.ti,ab. OR Homografts .ti,ab. OR Homo-grafts .ti,ab. OR Homologous 
implants .ti,ab. OR Homotransplant .ti,ab.  OR Homotransplantation .ti,ab. 
OR Homo-transplantation .ti,ab. OR Homotransplantations .ti,ab. OR Homo-
transplantations .ti,ab. OR Homotransplanted .ti,ab.  OR Homo-transplanted 
.ti,ab.  OR Homotransplants .ti,ab. OR Homo-transplants .ti,ab. OR Transplant 
.ti,ab. OR Transplantation .ti,ab. OR Transplantations .ti,ab. OR Transplanted 
.ti,ab. OR Transplanting .ti,ab. OR Transplants .ti,ab.
Component 3: 
Animal
Search filter for animal studies [de Vries 2011]
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Supplementary Table 2  Individual risk of bias scores.
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1 selection bias Was the allocation sequence adequately generated and applied? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
2 Selection bias Were the groups similar at baseline or were they adjusted for 
confounders in the analysis?
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
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Abstract 
Background: Meniscus scaffolds are currently evaluated clinically for their efficacy in 
preventing the development of osteoarthritis as well as for their efficacy in treating 
patients with chronic symptoms. Procedural costs, therapeutic consequences, clinical 
efficacy, and future events should all be considered to maximize the monetary value of 
this intervention. Purpose: To examine the socioeconomic effect of treating patients with 
irreparable medial meniscus injuries with a meniscus scaffold. 
Study design: Economic and decision analysis. 
Methods: Two Markov simulation models for patients with an irreparable medial meniscus 
injury were developed. Model 1 was used to investigate the lifetime cost-effectiveness of 
a meniscus scaffold compared with standard partial meniscectomy by the possibility of 
preventing the development of osteoarthritis. Model 2 was used to investigate the short-term 
(5-year) cost-effectiveness of a meniscus scaffold compared with standard partial meniscectomy 
by alleviating clinical symptoms, specifically in chronic patients with previous meniscus surgery. 
For both models, probabilistic Monte Carlo simulations were applied. Treatment effectiveness 
was expressed as quality-adjusted life-years (QALYs), while costs (estimated in euros) were 
assessed from a societal perspective. We assumed €20,000 as a reference value for the 
willingness to pay per QALY. Next, comprehensive sensitivity analyses were performed to 
identify the most influential variables on the cost-effectiveness of meniscus scaffolds. 
Results: Model 1 demonstrated an incremental cost-effectiveness ratio of a meniscus 
scaffold treatment of €54,463 per QALY (€5991/0.112). A threshold analysis demonstrated 
that a meniscus scaffold should offer a relative risk reduction of at least 0.34 to become 
cost-effective, assuming a willingness to pay of €20,000. Decreasing the costs of the 
meniscus scaffold procedure by 33% (€10,160 instead of €15,233; an absolute change of 
€5073) resulted in an incremental cost-effectiveness ratio of €7876 per QALY. Model 2 
demonstrated an incremental cost-effectiveness ratio of a meniscus scaffold treatment 
of €297,727 per QALY (€9825/0.033). On the basis of the current efficacy data, a meniscus 
scaffold provides a relative risk reduction of ‘‘limited benefit’’ postoperatively of 0.37 
compared with standard treatment. A threshold analysis revealed that assuming a 
willingness to pay of €20,000, a meniscus scaffold would not be cost-effective within a 
period of 5 years. Most influential variables on the cost-effectiveness of meniscus scaffolds 
were the cost of the scaffold procedure, cost associated with osteoarthritis, and quality of 
life before and after the scaffold procedure. 
Conclusion: Results of the current health technology assessment emphasize that the 
monetary value of meniscus scaffold procedures is very much dependent on a number of 
influential variables. Therefore, before implementing the technology in the health care 
system, it is important to critically assess these variables in a relevant context. The models 
can be improved as additional clinical data regarding the efficacy of the meniscus scaffold 
become available. 
Introduction
 
The menisci fulfill key biomechanical functions in the knee joint. Unfortunately, traumatic 
meniscus injuries are quite common, accompanied by acute clinical symptoms such as 
knee pain, locking, and joint effusions. Early treatments embraced swift and total 
meniscectomy to ameliorate acute symptoms2 However, an increased understanding of 
the osteoarthritic changes that occur after total meniscectomy made clear that it is 
beneficial to save as much meniscus tissue as possible.20,29,33 However, even with the 
universal adoption of meniscus preservation, arthritic changes have still been observed 
over the long term after partial meniscectomy.27 This realization led to increased clinical 
and scientific interest to develop new strategies for meniscus injuries, aimed to prevent 
osteoarthritic changes otherwise encountered with arthroscopic (partial) meniscectomy.32 
For example, meniscus repair by suturing is nowadays being performed preferentially 
above arthroscopic partial meniscectomy.1 However, meniscus repair is only suited for a 
limited number of all traumatic meniscus injuries,25 and the majority of meniscus injuries 
are still treated with partial meniscectomy.1 To prevent cartilage damage after partial 
meniscectomy, degradable porous scaffolds have been developed to replace meni-
scectomized tissue (eg, Collagen Meniscus Implant [Ivy Sports Medicine] and the 
polyurethane Actifit implant [Orteq Ltd]). These porous scaffolds are designed to promote 
the formation of new meniscus tissue in a self-healing process and, as such, reassume 
the meniscus’ native form and function, hypothetically preventing damage to articular 
cartilage. These meniscus scaffolds are also evaluated for their efficacy in alleviating 
symptoms in chronic patients rather than primarily aiming for chondroprotection. Chronic 
patients are those who experience signs and symptoms attributed to the meniscus (eg, 
medial joint-line pain, swelling, locking, clicking, and catching) after they have undergone 
one or multiple prior procedures on the involved meniscus.31 Although this population is 
heterogeneous and ill defined, it is believed that these patients do not respond well to 
additional arthroscopic treatments, and a meniscus scaffold might be superior in providing 
the alleviation of symptoms.4,23,31 Osteoarthritis is a chronic disease accompanied by a 
substantial decrease in quality of life and an increase in costs accrued to society10 and, as 
such, is worthwhile preventing. On the other hand, clinical outcomes after standard partial 
meniscectomy are satisfactory,29 the radiographic progression of osteoarthritic changes 
may only occur in up to 37% of the patients by 10 years,28 not every patient with 
radiographic changes will experience symptomatic osteoarthritis, 22,24 and the onset of 
clinical symptoms lags behind radiographic changes by another 5 to 10 years.24 Therefore, 
although there is opportunity for preventing osteoarthritis, and possibly also for treating 
chronic patients, only a limited number of patients do not sufficiently benefit from 
standard treatment. Moreover, compared with standard treatment, procedures and the 
therapeutic consequences of these new meniscus scaffolds will come with increased 
costs. Currently, health care systems are dealing with the challenge of how to manage 
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health care delivery in conditions of resource constraint.35 Health care policy, practice, and 
decisions are needed to maximize the positive effect of health care interventions on 
population health while maximizing the monetary value of providing the interventions.35 
Health technology assessments can aid in this process by providing a framework for 
improving the uptake of cost-effective new technologies, preventing the uptake of 
technologies that are of questionable value for the health system, and delaying the 
introduction of technologies that seem promising but are of unproven benefit.35 
To achieve sustainable health care, costs related to procedures and the therapeutic 
consequences of innovative meniscus scaffolds should be taken into consideration 
simultaneously with the evaluation of their efficacy. The general objective of this study 
was to examine the socioeconomic effect of treating irreparable medial meniscus injuries 
with a meniscus scaffold either to prevent the development of osteoarthritis or as a 
treatment strategy for chronic patients. Next, for both scenarios, we also examined which 
were the most influential variables on the cost-effectiveness of meniscus scaffolds to 
provide means to maximize the monetary value of providing the interventions.
Methods
General and analytic overview 
Two state-transition (Markov) simulation models for patients with an irreparable medial 
meniscus injury were developed in specialized software (TreeAge Pro Suite 2014). In both 
models, 2 treatment strategies were defined: (1) standard treatment (arthroscopic partial 
meniscectomy, removing as little of the meniscus as possible, and joint debridement if 
indicated) and (2) a meniscus scaffold procedure (standard arthroscopic treatment, 
followed by the placement of a meniscus scaffold, and joint debridement if indicated).31 
Model 1 was used to investigate the lifetime cost-effectiveness of a meniscus scaffold 
compared with standard treatment by the possible prevention of symptomatic osteo-
arthritis in patients with an irreparable medial meniscus injury. Model 2 was used to 
investigate the short-term (5-year) cost-effectiveness of a meniscus scaffold compared 
with standard treatment by alleviating clinical symptoms in chronic patients who 
experience signs and symptoms attributed to the medial meniscus.
Model structure
Model 1: Prevention of osteoarthritis
The conceptual organization of the health states of model 1 is depicted in Figure 1A: 4 
acute states (partial meniscectomy, meniscus scaffold, total knee arthroplasty [TKA], and 
revision TKA) and 9 chronic states. The model structure representing the transition from 
radiographic knee osteoarthritis to TKA was adopted from Mather et al,21 and the model 
structure representing the transition from TKA onwards was adopted from Losina et al.19 Fi
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Patients may transition from any health state to the absorbing death state. Patients in the 
acute revision TKA state spent a single cycle (1 year) in this state before transitioning to the 
following postoperative states. For the chronic states, after each evaluation cycle, patients 
may either transition to another state or remain in the same state for another year.
Model 2: Treatment of chronic patients 
The conceptual organization of the health states of model 2 is depicted in Figure 1B: 2 
acute states (partial meniscectomy and meniscus scaffold) and 4 chronic states. After each 
evaluation cycle (1 year), patients may either transition to another state or remain in the 
same chronic state for another year. Patients may transition from any health state to the 
absorbing death state. With the limited time frame in mind, half-cycle corrections were 
applied.
Populations under consideration
We applied the Markov decision models to a representative cohort of the population 
described in a randomized controlled trial by Rodkey et al.31 In their cohort, Rodkey et al31 
did not make a distinction between patients with either acute traumatic or degenerative 
meniscus injuries. Model 1 included all patients who had an irreparable injury to the 
medial meniscus (mean age, 39 years). Model 2 specifically included chronic patients who 
had an irreparable injury to the medial meniscus (mean age, 39 years). Chronic patients 
were those who experienced signs and symptoms attributed to the medial meniscus (eg, 
medial joint-line pain, swelling, locking, clicking, and catching) after they had undergone 
one or multiple prior surgical procedures on the involved meniscus.31 
Clinical data
Clinical data used in the models were derived from several population-based studies. 
If event probabilities were provided over a time period longer than 1 year, we calculated 
the 1-year probability of the event, assuming a fixed rate with respect to time.5 Mortality 
rates were obtained from the latest available United States life tables.3
Model 1: Prevention of osteoarthritis
 Radiographic knee osteoarthritis. Data on radiographic knee osteoarthritis were obtained 
from the study described by Rodkey et al.31 Although results on radiographic knee 
osteoarthritis were not reported in their published article, results were presented in the 
corresponding United States Food and Drug Administration (FDA) executive summary of 
the collagen scaffold proposal for marketing clearance (510(k)).7 Results presented in the 
FDA’s executive summary summarized the changes in the radiographic appearance for 
both the acute and chronic study arms over a study period of 2 years. Although several 
radiographic parameters were presented, we used the parameter ‘‘osteophyte formation’’ 
in our base case analysis. We adopted this parameter because osteophyte formation 
forms the basis of the Kellgren and Lawrence radiographic grading system, which is the 
most commonly used radiographic grading system of osteoarthritis.16,17 After standard 
partial meniscectomy, patients have a 33.0% risk to develop radiographic knee 
osteoarthritis, whereas after a meniscus scaffold procedure, patients have a 26.0% risk to 
develop radiographic knee osteoarthritis (Table 1).
 Symptomatic knee osteoarthritis. Following the example of Mather et al,21 the risk of 
developing symptomatic knee osteoarthritis for patients with radiographic knee 
osteoarthritis was derived from a longitudinal population- based cohort study of 
radiographic knee osteoarthritis and knee pain.24 Muraki et al24 reported a 21.1% prevalence 
of knee pain in patients with radiographic osteoarthritis at baseline and an incidence of 
25.0% over the next 3.3 years of the study. Accordingly, we assumed a 21.1% baseline rate 
of symptoms associated with radiographic knee osteoarthritis and an 8.0% annual 
increase in the rate of knee pain thereafter (Table 1).
 Total knee arthroplasty. Following the example of Mather et al,21 the risk of requiring 
TKA for symptomatic knee osteoarthritis was derived from data obtained from the United-
Healthcare database. The unitedHealthcare database suggested an annual conversion 
rate of approximately 2.3% on the basis of 2009 data showing that 12,806 patients 
underwent TKA with a coded diagnosis of osteoarthritis, while a total of 566,027 patients 
received a coded diagnosis of knee osteoarthritis.21 Following the example of Losina et al,19 
data on the long-term postoperative functional status in patients undergoing TKA, failure 
rates and revision rates were derived from longitudinal data of a national cohort of 
Medicare beneficiaries undergoing TKA14 (Table 1).
Model 2: Treatment of chronic patients 
 Outcomes in patients undergoing meniscus treatment. Data on outcomes after different 
meniscus treatment strategies were derived from the study described by Rodkey et al.31 
After 5 years of follow-up, 51% of the 69 chronic patients treated by standard partial 
meniscectomy, and 34% of the 85 chronic patients treated with the collagen scaffold, 
were not ‘‘very or somewhat satisfied’’ (limited benefit). This corresponds to annual rates 
of 13% and 8%, respectively (Table 1).
Quality of life estimates
The value assigned to health-related quality of life as applied to the economic evaluation 
of health-related interventions is formulated in terms of utility. Utility is the score attributed 
to a given health state, varying from perfect health (utility value = 1.00) to death (utility 
value = 0.00). The study by Rodkey et al31 did not report data on quality of life. Therefore, 
we derived estimates of quality of life for the postoperative health states after meniscus 
surgery from a randomized controlled trial that reported on the quality of life of patients 
postoperatively after routine arthroscopic partial meniscectomy.8 In model 1, patients 
were assigned a mean utility value of 0.81 postoperatively after meniscus surgery.8 
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Radiographic knee osteoarthritis was assigned the same utility value as its previous 
postoperative state, which was subsequently decreased if patients transitioned to 
symptomatic osteoarthritis (mean utility value = 0.70). Post-TKA utility values ranged from 
0.84 (for successful TKA) to 0.53 (for failed TKA)19 (Table 1). In model 2, patients were 
assigned a mean utility value of 0.81 postoperatively after meniscus surgery.8 Next, 
patients with a limited benefit after the meniscus procedures were assigned a quality 
of life approximated by the 25th percentile of the standard utility value of 0.81. To be 
conservative, we assigned the same utility values for both meniscus treatment strategies.
Costs 
Costs were calculated from a societal perspective using the costs accrued to society 
rather than to an individual hospital or practice. Resources were valuated according to the 
Dutch pharmacoeconomic guidelines.9 Data on absenteeism were derived from the Work 
Loss Data Institute.34 Direct medical costs related to arthroscopic partial meniscectomy, 
TKA, and revision TKA were obtained by using the standard reimbursement costs within 
the Radboud University Medical Center.26 Subsequently, indirect medical and (in-) direct 
nonmedical costs were added to obtain a final cost estimate per health state. Indirect 
medical and (in-) direct nonmedical costs were made up of costs from physical therapy, 
absenteeism, and traveling expenses. Moreover, the costs of early surgical revision 
procedures within the first year related to treatment failures were added by multiplying 
the risk for reoperation by the total costs. Productivity and medical costs of nonoperatively 
treated symptomatic knee osteoarthritis were derived from Hermans et al10 and represent 
the median costs made on a yearly basis. Currently, the meniscus implant procedure is not 
a standard treatment for meniscus injuries and, as a consequence, there is no standard 
reimbursement cost. Therefore, we calculated the costs based on resource utilization. For 
Table 1   Model parameters.
Parameter Base Value Distribution Source
Health state utilities, mean ± SE,  QALYs 
   Postoperative outcome  0.81 ± 0.02 Normal Goodwin 20039
   Symptomatic knee OA 0.70 ± 0.02 Normal Hermans 201211
   Full benefit after (revision) TKA 0.84 ± 0.00 Normal Losina 200920,  
Lingard 200419
   Limited benefit  after (revision) TKA 0.76 ± 0.01 Normal Losina 200920,  
Lingard 200419
   Failed TKA 0.53 ± 0.01 Normal Losina 200920,  
Hermans 201211
    Postoperative outcome,  
Limited benefit (Model 2)
0.73 ± 0.02 Normal Expert opinion
Transition probabilities, mean ± SE, % 
    Radiographic knee OA, meniscus 
scaffold (Osteophytes / JSN)
0.26 ± 0.05 /  
0.42 ± 0.06 
Beta FDA Executive  
summary 20088
    Radiographic knee OA, APM 
(Osteophytes / JSN)
0.33 ± 0.05 /  
0.32 ± 0.06 
Beta FDA Executive  
summary 20088
   Symptomatic OA baseline 0.21 ± 0.01 Beta Mather 200922;  
Muraki 201225
   Progression of Symptomatic OA 0.08 ± 0.01 Beta Mather 200922;  
Muraki 201225
   TKA for symptomatic OA 0.02 ± 0.00 Beta Mather 200922
   Limited benefit after TKA 0.12 ± 0.01 Beta Losina 200920;  
Katz 200716
   Late failure of TKA 0.01 ± 0.01 Beta Losina 200920;  
Katz 200716;  
Rand 200331
   Revision for failed TKA 0.50 Fixed Losina 200920
   Limited benefit after APM (Model 2) 0.13 ± 0.04 Beta Rodkey 200832
    Limited benefit after meniscus  
scaffold (Model 2)
0.08 ± 0.03 Beta Rodkey 200832
Costs (base value), €
   APM 5408 Fixed RadboudUMC,  
Table 2
   Meniscus scaffold 15,233 Fixed RadboudUMC,  
Table 2
   Symptomatic OA (incremental) 4932 Fixed Hermans 201211
   TKA 19,786 Fixed RadboudUMC
   Revision TKA 23,868 Fixed RadboudUMC
Table 1   Continued.
Parameter Base Value Distribution Source
Miscellaneous 
   Willingness-to-pay (€ per QALY gained) 20,000 Fixed Zwaap 201536
   Cost discount rate, % per year 4.0 Fixed Hakkaart-  
van Roijen 200910
   Effect discount rate, % per year 1.5 Fixed Hakkaart-  
van Roijen 200910
APM, arthroscopic partial meniscectomy; FDA, Food and Drug Administration; JSN, joint space narrowing; 
OA, osteoarthritis; QALY, quality-adjusted life-year; RUMC, Radboud University Medical Center; SE, standard 
error of the mean; TKA, total knee arthroplasty
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direct medical costs, the standard reimbursement for arthroscopic partial meniscectomy 
was used as a reference case, and additional costs associated with the implant procedure 
were added (eg, meniscus implant, meniscus sutures, longer duration of surgical 
procedure). With respect to treatment failures, we assumed identical surgical procedures 
(and resource utilization) after treatment failure for both treatment strategies: routine knee 
arthroscopic surgery with removal of either the failed implant or loose bodies after partial 
meniscectomy. Subsequently, indirect medical and nonmedical costs were added to 
obtain a final cost estimate. Resource utilization was determined by using supplementary 
information on the surgical procedure and postoperative rehabilitation as provided by the 
manufacturer of the meniscus implant (Ivy Sports Medicine)12,13 and expert panel 
consensus. An overview of resource utilization and costs for partial meniscectomy and the 
meniscus scaffold procedure is presented in Table 2.
Model assumptions
Where the data were limited, we used the following assumptions, ensuring a conservative 
approach. In both models, we assumed identical quality of life postoperatively after 
meniscus surgery for the 2 treatment strategies. In model 1, the aim of the implant is 
to prevent osteoarthritis. Assuming equal quality of life postoperatively for different 
treatment strategies implies that any difference in the final outcome (costs and 
effectiveness) can be attributed to differences in the pursued treatment effect (prevention 
of osteoarthritis). In model 2, the added value of the scaffold in treating symptoms and 
increasing quality of life is reflected in the difference in patients transitioning to the limited 
benefit health state. Patients who underwent partial meniscectomy were prescribed 
standard physical therapy, including full weightbearing and unrestricted range of motion 
postoperatively as tolerated (return to full activities already by 2-3 weeks postoperatively). 
According to information provided by the manufacturer, the rehabilitation protocol after 
collagen scaffold implantation aims for a slow progression to full activities by 6 months. 
This rehabilitation program encompasses a prolonged nonweightbearing and limited 
weightbearing period and restrictions in allowed range of motion postoperatively.12,31 
Considering the weight and consequences of this program, we assumed resource 
utilization of physical therapy and absenteeism after a meniscus scaffold procedure to 
be, at least, comparable as described for (rehabilitation after) anterior cruciate ligament 
reconstruction.12,21 With respect to model 1, we assumed that the ‘‘osteophyte formation’’ 
outcome measure representing the radiographic progression of osteoarthritic changes 
was the most appropriate determinant to represent the transition to radiographic knee 
osteoarthritis in our model. Next, also for model 1, by applying the model of Losina et al,19 
we also adopted their model assumptions: failed TKA (loosening of prosthesis) would 
result in a 25% reduction in quality of life and a 50% increase in costs compared with 
symptomatic knee osteoarthritis, and 50% of patients with late TKA failure would elect 
revision.19 In model 2, we ran the model for 5 years in the base case analysis; this was 
chosen because Rodkey et al31 presented results on the treatment effect in chronic 
patients after a mean follow-up of 5 years and because it is unclear what the course of this 
treatment effect will be over time in chronic patients. 
Table 2   Overview of Costs of a Meniscus Scaffold Procedure.
Resource (numerator) Cost per 
volume (€)
Volume
STANDARD
Volume
SCAFFOLD
Direct cost
      Standard DTC reimbursement for  
arthroscopic partial meniscectomy
1965† 1† 1†
     Additional surgery time (hours) 670† 0 0.75δ
      Sterilization of additional surgical equipment  
(No. packages)
11† 0 1 ф
     Collagen Meniscus Implant (No.) 2 120§ 0 1 ф
     Meniscus suture, all inside (No.) 251† 0 4 ф
     Meniscus suture, inside out (No.) 93† 0 1 ф
     Meniscus knot pusher (No.) 188† 0 1 ф
     Additional visits to outpatient clinic (No.) 72‡ 0 2δ
     Early reoperation procedure (risk) 5039δ 0.07Ω 0.07Ω
     Physical Therapy (No. visits) 36‡ 0 18δ 
      Physical Therapy traveling expenses  
(No. visits)
4‡ 0 18δ 
      Traveling expenses to and from hospital  
(No. visits)
6‡ 3† 5δ
     Crutches (No.) 13¥ 1† 1 ф
     Knee brace, adjustable (No.) 499¥ 0 1 ф
Indirect costs (Non medical cost)
     Absenteeism, productively loss (No. days) 217‡ 14 ε 35 ε
Total Costs (€) 5407 15,233
DTC =  Diagnosis treatment combination, Source:  † = Radboud University Medical Center; ‡ = Dutch 
pharmaco-economic guidelines10; ¥ = From qualified home care companies; § = iMove medical, national 
distributor of the collagen meniscus implant (CMI®); ф = Ivy Sports Medicine, company responsible for 
manufacturing the CMI®; ε = Work loss data institute; Ω = Rodkey et al32; δ = Expert opinion;   = Mather et al.21 
§ = iMove Medical (national distributor of Collagen Meniscus Implant)
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Base case analysis
For both models, probabilistic Monte Carlo simulations were applied and repeated over 
large numbers of samples (N = 100,000). Outcome measures were assessed from a societal 
perspective and reported on a present value basis using a 4.0% and 1.5% discount rate for 
costs and effects, respectively.9 Treatment effectiveness was expressed as quality-adjusted 
life-years (QALYs), and costs were estimated in euros. We expressed the comparative value 
in euros per QALY gained. The generally accepted willingness to pay per QALY gained 
varies between €10,000 and €80,000, depending on the burden of disease. Diseases 
with a higher burden of disease warrant a higher willingness to pay per QALY. Our models 
were developed around osteoarthritis and limited benefit after meniscus surgery; both 
are health states with a relatively low burden of disease (eg, compared with cardiac trans-
plantation). Therefore, in line with the recommendations by the Dutch health care 
authority, we assumed €20,000 as a reference value for the willingness to pay per QALY.36 
Next, for both models, we produced cost-effectiveness acceptability curves showing the 
chance of obtaining net benefits with a meniscus scaffold procedure compared with 
standard treatment at different willingness-to-pay thresholds based on the current 
efficacy data. Moreover, for both models, we created threshold efficacy curves showing 
the euros per QALY gained for the meniscus scaffold procedure over a range of different 
efficacies of the meniscus scaffold (presented as relative risk reductions). These curves 
show how effective a meniscus scaffold procedure should be (relative to standard 
treatment) to be considered cost-effective at any willingness to- pay threshold. The 
relative risk reduction was defined as the difference between the risks of an event 
(osteoarthritis in model 1 and limited benefit in model 2, respectively) between the 2 
treatment strategies, expressed as a percentage of the risk for the standard treatment 
strategy. 
Sensitivity analysis
In both models 1 and 2, we applied probabilistic Monte Carlo simulations, which took into 
account the relevant (second-order) uncertainty related to the sampling distribution of all 
the parameters. Next, we used deterministic 1-way probabilistic sensitivity analysis 
(systematically and deterministically varying 1 parameter at a time across intervals of 
interest) to identify the most influential variables on the cost-effectiveness of the scaffold 
and to illustrate the relative effect of each individual assumption on the cost-effectiveness 
of the procedure. In model 1, we tested the effect of wrongly assuming that ‘‘osteophyte 
formation’’ is the most appropriate determinant to use as the transition to radiographic 
knee osteoarthritis. For this purpose, instead of using osteophyte formation as the 
determinant for the transition to radiographic knee osteoarthritis, we also ran the model 
by adopting the ‘‘joint space narrowing’’ parameter as the determinant for the transition 
to radiographic knee osteoarthritis. We also ran model 1 on another population, patients 
with an acute traumatic meniscus injury, to be able to determine the threshold 
effectiveness of the meniscus scaffold in this target population. We used data from a 
systematic review by Paxton et al,28 who systematically reviewed the literature for 
long-term outcomes of partial meniscectomy in patients (age 630 years) with a traumatic 
meniscus tear. After a minimum 10-year follow-up, 37% of the 104 patients demonstrated 
radiographic changes related to osteoarthritis.28 Instead of running model 2 for 5 years, we 
also ran the model for a longer time period (10 years and lifetime, respectively).
Results
Base case analysis 
Model 1: Prevention of osteoarthritis
On the basis of the efficacy data from the study by Rodkey et al,31 the meniscus scaffold 
was associated with a projected quality-adjusted life expectancy of 23.69 years, compared 
with 23.58 years for patients undergoing standard treatment. Lifetime discounted costs 
varied from €23,660 per person for standard treatment to €29,651 per person undergoing 
the meniscus scaffold treatment. The incremental cost-effectiveness ratio of the meniscus 
scaffold treatment was €54,463 per QALY (Table 3). The acceptability curve, summarizing 
the information on uncertainty in the cost-effectiveness analysis, is provided in Figure 2A. 
On the basis of the current efficacy data, the meniscus scaffold provides a relative risk 
reduction of osteoarthritis of 0.21 relative to standard treatment. The threshold analysis 
revealed that assuming a willingness to pay of €20,000, the meniscus scaffold should at 
least offer a relative risk reduction of osteoarthritis of 0.34 compared with standard 
treatment to be considered cost-effective. To be dominant (eg, both more effective and 
less cost), the meniscus scaffold should offer a relative risk reduction of at least 0.54 (Table 3 
and Figure 3A).
Model 2: Treatment of chronic patients 
On the basis of the efficacy data from the study by Rodkey et al31 over a 5-year period, the 
meniscus scaffold procedure was associated with a projected quality-adjusted life 
expectancy of 3.82 years, compared with 3.79 years for patients undergoing standard 
treatment. Costs over this 5-year period varied from €5408 per person for standard 
treatment to €15,233 per person undergoing the meniscus scaffold treatment. The 
incremental cost-effectiveness ratio of the meniscus scaffold treatment was €297,727 per 
QALY (Table 3). The acceptability curve, summarizing the information on uncertainty in 
the cost-effectiveness analysis, is provided in Figure 2B. On the basis of the current efficacy 
data, the meniscus scaffold provides a relative risk reduction of limited benefit postopera-
tively of 0.37 compared with standard treatment. The threshold analysis revealed that 
assuming a willingness to pay of €20,000, the meniscus scaffold would not be cost-effective 
within a period of 5 years (Table 3 and Figure 3B).
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Sensitivity analysis
Model 1: Prevention of osteoarthritis
Results from the 1-way sensitivity analysis demonstrated that the greatest variation in the 
cost-effectiveness ratio was seen with changes in 2 parameters: the cost associated with 
the meniscus scaffold procedure and the cost associated with symptomatic osteoarthritis 
(Figure 4A). Increasing the incremental costs of symptomatic osteoarthritis from the 
median to its highest interquartile value (€14,400 annually compared with €4932 in the 
base case) resulted in the meniscus scaffold treatment being dominant (less cost and 
more effect). Decreasing the cost of the meniscus scaffold procedure by 33% (€10,160 
instead of €15,233; an absolute change of €5073) resulted in an incremental cost-effectiveness 
ratio of €7876 per QALY. Equal discounting of costs and effects by 3% resulted in an 
increased incremental cost-effectiveness ratio for the meniscus scaffold (€60,655 per 
QALY) (Figure 4A). If the model was run by using the ‘‘joint space narrowing’’ parameter as 
the determinant for the transition to radiographic knee osteoarthritis, standard treatment 
became dominant (less cost and more effect) over the meniscus scaffold procedure. If the 
model was used to determine the threshold effectiveness in a different target population 
(patients with an acute traumatic meniscus injury), results demonstrate that a meniscus 
scaffold should deliver a relative risk reduction of at least 0.30 relative to standard treatment 
Table 3   Base Case Analysis of the Cost-effectiveness of a Meniscus Scaffolda.
Threshold (RRR)
Treatment strategy Cost,  
mean ± SD
Effect,  
mean ±S D
ICER,  
mean
 Cost NMBb
Model I: Prevention of osteoarthritis (lifetime)
     Partial meniscectomy €23,660 ± 3028 23.58 ± 0.46 NA NA NA
     Meniscus scaffold €29,651 ± 2930 23.691 ± 0.48 €54,463 0.54 0.34
Model II: Treatment of symptoms in chronic patients (5 year)
     Partial meniscectomy €5408 3.79 ± 0.08 NA NA NA
     Meniscus scaffold €15,233 3.82 ± 0.08 €297,727 NAc NAc
a)  Costs are reported in euros and are discounted at 4.0% annually; effects are reported in quality-adjusted 
life-years (QALYs) and are discounted at 1.5% annually. ICER, incremental cost-effectiveness ratio (ratio of 
additional costs to additional benefits); NA, not applicable; NMB, net monetary benefit; RRR, relative risk 
reduction (compared with standard treatment).
b)  NMB was calculated as the total number of health effects (in this case, QALYs) multiplied by the willingness 
to pay (€20,000) per QALY minus the total costs.
c)  The threshold analysis revealed that assuming a willingness to pay of €20,000, the meniscus scaffold would 
never be cost-effective in the short term.
Figure 2   The cost-effectiveness acceptability curves for (A) model 1 (prevention of osteo-
arthritis) and (B) model 2 (treatment of chronic patients) showing the chance of 
obtaining net benefits with a meniscus scaffold strategy compared with standard 
treatment at different willingness-to-pay thresholds in patients with an irreparable 
meniscus injury.
A
B
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Figure 3   Threshold analysis of a meniscus scaffold procedure. Graphical representation 
of the incremental cost-effectiveness ratio (ICER; ratio of additional costs to 
additional benefits) for any given relative risk reduction on (A) model 1: development 
of osteoarthritis (meniscus scaffold vs standard treatment) and (B) model 2: 
treatment of chronic patients (meniscus scaffold vs standard treatment).
Figure 4   The tornado diagram presents the sensitivity analysis of potentially important 
model parameters for (A) model 1 (prevention of osteoarthritis) and (B) model 2 
(treatment of chronic patients). 
The bars represent ranges of incremental cost-effectiveness ratio values when the value of an indicated 
parameter is changed over the range shown in parentheses. As an example, in the base case, the analysis cost of 
the meniscus scaffold itself was €2120 and made up 14% of the total costs of the meniscus scaffold procedure 
from a societal perspective (Table 2). Reducing the cost of the meniscus scaffold itself by 25% to €1590 (ie, 
different retail price) had an effect of 3.5% of the total costs of the meniscus scaffold procedure from a societal 
perspective. The tornado diagram presents the results of what happens to the cost-effectiveness of the 
procedure if the total costs of the meniscus scaffold procedure decreased by 33%. So, the effect of solely 
decreasing the costs of the meniscus scaffold itself by 25% is about one-tenth of that effect presented in the 
tornado diagram. OA, osteoarthritis; QoL, quality of life; TKA, total knee arthroplasty.
A A
B B
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to be considered cost-effective. A relative risk reduction of 0.47 will make a meniscus 
scaffold dominant compared with standard treatment.
Model 2: Treatment of chronic patients 
Results from the 1-way sensitivity analysis demonstrated that the greatest variation in the 
cost-effectiveness was seen with changes in the model run time and quality of life of the 
limited benefit health state (Figure 4B). If the model was run for 10 years or for a lifetime 
period, the incremental cost-effectiveness ratio of the meniscus scaffold treatment was 
€107,967 and €36,936 per QALY, respectively. If we decreased the quality of life for the 
limited benefit health state to the lowest fifth percentile, the incremental cost-effectiveness 
ratio of the meniscus scaffold treatment was €118,373 per QALY. By decreasing the total 
costs of the meniscus scaffold procedure by 33%, the incremental cost-effectiveness ratio 
was reduced to €137,765 per QALY.
Discussion
Pursuing the prevention of osteoarthritis, results from model 1 demonstrated that the 
incremental cost-effectiveness ratio of a meniscus scaffold (ie, €54,463) was higher than 
our reference value of willingness to pay (ie, €20,000). On the basis of the current efficacy 
data, the meniscus scaffold provides a relative risk reduction for osteoarthritis of 0.21. 
The threshold analysis demonstrated that a meniscus scaffold should offer a relative risk 
reduction of at least 0.34 to become cost-effective, assuming a willingness to pay of 
€20,000. Pursuing the treatment of chronic patients, results from model 2 demonstrated 
that the incremental cost-effectiveness ratio of treatment with a meniscus scaffold 
(€297,727) was a plurality of willingness to pay per QALY (€20,000) within a 5-year period. 
On the basis of the current efficacy data, the meniscus scaffold provides a relative risk 
reduction of 0.37. The threshold analysis demonstrated that a meniscus scaffold procedure 
is not likely to become cost-effective within a period of 5 years. These results emphasize 
that the monetary value of meniscus scaffold procedures highly depends on a number 
of influential variables. Therefore, before implementing the technology in the health care 
system, it is important to critically assess these variables in the relevant context. Pursuing 
the prevention of osteoarthritis, the sensitivity analysis demonstrated that the meniscus 
scaffold procedure is more likely to become cost-effective when applied in a target 
population of patients with traumatic irreparable meniscus injuries. Next, both changes in 
the costs associated with knee osteoarthritis and the costs of the meniscus scaffold 
procedure had a relatively high influence on the cost-effectiveness of the scaffold. 
Meniscus scaffolds could be more strategically implemented if it is possible to target 
those patients who are most likely to generate high costs when they develop knee 
osteoarthritis. Pursuing the treatment of chronic patients, the sensitivity analysis 
demonstrates that it is paramount to gain more insight on how the treatment effect 
sustains over time and on what the quality of life is of chronic patients. For both treatment 
goals, the means to reduce costs accrued to society by meniscus scaffold procedures will 
have a positive effect on their cost-effectiveness. For example, there might be opportunities 
to refine the scaffold in such a way that faster tissue ingrowth is promoted or other means 
to increase the rate of rehabilitation and subsequently reduce the costs associated with 
absenteeism. 
Limitations of study
Some limitations that might hamper the interpretation of the obtained results and 
subsequent translation to the clinical setting have to be discussed. First of all, the models 
were limited to the medial meniscus only, hindering the extrapolation to lateral meniscus 
scaffold procedures. The progression from a meniscus injury to symptomatic osteoarthritis, 
and subsequently to TKA, is not straightforward. The radiographic progression of 
osteoarthritic changes may only occur in a subset of patients,28 not every patient with 
radiographic changes will experience symptomatic osteoarthritis,22,24 and the onset of 
clinical symptoms lags behind radiographic changes by another 5 to 10 years.24 Moreover, 
little published evidence exists to quantify the transition of symptomatic osteoarthritis to 
endstage osteoarthritis requiring TKA. However, using parts of other dedicated and 
published models improved the overall strength of our model.19,21 In our model, we 
adopted a willingness to pay of €20,000. The generally accepted willingness to pay per 
QALY gained varies between €10,000 and €80,000, depending on the burden of disease. 
We acknowledge that this value also varies substantially over different health care systems. 
Adopting a higher willingness to pay per QALY will decrease the minimal needed efficacy 
of the meniscus scaffold before it is considered to be cost-effective. By providing cost- 
effectiveness acceptability curves and threshold efficacy curves, it is possible to extrapolate 
results to situations in which a higher willingness to pay is adopted. Still, it remains 
necessary to critically look at the most influential variables to be able to increase the 
monetary value of using the meniscus scaffold. To evaluate the efficacy of the meniscus 
scaffold, we were limited to the use of experimental data from the study by Rodkey et al.31 
This study, which was funded by ReGen Biologics, is the only randomized controlled trial 
that has evaluated the efficacy of a meniscus scaffold compared with standard treatment. 
Although this study was published in 2008, the technology under consideration has not 
changed since, and the costs were valued from a current perspective. So, the time span 
between the trial and this health technology assessment did not invalidate the results of 
our model. Next, although the trial was not registered, additional data on the study design 
and supplementary results could be retrieved by consulting the FDA’s executive summary 
of the collagen scaffold proposal for marketing clearance (510(k)).7 Reviewing the original 
design and supplementary data revealed potential sources of bias that might well 
have overestimated the effect of the collagen scaffold. By taking into account relevant 
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(second-order) uncertainty related to the sampling distribution of the parameters in our 
models, we partly overcame this problem. The models can be improved as additional 
clinical data regarding the efficacy of the meniscus scaffold become available. Rodkey et 
al31 did not provide data on the quality of life of patients postoperatively after meniscus 
surgery. Therefore, we were forced to obtain these data elsewhere. Because data on 
quality of life for patients undergoing meniscus surgery are only provided scarcely in the 
literature, we used the data on quality of life from the randomized controlled study by 
Goodwin et al.8 This study was most appropriate for the data that we needed. Moreover, 
assuming equal initial postoperative quality of life for both treatment strategies implied 
that the results of the models were the consequence of the pursued treatment effect of 
the meniscus scaffold. In the FDA’s executive summary of the collagen scaffold proposal 
for marketing clearance (510(k)), radiographic progression of osteoarthritic changes was 
presented by the worsening of osteophyte formation and the worsening of joint space 
narrowing. In our base case analysis, we chose to use osteophyte formation as the 
determinant for the transition to radiographic knee osteoarthritis. The presence and 
number of osteophytes are the most defining parts of the Kellgren and Lawrence 
classification system, which is the most commonly used radiographic grading system for 
osteoarthritis.17 On the other hand, the assessment of loss of joint space on plain 
radiographs of the knee is assumed to be a validated measure of osteoarthritis progression 
and, as such, recommended for use in randomized clinical trials in osteoarthritis. However, 
the meniscus (both its position and degeneration) accounts for a substantial proportion 
of the variance and change explained in joint space narrowing.11 The removal and/or 
manipulation of meniscus tissue, inherent to the arthroscopic meniscus procedures under 
investigation, may thus influence the changes in joint space narrowing postoperatively. 
So, not all observed changes in this parameter may be attributed to the development of 
radiographic knee osteoarthritis. Therefore, we believe that osteophyte formation was the 
best parameter to use. Rodkey et al31 defined 2 populations: acute and chronic patients. 
Both make up for the results used in the radiographic evaluation of osteoarthritis. In their 
trial, Rodkey et al31 did not make the distinction between patients with either traumatic or 
nontraumatic (degenerative) meniscus tears. Traumatic tears tend to occur in younger 
active people (<40 years) and are caused by a serious traumatic injury, often while playing 
sport. Degenerative tears are typically seen in middle-aged or older people and often 
accompany knee osteoarthritis and are a part of the same disease process.6 Patients with 
a traumatic meniscus injury might be a better suited target population for the  prevention 
of osteoarthritis, whereas the possibility for the prevention, or forestalling, of osteoarthritis 
in patients with degenerative tears is less obvious. Moreover, it is disputed whether 
arthroscopic surgery should be the standard treatment procedure for this population at 
all.6 To maximize the monetary value of applying a meniscus scaffold, it might be better 
suited to apply a meniscus scaffold in patients with traumatic medial meniscus tears. 
Indeed, our sensitivity analysis demonstrated that the meniscus scaffold is more likely to 
become cost-effective in this target population (the relative risk reduction needed for the 
meniscus scaffold to become cost-effective was lower in this population compared with 
the base case analysis). Currently, the meniscus scaffold procedure is not a standard 
treatment for meniscus injuries, and there is no clear view on total resource utilization. 
Based on the information as provided by the manufacturer, it was possible to make a 
thorough estimation of resource utilization that makes up the direct medical costs. 
Resource utilization was valuated according to the Dutch pharmacoeconomic guidelines. 
Still, some cost estimates were institutional, and we acknowledge that these may vary 
from one institution to another. Nevertheless, we believe that our estimate provided a 
sound basis for the base case analysis. Compared with the direct medical costs, mapping 
of the indirect costs was more difficult. We assumed the duration of absenteeism after the 
meniscus scaffold procedure to be comparable with anterior cruciate ligament 
reconstruction, which shares similarities in rehabilitation.21 For patients undergoing a 
collagen scaffold procedure, the return to full normal function is much later than for 
patients undergoing standard treatment. This assumption is well recognized by the study 
sponsor.7 Rehabilitation after a collagen scaffold procedure is designed to allow the 
implant to stabilize in place, supporting tissue ingrowth by providing a protective non-
weightbearing environment with passive motion for a period of 1 week followed by 5 
weeks of partial weightbearing with passive motion to a slow progression to full activities 
by 6 months. In contrast, the rehabilitation program for standard treatment included only 
standard physical therapy, including full weightbearing and unrestricted range of motion 
postoperatively (return to full activities already by 2-3 weeks postoperatively), because 
there is no period of ‘‘meniscus healing’’ required.7 This difference in the time to return to 
full activities justified the difference in absenteeism between the 2 treatment strategies.
Conclusion 
Meniscus scaffold procedures are currently evaluated for the prevention of osteoarthritis 
as well as the treatment of chronic symptoms in patients with irreparable medial meniscus 
injuries. Results of the current health technology assessment suggest that these treatment 
strategies should currently not be implemented on a large scale in the health system. 
However, we identified the most influential variables (cost of the scaffold procedure and 
quality of life before and after the scaffold procedure) that could be addressed to increase 
the monetary value of meniscus scaffold procedures.
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Abstract 
Background: The selective reporting of a subset of the outcomes that had been originally 
reported to a registry is a potential threat to the validity of evidence-based medicine. The 
extent of selective reporting has not been described for randomized controlled trials 
(RCTs) assessing the effectiveness of orthopaedic surgical interventions. The objective of 
this study was (1) to determine the  percentage of orthopaedic surgical RCTs published in 
high-impact orthopaedic journals that were reported to have been registered, (2) to 
evaluate the consistency between the primary outcome measures recorded in the registry 
and those reported in the article, and (3) to evaluate whether selective reporting favored 
statistically significant outcomes. 
Methods: We searched PubMed for articles on RCTs assessing orthopaedic surgical 
interventions indexed from January 2010 through December 2014 and published in the 
ten orthopaedic journals with the highest impact factors. For every article in which the 
authors reported registration of the RCT, we extracted the number and nature of the 
outcome measures from the article and the corresponding information from the registry. 
We then evaluated the consistency between the primary outcome measures reported in 
the registry and those reported in the published article. Moreover, we evaluated whether 
selective reporting favored statistically significant outcomes.
Results: Of the 362 articles on orthopaedic surgical RCTs, ninety (24.9%) reported that 
the RCT had been registered and thirtyfour (37.8%) of the ninety had been registered 
adequately (registered before the study end with a clear description of the primary 
outcome measure and its time frame, with no substantial change after the study end). 
Twenty-six reports were eligible for our evaluation of the consistency between the 
registered primary outcome measures and those reported in the published article. This 
analysis identified one or multiplemajor discrepancies for fourteen articles, eight of which 
favored statistically significant results. 
Conclusions: Few articles on orthopaedic surgical RCTs reported registration of the trial, 
and even fewer of these trials were registered adequately. Inconsistencies between 
registered primary outcome measures and those reported in the published articles, as 
well as selective outcome reporting favoring statistically significant outcomes, were 
prevalent. 
Introduction
Randomized controlled trials (RCTs) are regarded as the best means of obtaining evidence 
in support of or against specific treatment strategies. Traditionally, orthopaedic research 
has focused on retrospective cohort studies, and orthopaedic surgeons (like other 
surgeons) have often been criticized for not adhering to scientific standards and for 
ignoring RCTs as the best methodology for evaluating the effectiveness of treatment 
strategies.1-5 However, orthopaedic investigators are increasingly adopting the principle of 
random allocation in clinical research.6 In an effort to encourage the implementation of 
evidence-based medicine in the daily practice of the orthopaedic scientific community, 
initiatives have been taken to promote and improve performance of RCTs.7-9
 Despite being considered the best means of obtaining evidence, even RCTs are at risk 
for bias. Two important potential sources of bias are publication bias and outcome 
reporting bias. Publication bias is introduced by not submitting or publishing reports 
because of the direction and magnitude of the results of a trial.10,11 Selective reporting of 
a subset of the originally defined outcome measures on the basis of their results is known 
as outcome reporting bias. Selective reporting of results is a potential threat to the validity 
of evidence-based health care: first, because it increases the prevalence of false-positive 
results, and second, because subsequent systematic reviews and meta-analyses using 
these false-positive results tend to overrate treatment effects. The worst possible situation 
for patients, health-care professionals, and policy-makers is when ineffective or harmful 
interventions are promoted. It is also a problem when expensive therapies that are 
thought to be better than cheaper alternatives are not truly superior.10,12,13 In 2005, the 
International Committee of Medical Journal Editors (ICMJE) initiated the policy that 
member journals require investigators to register their trial in a public trials registry before 
the onset of patient enrollment as a condition for consideration for publication.14,15 
The main objective of trial registration is to achieve full transparency with respect to 
performance and reporting of clinical trials.16,17 Complete transparency allows exploration 
of the full range of clinical evidence and decreases the risk of selective outcome reporting 
and publication bias. Although outcome reporting bias has been investigated for general 
medicine18 and for general surgical interventions,19 it has not been evaluated for 
orthopaedic surgical RCTs to our knowledge. It is important for the orthopaedic scientific 
community to be aware of selective reporting, both for correct interpretation of results 
from RCTs and to ensure a sound basis for quality improvement. The objective of this 
study was threefold: (1) to determine the percentage of orthopaedic surgical RCTs 
published in high-impact orthopaedic journals that were reported to have been 
registered, (2) to evaluate the consistency between the primary outcomemeasures 
published in the registry and those reported in the article, and (3) to evaluate whether 
selective reporting favored statistically significant outcomes.
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Materials and methods
Search Strategy and Selection of Studies 
On February 23, 2015, we searched PubMed for original articles concerning RCTs assessing 
orthopaedic surgical interventions. We combined the Cochrane search strategy for 
identifying RCTs with a search for all subheadings and entries categorized as either 
“orthopedic surgical procedures,” or “surgical procedures” combined with “musculo-
skeletal system.” This strategy was developed in collaboration with information specialists 
from the medical library of the Radboud University Medical Center, Nijmegen, the 
Netherlands. We limited our search to a five-year period from January 1, 2010, through 
December 31, 2014. Next, the search results were limited to the ten journals with the 
highest impact factors in the “orthopedics” subject category, according to the Institute for 
Scientific Information Web of Knowledge (2013). The detailed search strategy is provided 
in the Appendix. During the initial screening phase, articles on primary RCTs assessing an 
orthopaedic surgical intervention were selected on the basis of their title and abstract 
only (unless there was insufficient information with which to make a valid judgment, in 
which case the entire publication was evaluated). An orthopaedic surgical intervention 
was defined as a surgical procedure, conducted in an operating theater by an orthopaedic 
surgeon, used to treat and correct any deformity, disease, and/or injury to the musculo-
skeletal system, its articulations, and/or associated structures. A surgical intervention was 
defined as a physical intervention on tissue, involving cutting tissue or closure of a 
previously sustained wound. An RCT assessing an orthopaedic surgical intervention was 
defined as a comparative study designed to test the efficacy or effectiveness of an 
orthopaedic surgical intervention with random allocation of participants to an orthopaedic 
surgical intervention in at least one study arm. After the initial screening, full-text copies 
of all articles eligible for inclusion were reviewed. Articles not explicitly reporting trial 
registration were excluded from further analysis. If only a registration number without a 
corresponding trial registry or a trial registry without a corresponding number was 
provided, we manually searched for the corresponding trial registry or corresponding 
number, respectively. The “instructions for authors” of the selected journals were searched 
for an explicit request for trial registration in a public trials registry as a condition for 
consideration for publication and to determine whether authors were being referred to 
the ICMJE guidelines on trial registration. 
Data Extraction 
In addition to the bibliographic details, the following information was extracted from the 
article and entered into a standardized extraction form: orthopaedic subspecialty, funding 
source, registry, registration number, whether it was explicitly stated that the article was 
reporting an ancillary analysis or follow-up of an earlier reported RCT, nature and number 
of reported outcome measures, and study time frame. Primary outcome measures were 
outcome measures explicitly described as primary in the published article. If no outcome 
was explicitly described as primary, we assumed that the outcome measure stated in the 
sample size calculation was the primary outcome measure. If both were absent, the 
published article was considered to have not reported a primary outcome. Next, for each 
registered trial, the following information was extracted from the registry: registration 
date, current status, onset of participant enrollment, primary completion date (e.g., date of 
final collection of data for the primary outcome), nature and number of the reported 
outcome measures with their time frame for data collection, and registered changes in 
outcome measures with corresponding dates. 
Data Analysis
Data analysis started with identification of the number of reports on orthopaedic surgical 
RCTs in which the authors stated that the trial had been registered. Subsequently, to allow 
for objective and unbiased evaluation of the consistency between registered primary 
outcome measures and those reported in the published articles, we included only 
adequately registered trials—i.e., those registered before the study end with a clear 
description of the primary outcome measure(s) and the time frame during which they 
were evaluated and without clear changes in the primary outcome measure(s) after the 
study end. Trials registered after the study end were excluded because the trial could have 
been registered after data analyses, allowing selective registration of certain outcome 
measures dependent on the outcome direction. Trials with clear changes in the registered 
primary outcome measure(s)—i.e., those in which the current registered outcome 
measure( s) were clearly different from the previous registered primary outcome measure(s) 
after the study end—were excluded because those changes could have been made after 
data analysis, again allowing selective changes of certain outcome measures dependent 
on the outcome direction. Trials with imprecise outcome registration were also excluded 
because this impeded objective evaluation of inconsistencies with reported primary 
outcome measures18. Outcome registration was classified as “imprecise” if an inconsistency 
between the registered and reported primary outcome measures was the consequence 
of a less accurate description of the outcome measure in the trial registry compared with 
that reported in the article (e.g., primary outcome measures reported as “safety” and 
“preliminary efficacy” of an orthopaedic implant in the registry but expressed in the paper 
in terms of therapeutic “responders” versus “nonresponders” based on a change in the 
KOOS [Knee injury and Osteoarthritis Outcome Score] pain score of ≥12 points and a 
change in the IKDC [International Knee Documentation Committee] function score of ≥20 
points). In addition to inadequately registered trials, articles that did not define a primary 
outcome measure were excluded from further analyses because this lack made it 
impossible to evaluate the consistency between the primary outcome measure reported 
in the article and the registered primary outcome measure. In addition, studies that were 
explicitly reported to be an ancillary analysis or a follow-up of an earlier reported RCT were 
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excluded because such reports clearly inform readers of the intention to describe results 
that are different from their original primary outcome within its original time frame. Finally, 
to prevent the possibility of assigning too much weight to inconsistencies of one 
registered trial, we included only the first trial report if more than one article reported the 
results of one RCT. For the included trial reports, we evaluated the primary outcome 
measure(s) registered in the trial registry and those reported in the published article for 
consistency. Outcome measures were classified as inconsistent if they were obviously 
different (e.g., an IKS [International Knee Society] score versus loss of blood) or had been 
evaluated at different time points (e.g., pain at six months versus pain at one week). 
Subsequently, these discrepancies were classified according to a modification of the 
classification system of Chan et al.13,18 (1) the primary outcome in the trial registry was 
reported as a secondary outcome in the published article, (2) the primary outcome in the 
trial registry was absent in the published article, (3) a new primary outcome (not registered in 
the registry) was introduced in the published article, (4) the primary outcome reported in 
the published article was described as a secondary outcome in the registry, and (5) the 
time frame of assessment of the published and registered primary outcome measures 
differed (Table 1). If the registry contained more than one primary outcome, we used 
these  definitions to classify each. Each primary outcome that was considered to be a 
discrepancy, and each clear change in the registered outcome after the study end, was 
confirmed by the two of us, and disagreements were resolved by consensus. Next, we 
assessed whether these discrepancies favored significant results, using the classification 
system of Chan and Altman for this purpose.16 We extracted the p values from the articles 
for both the registered primary outcome measures and the primary outcome measures 
reported in the article. A discrepancy was considered to favor significant results when (1) 
a new significant primary outcome was introduced in the article, or (2) a non-significant 
registered primary outcome was omitted or defined as nonprimary in the article. 
Results 
The search strategy retrieved 1266 unique records (Figure 1), and the subsequent selection 
procedure identified 362 RCTs of orthopaedic surgical interventions. The majority of the 
journals provided explicit requests for trial registration in their instructions to authors 
(Table II). However, the content of these requests for registration was not uniform, and 
only a minority of the journals explicitly referred to the ICMJE guidelines for trial registration 
(Table 2). The orthopaedic subspecialties of the identified articles were arthroplasty 
(47.8%), sports (23.3%), trauma (16.7%), spine (5.6%), hand/upper extremity (4.4%), foot/
ankle (1.1%), and oncology (1.1%). Ninety (24.9%) of the 362 identified articles reported trial 
registration (Table 3). The status of the trial was recorded in the registry as completed 
(68.9%), active but not recruiting (15.6%), recruiting (7.8%), terminated (4.4%), not reported 
(1.1%), withheld (1.1%), or recruitment planned (1.1%).
 Of the ninety trials that were reported in the articles as having been registered, 
forty-two (46.7%) were registered before the end of the trial and only twelve (13.3%) 
were registered within the appropriate time frame specified by the ICMJE (e.g., before 
enrollment of the first participant). Year-by-year analysis demonstrated a modest 
improvement in the rate and timing of registration during the five years from2010 to the 
end of 2014 (Table 4). Evaluation of the forty-two trials that had been registered before the 
end of the trial showed clear changes in the primary outcome measures after the study 
end in four of them and imprecise outcome registration in four others. Altogether, 
thirty-four (37.8%) of the ninety trials that were reported in the article as having been 
registered had been adequately registered. Eight of these articles were excluded from 
the evaluation of the consistency between reported and registered primary outcome 
measures because, in seven, the authors had explicitly reported the results of an ancillary 
analysis or a follow-up of an earlier reported RCT and, in one, the authors had not explicitly 
Table 1   Examples of Discrepancies Between Primary Outcome Measures Reported in 
Registry and Published Article*.
Discrepancy Example
Registered primary 
outcome reported as 
secondary outcome  
in article
In trial about fracture treatment, registered primary outcome 
“time to healed fracture” was reported as a secondary outcome 
in published article. (WOMAC [Western Ontario and McMaster 
Universities Arthritis Index] hip function scores reported as primary 
outcome measure in published article)
Registered primary 
outcome omitted  
in article
In trial about total knee arthroplasty, registered primary outcome 
“International Knee Society score” was omitted in published article. 
(Blood loss reported as primary outcome measure in published article)
New primary outcome 
introduced in article
In trial about shoulder arthroplasty, a primary outcome “muscle 
strength” that had not been prespecified in registered protocol 
was introduced in published article. (Quality of life postoperatively 
was prespecified as primary outcome in registered protocol)
Published primary 
outcome described as 
secondary outcome  
in registry
In trial about rotator cuff repair, primary outcome “tendon healing” 
reported in published article was described as a secondary 
outcome in registered protocol. (Primary outcomes in registered 
protocol included two standardized shoulder outcome scales)
Different timing of 
assessment of primary 
outcome
In trial about fracture treatment, primary outcome “pain” was 
assessed at 3 and 12 mo in published article while it was 
prespecified that pain be assessed at 1 wk in registered protocol
*Specific details of primary outcome measures were omitted to maintain anonymity. In addition to the 
example of each discrepancy, information is provided in italics in the parentheses to support interpretation 
of the discrepancies.
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reported a primary outcome. In total, twenty-six trial reports were eligible for evaluation 
of the consistency between the primary outcome measure(s) registered in the registry 
and those reported in the published article. Of these twenty-six reports, fourteen (53.8%) 
were identified as having one or more discrepancies, eight of which favored significant 
results (Table 4).
Figure 1   Flowchart of article selection, reported trial registration, and comparison of 
published and registered primary outcome measures.
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Discussion
Our results demonstrated inadequate registration of orthopaedic surgical RCTs and 
prevalent selective outcome reporting in articles on orthopaedic surgical RCTs. In general, 
our results are in accordance with those of other studies, in other therapeutic areas, that 
also described considerable discrepancies in primary outcome measures between trial 
registries and/or trial protocols and published articles.18-21 One of us (G.H.) and colleagues 
reported an overall registration rate of 218 (66.7%) of 327 identified surgical RCTs.19 Of the 
218 registered trials, 152 (69.7%) were adequately registered and seventy-five (49.3%) of the 
152 were identified as having one or more major discrepancies between registered and 
reported primary outcome measures; twenty-one (28.0%) of the seventy-five favored 
significant results. Mathieu et al. reported an overall registration rate of 234 (72.4%) of 323 
identified RCTs in cardiology, rheumatology, and gastroenterology.18 Of the 234 registered 
trials, 147 (62.8%) were adequately registered and forty-six (31.3%) of the 147 were identified 
as having one or more major discrepancies between registered and reported primary 
outcome measures; nineteen (41.3%) of forty-six favored significant results. In our study, 
only twelve (13.3%) of the ninety orthopaedic surgical RCTs that were reported in the 
article as having been registered had been registered within the appropriate time frame 
specified by the ICMJE (e.g., before enrollment of the first participant). Califf et al. examined 
fundamental characteristics of interventional clinical trials in three major therapeutic areas 
Table 3   Characteristics of the Ninety Trials Reported in Article as Being Registered.
No. papers 90
Median 5-Year Impact factor [Range] 3.45 [2.9 ; 5.0]
Registry *, (No (%))
ClinicalTrials.gov 63 (70.0)
ISRCTN registry 11 (12.2)
ANZCTR 6 (6.7)
Dutch Trial Register 4 (4.4)
Other 6 (6.7)
Funding source, (No (%))
Not reported 13 (14.4)
No funding 22 (24.4)
Government, university, hospital, or association 23 (25.6)
Industry 32 (35.6)
Orthopedic subspeciality, (No (%))
Arthroplasty 43 (47.8)
Sports 21(23.3)
Trauma 15 (16.7)
Spine 5 (5.6)
Hand/upper extremity 4 (4.4)
Foot/ankle 1 (1.1)
Oncology 1 (1.1)
*ISRCTN = International Standard Randomised Controlled Trials Number, and ANZCTR = AustralianNew 
Zealand Clinical Trials Registry.
Table 5   Differences Between Primary Outcome Measures in Trial Registry and 
Published Article and Discrepancies Favoring Significant Results.
RCTs registered before study end ((no. [% of RCTs reported registered])) 42 (46.7)
RCTs adequately registered (no. [% of RCTs reported registered]) 34 (37.8)
Adequately registered RCTs eligible for analysis (no. [% of RCTs reported registered]) 26 (28.9)
Median reported primary outcome measures (range) (no.) 1 [1-3]
Median registered primary outcome measures (range) (no.) 1 [1-3]
RCTs with inconsistencies between primary outcome measure in registry and 
published article report (no. [% of adequately registered RCTs eligible for analysis])
14 (53.8)
  1. Registered primary outcome reported as secondary outcome in article, No. 9
  2. Registered primary outcome omitted in article, No. 2
  3. New primary outcome introduced in article, No. 5
  4. Published primary outcome described as secondary outcome in registry, No. 1
  5. Different timing of assessment of primary outcome, No. 4
Discrepancies in primary outcome favoring significant results (no. [% of trials with 
inconsistencies])
8 (57.1)
Table 4   Year-by-Year Analysis of RCT Registration Rates.
Year RCTs (No.) Reported  
registration   
(No. (%))
Registration  
before study end 
(No. (%))
2010 64 11 (17.2%) 2 (3.1%)
2011 71 14 (19.7%) 7( 9.9%)
2012 78 23 (29.5%) 9 (11.5%)
2013 68 19 (27.9%) 10 (14.7%)
2014 81 23 (28.4%) 14 (17.3%)
Total (2010-2014) 362 90 (24.9%) 42 (11.6%)
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included in the ClinicalTrials.gov registry (cardiovascular, mental health, and oncology).22 
They reported that, from October 2004 to September 2012, only 41.7% (28,388) of 68,000 
trials were registered before enrollment of the first participant. Our study has limitations. 
First, by excluding all articles in which trial registration had not been explicitly reported in 
the text, we potentially missed trials that had been registered even though the authors 
did not report this in the article. Second, only adequately registered trials could be 
included in our evaluation of consistency between the registered and published primary 
outcome measures. It was not possible to compare published primary outcome measures 
with primary outcomes reported to the research ethics committees for inadequately 
registered trials. Third, we focused on the orthopaedic journals with the highest impact 
factors. Most of these journals required trial registration as a condition for consideration 
for publication in their instructions for authors. Consequently, our results might well 
overestimate the proportion of registered trials and underestimate selective outcome 
reporting for orthopaedic surgical trials. Fourth, the included orthopaedic journals might 
not have endorsed guidelines in line with the ICMJE recommendations immediately after 
they were published in 2005. This might have led to improvement in the number of 
adequately registered trials beginning after 2005 because researchers, authors, peer 
reviewers, and editors were more likely to be aware of clinical trial registration policy. This 
was indeed demonstrated by our year-by-year analyses, although rates of improvement 
were only modest. Even journals that required adequate trial registration before 
submission did not have a 100% rate of trial registration. This might be explained in part 
by a time lag in adopting requirements for trial registration by the journal and unclear 
language in the instructions for authors. It may also signal that peer reviewers and editors 
do not flawlessly monitor adherence to their own reporting guidelines. Our results 
highlight several issues and demonstrate a need for improvement in adequate registration 
of orthopaedic surgical trials. First, all orthopaedic journals should require, as a condition 
for consideration for publication, trial registration as defined by the ICMJE, including 
provision of the minimum twenty-item trial registration data at the time of registration, 
before enrollment of the first participant in a trial. Next, journals should be clear in 
communicating this policy in their instructions to authors. There is nothing inherently 
wrong with amendments and/ or changes in a registered trial based on sound arguments. 
However, any such amendments and/or changes and their justifications should be 
transparently discussed by the authors so that editors, reviewers, and subsequently 
readers can judge their legitimacy. Last, to obtain the full benefit of clinical trial registration, 
there must be active participation by different stakeholders (principal investigators, 
sponsors, editors, peer reviewers, and readers), who must routinely check the comprehen-
siveness and consistency of the registration and publication. In conclusion, although trial 
registration is now the rule, it is currently far from optimal for orthopaedic surgical RCTs 
and selective outcome reporting is prevalent. Full involvement of authors, editors, and 
reviewers is necessary to ensure publication of quality, unbiased results.
Appendix
The search strategy used in this study is available as a supplement 
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Appendix 1  Search strategy.
Search Strategy:
((Orthopedic surgical procedures) OR (Surgical procedures AND Musculoskeletal System))
AND 
(Randomized controlled trials)
AND  
(Top ten orthopaedic journals)
AND
Filters: Publication date from 2010/01/01 to 2014/12/31
Orthopedic 
surgical 
procedures
(Orthopedics [Mesh] OR Orthopedic Procedures [Mesh] OR orthopaedic 
[tiab] OR orthopedics [tiab] OR orthopaedics [tiab]  OR orthopedic [tiab] 
OR ((Bone [tiab] OR bones [tiab] OR bony [tiab]) AND (Transplant [tiab] 
OR Transplantation [tiab] OR Transplantations [tiab] OR graft [tiab] OR 
grafting [tiab] OR graftings [tiab])) OR ((bone [tiab] OR bones [tiab]) AND 
Lengthening [tiab] OR  Lengthenings [tiab])) OR ((Capsule [tiab] OR 
capsular [tiab]) OR contracture [tiab]) AND Release [tiab]) OR ((fixators 
[tiab] OR fixation [tiab] OR fixator [tiab]) AND (external [tiab] OR internal 
[tiab] OR intramedular [tiab])) OR ((Fracture [tiab] OR Fractures [tiab] OR 
fractured [tiab]) AND (Fixation [tiab] OR Fixations [tiab] OR treatment 
[tiab] OR treated [tiab] OR treatments [tiab])) OR ((Osteogeneses [tiab] 
OR Osteogenesis[tiab]) AND Distraction [tiab])) OR ((Replacement [tiab] 
OR Replacements [tiab]) AND joint [tiab] OR prosthesis [tiab] OR hip 
[tiab] OR knee [tiab] OR ankle [tiab] OR elbow [tiab] OR finger [tiab]))  OR 
(Heel-Cord [tiab] AND (Release [tiab] OR releases [tiab])) OR (limb [tiab] 
AND Salvage [tiab]  ) OR (Tendon [tiab] AND (Release [tiab] OR releases 
[tiab] OR Lengthening [tiab] OR Lengthenings [tiab])) OR (Tendon [tiab] 
AND (Transfer [tiab]  OR Transfers [tiab])) OR acetabuloplasties [tiab] OR 
Acetabuloplasty [tiab] OR Amputation [tiab]  OR Amputations [tiab]  OR 
Arthrodesis [tiab] OR Arthroplasties [tiab]  OR Arthroplasty [tiab]  OR 
Arthroscopic [tiab] OR Arthroscopical [tiab] OR Arthroscopically [tiab] 
OR Arthroscopies [tiab] OR Arthroscopy [tiab] OR Callostases [tiab] OR 
Callotasis [tiab] OR Cementoplasties [tiab] OR Cementoplasty [tiab] OR 
Disarticulation [tiab]  OR Disarticulations [tiab]  OR Discectomies [tiab]  
OR Discectomy [tiab]  OR Diskectomies [tiab]  OR Diskectomy [tiab]  OR 
Hemiarthroplasties [tiab] OR Hemiarthroplasty [tiab]  OR hemipelvectomies 
[tiab] OR Hemipelvectomy [tiab] OR Ilizarov [tiab]  OR ((Intramedullar 
[tiab] OR  Intramedullary [tiab]) AND (Nailing [tiab] OR nailings [tiab])) OR 
Kyphoplasty [tiab]  OR Meniscectomies [tiab] OR Meniscectomy [tiab] 
OR Mosaicplasty [tiab] OR Osteoplasties [tiab] OR Osteoplasty [tiab] OR 
Osteosynthesis [tiab] OR Osteotomies [tiab] OR Osteotomy [tiab]  OR 
Prostheses [tiab] OR Prosthesis [tiab] OR spinal Fusion [tiab] OR spinal 
fusions [tiab] OR Spondylodeses [tiab] OR Spondylodesis [tiab] OR 
Spondylosyndeses [tiab] OR Spondylosyndesis [tiab] OR Tenodesis [tiab] 
OR Tenotomies [tiab] OR Tenotomy [tiab]   OR Traction [tiab]   OR Tractions 
[tiab]   OR Vertebroplasties [tiab] OR Vertebroplasty [tiab])
Appendix 1  Continued.
Surgical 
procedures
(surgical procedures, operative[MeSH] OR operative [tiab] OR surgery [tiab] 
OR surgical [tiab] OR surgeries [tiab] OR surgically [tiab] OR operatively 
[tiab])
Musculoskeletal 
System
(Musculoskeletal System [Mesh]  OR Acetabula [tiab] OR acetabular [tiab] 
OR Acetabulas [tiab] OR Acetabulum [tiab] OR Acetabulums [tiab] OR 
Achilles [tiab] OR ACL [tiab] OR Acromioclavicular [tiab]  OR Acromion [tiab] 
OR acromions [tiab] OR ankle  [tiab]  OR ankles [tiab] OR arm [tiab] OR arms 
[tiab] OR Atlantoaxial [tiab] OR atlanto-axial [tiab]  OR atlanto-occipital [tiab] 
OR atlas [tiab] OR Atloido-Occipital [tiab] OR axis [tiab] OR bone [tiab] OR 
bones [tiab] OR bony [tiab] OR bursa [tiab]  OR bursas [tiab]  OR calcaneal 
[tiab] OR calcaneus [tiab] OR capitate [tiab] OR Capitatum [tiab] OR Capsula 
[tiab] OR capsular [tiab] OR capsule [tiab]  OR capsules [tiab]  OR carpal 
[tiab]  OR carpo [tiab] OR carpo-metacarpal [tiab] OR carpometacarpal 
[tiab]  OR Cartilage [tiab] OR Cartilages [tiab] OR cervical [tiab] OR cervically 
[tiab] OR clavicle [tiab] OR clavicles [tiab] OR clavicular  [tiab] OR coccyx 
[tiab] OR Cotyloid [tiab] OR coxa [tiab] OR coxas [tiab] OR Cuboid [tiab] 
OR Cuneiform [tiab] OR Dens Axis [tiab] OR diaphyses [tiab] OR Diaphysis 
[tiab] OR elbow [tiab]  OR elbows [tiab]  OR Epiphyseal {tiab] OR epiphyses 
[tiab] OR Epiphysis [tiab] OR extremities [tiab] OR extremity [tiab] OR Fascia 
[tiab]  OR Fascias [tiab]  OR feet [tiab] OR femoral [tiab] OR Femoropatellar 
[tiab] OR Femoro-patellar [tiab] OR femur [tiab] OR Fibrocartilage [tiab] 
OR Fibrocartilages [tiab] OR fibula [tiab] OR fibular [tiab] OR fibulas [tiab] 
OR finger [tiab]  OR fingers [tiab] OR foot [tiab]  OR genu [tiab] OR genus 
[tiab] OR Glenohumeral [tiab] OR gleno-humeral [tiab] OR glenoid [tiab] 
OR Glenoidal [tiab] OR growth plate [tiab] OR growth plates [tiab] OR 
hamate [tiab] OR Hamatum [tiab] OR hand [tiab]  OR hands [tiab] OR hip 
[tiab]  OR hips [tiab] OR humeral [tiab] OR humerus  [tiab] OR hyoid  [tiab] 
OR ilium [tiab] OR iliums [tiab] OR Intertarsal [tiab] OR intertarsales [tiab] OR 
intertarseae [tiab] OR intervertebral[tiab] OR intervertebreal [tiab] OR ischial 
[tiab] OR ischium [tiab] OR ischiums [tiab] OR joint [tiab] OR joints [tiab] OR 
knee [tiab]  OR knees [tiab] OR leg [tiab] OR legs [tiab] OR Ligament [tiab] 
OR ligamental [tiab] OR Ligaments [tiab] OR Ligamentum [tiab] OR limb 
[tiab] OR limbs [tiab] OR lumbar  [tiab] OR lunate [tiab] OR Lunatum [tiab] 
OR Meniscal [tiab] OR Menisci [tiab] OR Meniscus [tiab] OR metacarpal 
[tiab] OR Metacarpals [tiab] OR Metacarpophalangeal [tiab]  OR Metatarsal 
[tiab] OR Metatarsals [tiab] OR metatarsophalangeal [tiab]  OR Muscle [tiab] 
OR Muscles [tiab] OR muscular [tiab] OR Navicular [tiab] OR Naviculare  
[tiab] OR neck [tiab] OR odontoid [tiab] OR olecranon [tiab] OR olecranons 
[tiab] OR os [tiab] OR Palmar Plate [tiab]  OR Palmar Plates [tiab]  OR patella 
[tiab] OR patellar [tiab] OR patellas [tiab] OR patello-femoral [tiab] OR 
patellofemoral [tiab]  OR Phalanges [tiab] OR pisiform [tiab] OR Pisiforme 
[tiab] OR pubic bone [tiab] OR Pubic Symphyses [tiab] OR Pubic Symphysis 
[tiab]  OR radius  [tiab] OR Rotator Cuff [tiab] OR Rotator Cuffs [tiab] OR 
Sacroiliac  [tiab]  OR sacrum [tiab] OR scaphoid [tiab] OR Scaphoideum 
[tiab] OR scapula [tiab] OR Scapulae [tiab] OR scapular [tiab] OR Semilunar 
Cartilage [tiab] OR Semilunar Cartilages [tiab] OR sesamoid [tiab] OR 
sesamoids [tiab] OR Shoulder  [tiab]  OR shoulders [tiab] OR Skeleton [tiab] 
OR Skeletons [tiab] OR spinal [tiab] OR spinal canal [tiab] OR spine [tiab] OR 
Sternoclavicular  [tiab]  OR Sternocostal  [tiab]  OR subtalar [tiab]  OR 
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Appendix 1  Continued.
Musculoskeletal 
System
synovial [tiab]  OR Synovialis [tiab] OR synovium [tiab] OR Talocalcaneal 
[tiab] OR tarsal [tiab]  OR Tarsus [tiab] OR thoraric  [tiab] OR tibia [tiab] 
OR tibial [tiab] OR tibias [tiab] OR Tibiofibular [tiab] OR toe [tiab]  OR toes 
[tiab] OR trapezium [tiab] OR trapezoid [tiab] OR Trapezoideum [tiab] OR 
Triquetral [tiab] OR Triquetrum [tiab] OR Trochanter [tiab] OR Trochanters 
[tiab] OR ulna [tiab] OR ulnar [tiab] OR ulnas [tiab] OR Vertebra [tiab] OR 
Vertebrae [tiab] OR Vertebral  [tiab] OR volar plate [tiab]  OR volar plates 
[tiab]  OR wrist [tiab]  OR wrists [tiab] OR heel-cord [tiab])
Top ten 
orthopedic 
journals
(J Bone Joint Surg Br [ta] OR Knee Surg Sports Traumatol Arthrosc [ta] OR 
Clin Orthop Relat Res [ta] OR J Physiother [ta] OR J Orthop Res [ta] OR 
Arthroscopy [ta] OR Physical Therapy [ta] OR J Bone Joint Surg Am [ta] OR 
Osteoarthritis Cartilage [ta] OR Am J Sports Med [ta])
Randomized 
controlled trials
(( randomized controlled trial [pt] OR controlled clinical trial [pt] OR 
randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] 
OR randomly [tiab] OR trial [ti]) NOT (animals[mh] NOT (animals[mh] AND 
humans [mh]) ))
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Abstract
Background: Studies have demonstrated rising incidences of meniscus procedures for 
degenerative meniscus tears in several countries despite accumulating evidence that 
questions the efficacy of the treatment. It is not clear whether this rise in incidences also 
applies to the practice of arthroscopic surgery in the Netherlands. The objective of this 
study was therefore to evaluate the number of surgical meniscal procedures performed in 
the Netherlands over 2005 to 2014.
Methods: We used registry based data on surgical meniscal procedures that originated 
from the nationwide Dutch National Hospital Care Basic registrations from 2005 to 2014. 
The annual incidence rates of the meniscal procedures were calculated per 100,000 
persons for different age groups. Incidence numbers of age groups were used to assess 
differences in proportions of meniscal procedures performed on defined age groups in 
2005 as compared to 2014, using χ2tests.
Results: The number of procedures and incidences of meniscus surgery were highest in 
patients aged 40-65, accounting for half of the total number of meniscal surgeries. 
Procedural incidences decreased by 25% over 2005 to 2014. There were no differences in 
proportions of meniscal procedures performed on defined age groups in 2005 as compared 
to 2014 (χ2(4)  = 4.31, p-value 0.37).
Interpretation: Despite accumulating evidence questioning the rationalization and 
effectiveness of the treatment, meniscus surgery is still performed disproportionately 
often in the treatment of degenerative meniscus tears in the Netherlands.
Introduction
Arthroscopic knee surgery with meniscectomy is a well established surgical procedure in 
the treatment of symptoms attributed to degenerative meniscus tears.1 Degenerative 
meniscus tears are typically seen in middle aged and older patients in knees that already 
demonstrate signs of knee osteoarthritis, and are caused by chronic degenerative processes.2, 3
 Clinical symptoms routinely attributed to the degenerative meniscus tear generally 
have a gradual onset and encompass localized knee pain and mechanical symptoms such 
as occasional catching or locking of the knee.4-6 Common rationalization for arthroscopic 
surgery is that the clinical symptoms are attributable to a mechanical problem, and that 
the degenerative meniscus tear is the cause of this mechanical problem.5
However, over the past decade evidence has accumulated that questions both the ratio-
nalization and the effectiveness of arthroscopic surgery for degenerative meniscus tears. 
First, it has been demonstrated that the sensitivity and specificity of the symptoms attributed 
to the degenerative meniscus tear in the osteoarthritic knee are low.7-10 Moreover, 
asymptomatic meniscus tears are highly prevalent among people with knee osteoarthritis.11 
These observations cast doubt on the rationalization for the arthroscopic treatment of 
degenerative meniscus tears. 
 Second, randomized controlled trials have demonstrated that the treatment effect, 
if present at all, is inconsequential and does not outweigh the short term harms.6, 12, 13
Based on this accumulating evidence a decrease in procedural incidences would be 
expected. Though, studies have demonstrated rising incidences of meniscus procedures 
for degenerative meniscus tears in several countries instead.1, 14, 15 This observation 
demonstrates a delay in dissemination, acceptance and implementation of clinical evidence 
into the orthopedic practice. However, it is not clear whether this apparent contradiction 
also applies to the practice of arthroscopic surgery in the Netherlands. The objective of 
this study was therefore to evaluate the number of meniscal procedures performed in 
the Netherlands over the past decade.
Methods
Registry based data on arthroscopic procedures for meniscus tears used in the preparation 
of this observational study originated from the Dutch National Hospital Care Basic 
registrations (LBZ), a registry managed by the Dutch Hospital Data foundation.16 
The Dutch Hospital Data foundation, founded by the Dutch Association of Hospitals 
(NVZ) and the Netherlands Federation of University Medical Centres (NFU), manages, 
maintains and monitors collections of hospital data and provides information on 
hospital care.
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 The National Hospital Care Basic registration is a nationwide registry (covering data 
from all Dutch hospitals and University Medical Centers) of clinical, administrative and 
financial data from patients who have been hospitalized, received ambulatory surgery, 
or were treated in an outpatient setting. The registry includes, among others, information 
on patient demographics, primary and secondary diagnoses in terms of International 
Classification of Diseases (ICD) codes, and surgical procedures performed.
 Following on Dutch privacy laws, ensuring the anonymity and irreducibility of the 
provided data (irreducible to individual subjects or institutions), the Dutch Hospital Data 
delivered anonymous and aggregated data on subjects whom had undergone meniscus 
surgery either as the primary procedure or as a secondary procedure (specific procedural 
codes for meniscus surgery: ZA code 038643 / CVV code 5804X / CBV codes 338645X/ 
338646X) covering years from 2005 up to and including 2014. Data included type of 
hospital at which the surgery was performed (general hospital or University Medical 
Centers), subject age (divided into 5-year age cohorts), gender, and the primary diagnosis 
(coded according to ICD-9).
 Numbers of inhabitants in the Netherlands of each registration year from 2005 to 
2015 were obtained from the Statistics Netherlands.17 Total numbers of inhabitants were 
retrieved as well as numbers stratified for gender and age groups (0-20 year, 20-40 year, 
40-65 year, 65-80 year, and 85 and older) in order to calculate age and gender specific 
procedural incidences.17 
Statistical methods
For each registration year we had number of inhabitants on January 1st and number of 
subjects whom had undergone meniscus surgery from January 1st to December 31st. 
We estimated midyear population numbers as the average population number of the 
registration year and the following year. These midyear population numbers were used 
to calculate the annual incidence rate of the meniscal procedures per 100,000 persons. 
We used population numbers stratified for gender and defined age groups to calculate 
gender and age group specific incidence numbers.
 Gender and age group specific incidence numbers were used to assess differences 
in proportions of meniscal procedures performed on men and women and on defined 
age groups in 2005 as compared to 2014, using Chi-square tests. 
Results
Of the total number of meniscus procedures 98% were performed in general hospitals 
and only 2% in University Medical Centers. The number of procedures and incidences of 
meniscus surgery were highest in patients aged 50-55 (Figure 1). Patients aged 40-65 years 
accounted for half of the total number of meniscal surgeries. Besides, surgical meniscal 
procedures were performed more frequent on men than on women (Table 1). 
Procedural incidences decreased by 25% over 2005 to 2014 (Table 1). (Figure 2) The year 
2013 stands out by the disproportionately low number registered procedures compared 
to preceding and following years (33-35% less registered procedures). Disregarding 2013, 
the largest decrease in incidences was observed from 2010 to 2011 (a reduction of 17%). 
There were no differences in proportion of meniscal procedures performed on men and 
women, and also not on defined age groups in 2005 as compared to 2014 (χ2 (1) = 0.24, 
p-value = 0.62; and χ2(4)  = 4.31, p-value 0.37 respectively). 
Six diagnoses represented 99% of all the primary diagnoses, of which three were unspecific 
(‘other and unspecified disorders of joint’, ‘other disorders of bone and cartilage’, and 
‘other derangement of joint’). The three most common specific primary diagnoses were 
old meniscus tear, osteoarthritis, and acute/current meniscus tear. An old meniscus tear 
was the predominant diagnosis over all registration years accounting for 93% of the 
registered procedures (Table 2).
Figure 1   Cumulative numbers (thousands) of meniscal procedures performed from 2005 
to 2014 plotted against the age groups (5-year cohorts).
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Table 1   Number and incidences of meniscus procedures per year from 2004 up to and  
including 2014, stratified for gender and age.
YEAR YEAR
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 TOTAL
NUMBER OF PROCEDURES
Total, n (% of 10yr period) 35,823 (0.12) 32,797 (0.11) 31,769 (0.10) 34,034 (0.11) 34,583 (0.11) 34,312 (0.11) 28,654 (0.09) 26,843 (0.09) 17,972 (0.06) 27,520 (0.09) 304,307 (1.00)
According to gender,  
n (% of total registration year)
Men 21,630 (0.60) 19,486 (0.59) 18,961 (0.60) 20,179 (0.59) 203,25 (0.59) 19,937 (0.58) 16,707 (0.58) 15,764 (0.59) 10,285 (0.57) 16,156 (0.59) 179,430 (0.59)
Women 14,193 (0.40) 13,311 (0.41) 12,808 (0.40) 13,855 (0.41) 14,258 (0.41) 14,375 (0.42) 11,947 (0.42) 11,079 (0.41) 7687 (0.43) 11,364 (0.41) 124,877 (0.41)
According to age,  
n (% of total registration year)
0-20 year 1403 (0.04) 1232 (0.04) 1205 (0.04) 1339 (0.04) 1365 (0.04) 1340 (0.04) 1145 (0.04) 1122 (0.04) 734 (0.04) 1308 (0.05) 12,193 (0.04)
20-40 year 8428 (0.24) 7220 (0.22) 6730 (0.21) 6862 (0.20) 6642 (0.19) 6608 (0.19) 5238 (0.18) 5009 (0.19) 3167 (0.18) 5379 (0.20) 61,283 (0.20)
40-65 year 18,392 (0.51) 1,6727 (0.51) 16,130 (0.51) 17,329 (0.51) 17,850 (0.52) 17,410 (0.51) 14,620 (0.51) 13,763 (0.51) 9144 (0.51) 14,073 (0.51) 155,438 (0.51)
65-80 year 6593 (0.18) 6528 (0.20) 6656 (0.21) 7529 (0.22) 7747 (0.22) 7985 (0.23) 6849 (0.24) 6236 (0.23) 4402 (0.24) 6030 (0.22) 66,555 (0.22)
80 year and older 1007 (0.03) 1088 (0.03) 1048 (0.03) 975 (0.03) 979 (0.03 969 (0.03) 802 (0.03) 713 (0.03) 525 (0.03) 730 (0.03) 8836 (0.03)
INCIDENCES (per 105 persons/year)
Total* 220 201 194 207 210 207 172 160 107 164
According to gender†
Men 268 241 234 249 249 243 203 190 124 194
Women 172 161 155 167 171 172 142 131 91 134
According to age‡
0-20 year 35 31 30 34 35 34 29 29 19 34
20-40 year 189 164 156 161 157 158 126 121 77 131
40-65 year 331 297 282 300 305 294 244 230 153 237
65-80 year 384 374 377 418 421 422 355 307 207 274
80 year and older 176 185 174 158 155 150 120 104 75 102
* Annual incidence rates calculated as number of meniscal procedures performed per 100,000 Dutch inhabitants; 
† Gender specific incidence numbers, per 100,000 male/females; ‡ Age corrected incidence numbers, per 100,000 
Dutch inhabitants per age cohort; §; ||. 
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Discussion
The objective of this study was to evaluate the number of meniscus surgeries performed 
in the Netherlands from 2005 to 2014. Registry based data demonstrated that the majority 
of meniscus surgeries was performed on patients middle aged and older patient aged 
40-65 years. The total incidence of meniscus procedures decreased by 25% from 2005 to 
2014. However, this decrease was not the result of a disproportional reduction of 
procedures performed on patients with degenerative meniscus tears.
Regarding the distribution of ages, meniscal procedures are mainly performed to treat 
patients with degenerative meniscus tears. Over the past decade evidence has 
accumulated that questions both the rationalization and the effectiveness of arthroscopic 
surgery for degenerative meniscus tears. Therefore, a pronounced decrease in procedural 
incidences especially for patients aged 40 and older than would have been expected. 
Although this expected decrease was not observed, in contrast to other countries, 
procedural incidences did not rise.1, 14, 15 The lack of a pronounced decrease in procedural 
incidences in patients aged 40 and older demonstrates a delay in dissemination, 
acceptance and implementation of clinical evidence in the practice of arthroscopic 
surgery in the Netherlands. 
Figure 2   Incidences of meniscal procedures performed over the years 2005 to 2014 
stratified for gender.
Table 2   Most common primary diagnosis for patients undergoing meniscus procedures  
over 2005-2014 in the Netherlands*.
REGISTRATION YEAR REGISTRATION YEAR
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 TOTAL
NUMBER OF MENISCAL PROCEDURES
Total, n 35,823 32,797 31,769 34,034 34,583 34,312 28,654 26,843 17,972 27,520 304,307
According to primary diagnosis* 
(n, (% of total procedures in registration year)
Old meniscus tear† 33,811 (0.94) 30,777 (0.94) 29,940 (0.94) 32,265 (0.95) 32,694 (0.95) 32,246 (0.94) 26,503 (0.92) 24,622 (0.92) 16,749 (0.93) 24,176 (0.88) 283,783 (0.93)
Osteoarthritis‡ 475 (0.01) 426 (0.01) 431 (0.01) 436 (0.01) 453 (0.01) 394 (0.01) 536 (0.02) 272 (0.01) 169 (0.01) 368 (0.01) 3960 (0.01)
Acute meniscus tear || 125 (0.00) 90 (0.00) 58 (0.00) 147 (0.00) 77 (0.00) 116 (0.00) 153 (0.01) 130 (0.00) 114 (0.01) 508 (0.02) 1518 (0.00)
other φ 1136 (0.03) 1102 (0.03) 994 (0.03) 812 (0.02) 1098 (0.03) 1278 (0.04) 1102 (0.04) 1387 (0.05) 713 (0.04) 1191 (0.04) 10813 (0.04)
total 35,547 (0.99) 32,395 (0.99) 31,423 (0.99) 33,660 (0.99) 34,322 (0.99) 34,034 (0.99) 28,294 (0.99) 26,411 (0.98) 17,745 (0.99) 26,243 (0.95) 300,074 (0.99)
 *Most common primary diagnose for patients undergoing meniscus surgery according to ICD-9 † Old meniscus 
tear (ICD-9 code 717 Internal derangement of knee),  ‡ Osteoarthritis (ICD-9 code 715 Osteoarthrosis and allied 
disorders),  || Acute/current meniscus tear (ICD-9 code 836 Dislocation of knee) , φ Other unspecified disorders/
derangement *ICD codes 719 Other and unspecified disorders of joint, 733 Other disorders of bone and cartilage, 
and 718 Other derangement of joint
108 109
CHAPTER 5 MENISCUS SURGERIES IN THE NETHERLANDS
5
delay in the dissemination, acceptance, and implementation of clinical evidence in the 
practice of arthroscopic surgery in the Netherlands. Since the treatment is associated 
with harms, and only a small or inconsequential treatment effect, too many subjects are 
unnecessarily exposed to risks. 
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 The largest decrease in procedural incidences from 2010 to 2011 may be explained by 
the introduction of  guidelines for knee arthroscopy by the Netherlands Orthopedic 
Association.18 This guideline succeeded the consensus indication for arthroscopy in 
acute knee injuries from 1998.19 The 2010 guideline introduced the use of MRI in the 
diagnostic process of meniscus tears in younger patients. The use of MRI in may have led 
to a decrease in meniscus surgeries by providing additional diagnostic information in 
patients with aspecific symptoms. 
 The 2010 guideline also states that reticence is necessary in the surgical treatment of 
degenerative meniscus tears, and recommends non-operative management of degenerative 
meniscus tears without mechanical obstructions.18 This recommendation may have 
been responsible for a modest reduction in procedural incidences for degenerative 
meniscus tears after 2010. However, the still disproportionately high procedural incidences 
in patients aged 40-65 after 2010  is in contrary to the recommendations in the guideline. 
For this registry based study, coverage and the validity are potential limitations. Although 
Dutch hospitals are not required by law to participate in the National Hospital Care Basic 
registration, all hospitals affiliated with the Dutch Association of Hospitals (NVZ) and the 
Netherlands Federation of University Medical Centres (NFU) have a statutory obligation to 
participate in the registration. Therefore, virtually all Dutch hospitals participate in the 
registration.16 Next, the validity of the registration of demographics, diagnoses, and 
procedures has been demonstrated to be good (correct registration of 99%, 87% and 92% 
respectively).20 We assumed that validity of registered demographics, diagnoses, and 
procedures was comparable over 2005 to 2014. Completeness of registrations is another 
potential limitation. The year 2013 stands out by the disproportionately low number of 
registered procedures compared to other years. Whereas absolute numbers are lower, 
proportions of procedures performed on men and women and for defined age groups 
are not different from other years. Lower numbers of registered procedures can be related 
to a nationwide change in the registry platform. 2013 was the last year accepting registry 
data via the old platform, and as of January 1st 2014 the new registry definitively replaced 
the former platform. A change in infrastructure for management of registry data on 
hospital level in 2013 may have led to incomplete submission of data to the registry in 
that year.
 Disregarding 2013, we assumed that completeness of the registry was comparable 
over the registration years. Still, even without assuming comparable completeness, 
proportions of procedures performed on men and women and defined age groups 
demonstrated that procedural incidences did not decrease specifically for middle aged 
and older patients.
 In conclusion, despite accumulating evidence questioning the rationalization and 
effectiveness of the treatment, meniscus surgery is still performed disproportionately 
often in the treatment of degenerative meniscus tears. This observation demonstrates the 
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Abstract 
Background: Despite evidence questioning its efficacy, arthroscopic meniscectomy is still 
widely performed to treat degenerative meniscus tears. Concerns exist that arthroscopic 
meniscectomy hastens the progression of knee osteoarthritis.
Objective: To assess whether participants with, or at risk for, symptomatic knee 
osteoarthritis and whom undergo arthroscopic meniscectomy have an increased risk for 
future knee replacement surgery.
Design: Data used were obtained from the Osteoarthritis Initiative (OAI) study, which is a 
multi-center, longitudinal, observational study focusing on knee osteoarthritis.
Setting: Four clinical centers enrolled participants between 2004 and 2006, and 
participants were followed up on an annual basis for 108 months. 
Participants: In total, 4,674 participants aged between 45 and 79 years were included 
with, or at risk for, symptomatic knee osteoarthritis. 
Main outcome measures – Hazard ratio of knee replacement surgery for participants who 
underwent arthroscopic meniscectomy during follow up compared to propensity score 
matched participants who did not undergo arthroscopic meniscectomy during follow up.
Results: 335 participants underwent arthroscopic meniscectomy during follow up, of 
which 63 (18.8%) underwent knee replacement surgery in the same knee. Of the 335 
propensity score matched participants 38 (11.3%) underwent knee replacement surgery 
during follow up. The hazard ratio for knee replacement surgery was 3.0 (95%CI 1.7 to 5.3) 
for participants who underwent arthroscopic meniscectomy.
Conclusions: In patients with, or at risk for, symptomatic knee osteoarthritis arthroscopic 
knee surgery with meniscectomy is associated with a 3 fold increase in the risk for knee 
replacement surgery. 
Introduction
Arthroscopic knee surgery with (partial) meniscectomy and/or debridement is common 
practice for middle aged or older people with persistent knee problems.1-4 The ‘do not do 
recommendations’ from the National Institute for Health and Care Excellence (NICE) 
recommends no referring for arthroscopic lavage and debridement as part of treatment 
for osteoarthritis, unless the person has knee osteoarthritis with a clear history of 
mechanical locking. Acknowledging this recommendation, arthroscopic knee surgery 
with meniscectomy and/or debridement is still a well established procedure to treat 
mechanical symptoms attributed to degenerative meniscal tears.1,4 Degenerative meniscal 
tears are typically seen in middle aged or older patients, accompanied by knee osteo-
arthritis, and are caused by chronic degenerative processes and may be preceded by a 
trivial trauma.5-8 Emerging evidence on the role of arthroscopic surgery with meniscectomy 
for degenerative meniscal tears demonstrated that the practice of routine arthroscopic 
surgery is not supported and that non-operative management should be the first line 
treatment.5,9-11 However, even with the accumulation of evidence questioning its efficacy, 
arthroscopic knee surgery still remains current practice in treating patients with 
degenerative meniscal tears.1,4,12-15 Common rationalization for arthroscopic meniscectomy in 
patients with degenerative meniscus tears are symptoms due to mechanical factors. In 
this argumentation, these symptoms, such as locking, clicking or acute joint line 
tenderness, are assumed as arising from the degenerative meniscus. However, the 
sensitivity and specificity of these symptoms attributed to the degenerative meniscus in the 
osteoarthritic knee are low 16-19, and asymptomatic meniscal tears are highly prevalent among 
people with knee osteoarthritis 20,21. These factors make it challenging to determine whether 
localized symptoms in these patients are attributable to a meniscus tear or to other factors 
(e.g. cartilage damage, synovitis, ligamentous abnormalities) in the osteoarthritic knee.16,20-22 
 The weighing of both beneficial and harmful effects is paramount in the choice of 
treatment, and informing the patient of both beneficial and harmful effects is vital in 
order to obtain valid informed consent. Surgery related risks of knee arthroscopy include 
thrombosis, infection, and anesthesia-related complications.9 Moreover, retrospective 
studies have raised concerns that patients who undergo arthroscopic (partial) meniscectomy 
for a traumatic meniscus injury have an increased risk of late onset osteoarthritis.23 
However, it is unclear what the impact is of arthroscopic meniscectomy on the progression 
of already prevalent knee osteoarthritis. The primary objective of this study therefore was 
to assess whether patients with, or at risk for, symptomatic knee osteoarthritis and whom 
undergo arthroscopic meniscectomy have an increased risk for knee replacement surgery. 
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Methods
Study design
Data used in the preparation of this study were obtained from the Osteoarthritis Initiative 
(OAI) database, which is available for public access at http://www.oai.ucsf.edu/. The OAI 
cohort study is a multi-center, longitudinal, observational study focusing primarily on 
knee osteoarthritis. The two principal scientific objectives guiding the design of the OAI 
cohort were 1) to develop an ethnically diverse cohort of men and women ages 45-79 
suitable for studying the natural history of, and risk factors for, the onset and progression 
of knee osteoarthritis, and 2) to determine the validity of radiographic, magnetic resonance 
imaging, biochemical and genetic measurements as biomarkers and potential surrogate 
endpoints for knee osteoarthritis. 
 Participants were enrolled, involving four clinical centers, between February 2004 
and May 2006, and were followed up on an annual basis. In this ongoing cohort study we 
used data up to and including the 108-month follow-up data. 
 
Participants
The OAI recruited male and female participants, aged between 45 and 79 years, of all 
ethnic groups, who had, and those who were at high risk for developing, symptomatic 
knee osteoarthritis. Participants with inflammatory arthritis, bilateral end stage knee 
osteoarthritis, and contraindications for 3.0 Tesla MRI examinations were excluded.
 At baseline the cohort was divided into two sub-cohorts, a progression cohort 
(participants with symptomatic knee osteoarthritis) and an incidence cohort (participants 
without symptomatic knee osteoarthritis, but having characteristics that placed them at 
increased risk for developing symptomatic knee osteoarthritis during the study period)
 Symptomatic knee osteoarthritis was defined as frequent knee symptoms in the past 
12 months (defined as pain, aching or stiffness in or around the knee on most days for 
at least one month during the past 12 months) and radiographic tibiofemoral knee OA 
(defined as tibiofemoral osteophytes (OARSI atlas grades 1-3, equivalent to Kellgren and 
Lawrence grade ≥ 2) on the fixed flexion radiographs.
 Participants were eligible for the incidence subcohort based on the presence of a 
specific combination of risk factors for knee osteoarthritis: age, frequent use of medications 
for treatment of knee symptoms (defined as use of medications (all types) on most days of 
a month in the past 12 months), infrequent knee symptoms (defined as pain, aching or 
stiffness in or around the knee at any time in the past 12 months but not on most days for 
at least one month), overweight (defined using gender and age specific cut off points for 
weight), history of knee injury (defined as a history of knee injury causing difficulty walking 
for at least a week); history of knee surgery (any knee surgery); family history of total knee 
replacement for osteoarthritis in a biological parent or sibling; Herberden’s nodes (self 
reported bony enlargement of ≥1 DIP joint in both hands); occupational repetitive knee 
bending (defined as current daily activities at work or outside work requiring frequent 
climbing, stooping, bending, lifting, squatting, or kneeling).
Variables 
The OAI collected a core set of knee osteoarthritis status and outcome measurements 
(clinical and imaging) at baseline and at each follow up visit. We extracted baseline descriptive 
data (e.g. demographic, social, clinical), data on risk factors for knee osteoarthritis, and 
baseline questionnaire scores related to knee osteoarthritis (the Western Ontario and 
McMasters Osteoarthritis index (WOMAC), and non WOMAC components of the Knee 
injury and Osteoarthritis Outcome Score (KOOS)). Variables of interest were assessed using 
structured interview formats and questionnaires. Radiography of the tibiofemoral joint 
was performed in fixed flexion, standing knee films were obtained in PA projection with 
knees flexed to 20-30 degrees and feet internally rotated 10 degrees. Radiographs were 
assessed by trained readers for the presences of osteophytes and joint space narrowing 
using a classification based on the OARSI atlas grades.24,25
 For each OAI follow up contact we assessed whether participants reported to have 
undergone arthroscopic knee surgery with meniscectomy (defined as where they 
repaired or cut away a torn meniscus or cartilage), and whether patients underwent knee 
replacement surgery (where all or part of the joint was replaced). 
 Moreover we extracted data on time of the different OAI follow up contacts, the OAI 
follow up contact at which participants reported to have undergone meniscus surgery, 
and of the knee replacement surgery. Time was expressed in amount of days relative to 
date of enrollment. Since the exact time of arthroscopic meniscectomy was not provided 
we approximated it by taking a random time in the year preceding the OAI follow up 
contact during which arthroscopic meniscectomy was mentioned.
Statistical methods
Multiple imputation procedures were used for missing values to increase precision and to 
avoid bias, generating ten independent imputed datasets.26 KOOS Function in Sport and 
Recreation had 25.8% missing values at baseline whereas other variables had less than 
1.5% missing values. (Table 1) 
 Bilateral arthroscopic meniscectomies and/or knee replacement surgeries within one 
subject cannot be considered as being independent observations.27 Therefore, in case of 
both bilateral meniscectomies and knee replacement surgeries without meniscectomies, 
we randomly selected either the left of the right knee.
 The difference in risk for knee replacement surgery between participants who did 
and those who did not undergo arthroscopic meniscectomy during follow up could be 
biased by confounding baseline characteristics (confounding by indication). To adjust for 
these confounding baseline characteristics we matched participants based on their 
propensity scores.28-30 The propensity score was defined to be the probability of undergoing 
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arthroscopic meniscectomy during follow up conditional on a subject’s observed baseline 
characteristics.31 
 Propensity scores were estimated independently for each imputed dataset, using a 
logistic regression model with arthroscopic meniscectomy during follow up as the 
dependent variable in relation to the following baseline characteristics: treatment center, 
age, gender, weight, Physical Activity Scale for the Elderly (PASE) score, having any kind of 
health care coverage, knee replacement in either knee at baseline, presence of Herberden’s 
nodes in both hands, engaging in frequent knee bending activities, radiographic composite 
grade of osteoarthritis, history of serious knee injury, baseline knee symptoms, history of 
medication used for knee symptoms, history of knee surgery, family history on knee 
replacement surgery, WOMAC subscale scores, KOOS subscale scores, and SF-12 subscale 
scores.
 We used a 1:1 matching algorithm without replacement to match exposed and 
nonexposed individuals on propensity score within a caliper of 0.2 standard deviation of 
the logit of the propensity score.32,33 Balance after matching was checked graphically and 
descriptively. Standardized differences (difference in means divided by the pooled 
standard deviation) of the pooled baseline characteristics for matched datasets are 
provided in table 1. 
 We used a Cox proportional hazards survival model with time to knee replacement 
surgery as the dependent variable. Status of arthroscopic meniscectomy during follow up 
period was allowed to vary over time and was applied as a time dependent covariate. 
Ten Cox proportional hazards survival models were conducted, on the ten imputed and 
propensity matched datasets separately, and the resulting estimates were pooled.34
 To assess the robustness of the obtained results we performed sensitivity analyses in 
which we stratified the results of the progression and the incidence subcohorts; used the 
imputed datasets without matching participants; and adopted the timing of the OAI 
follow up as the actual timing for arthroscopic meniscectomy.
All analyses were performed in IBM SPSS statistics version 22.0. 
Results
The OAI enrolled 4,674 participants, of which 1,390 and 3,284 were recruited for the 
progression and incidence cohort, respectively. Of the 4,674 participants, 150 had missing 
information on whether they had undergone arthroscopic surgery at any time during 
follow up. Of the 4,674 participants, 58.4% were female and the average age was 62.3 years 
(range 45– 79 years), see table 1 for baseline characteristics. 
 Figure 1 provides an overview of the flow of participants during OAI follow up visits; 
3,337 (71.4%) of the initial 4,674 eligible participants could be analyzed using the 108 
months OAI follow up. The mean follow up time of the participants was 2,778 days 
(median 3,242 days). 
Figure 1   Flow diagram of participants over OAI follow up visits.
Mx = arthroscopic meniscectomy; KR = knee replacement surgery
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 During this follow up, 335 participants (7.2%) reported to have undergone arthroscopic 
meniscectomy: 308 participants reported to have undergone arthroscopic meniscectomy 
in either their left and/or right knee and 27 participants in both knees. 439 participants 
(9.4%) had undergone knee replacement surgery during follow up: 330 participants had 
undergone knee replacement surgery in either their left and/or right knee and 109 
participants in both knees. 
 Of the 335 participants who underwent arthroscopic meniscectomy, 63 (18.8%) 
underwent knee replacement surgery in the same knee during follow up. Of the 335 
matched participants; 38 (11.3%) underwent knee replacement surgery during follow up. 
 Results from the Cox proportional hazards model demonstrated that the hazard ratio 
for knee replacement surgery was 3.0 (95%CI 1.7 to 5.3) for participants who underwent 
arthroscopic meniscectomy compared to matched participants who did not undergo 
arthroscopic meniscectomy. (Figure 2)
 The sensitivity analyses showed that this result was robust with hazard ratio estimates 
ranging between 2.2 and 4.8. (Figure 2)
Discussion
Using open access data from a multi-center, longitudinal, observational study, we 
evaluated the effect of arthroscopic meniscectomy on the risk for knee replacement 
surgery in participants with, or at risk for, symptomatic knee osteoarthritis. Our results 
show that arthroscopic knee surgery with meniscectomy is associated with an increased 
risk (hazard ratio 3.0, 95%CI 1.7 to 5.3) for knee replacement surgery. 
 This increased risk substantiates the concern that people who undergo arthroscopic 
meniscectomy may have an increased risk of progression of osteoarthritis and an increased 
likelihood of joint replacement. 3,22,23
The major strengths of our study are the large number and diversity of participants in the 
OAI cohort, the long prospective follow up period, and the setting in normal health care 
(i.e. real life situation). Moreover, the OAI provided information on clinically relevant 
outcomes acquired using standardized protocols and using structured interview formats 
and questionnaires.
 Some potential limitations should also be discussed. First, due to the observational 
nature, confounding (by indication) cannot be precluded. To control for this potential 
confounding (by indication), we matched participants based on propensity scores. 
Although matching of participants was successfully performed based on a considerable 
subset of baseline characteristics, differences could theoretically still exist in unmeasured 
characteristics. Our sensitivity analysis in which we evaluated the effect of propensity 
score matching, however, demonstrated that the observed effect was quite robust.
 Second, the imprecision in defining arthroscopic meniscectomy and its timing may 
have influenced the results. Arthroscopic meniscectomy was defined as a surgical 
procedure where a scope was put in the knee (arthroscopy) where a torn meniscus or 
cartilage was repaired or cut away (meniscectomy). This definition implies that it is also 
possible that cases were included in which the meniscus was actually left unharmed and 
only a piece of (floating) cartilage was removed. These treatments, as opposed to 
meniscectomy, theoretically may have lesser effect on the progression of osteoarthritis. 
Therefore including these cases may have caused an underestimation of the hazard ratio.
 Third, we primarily analyzed the data by using participants from the full OAI cohort, 
ignoring the subdivision into a progression and incidence subcohort. This may result in an 
imprecise estimate of the hazard ratio if applied to either a patient with, or a patient at risk 
for knee osteoarthritis. However, we chose not to separate both cohorts in the primary 
analysis because this would have been somewhat arbitrary. First, the development of 
knee osteoarthritis is a chronic process, and there is a continuum of pathology between 
incident and progressive osteoarthritis. Second, it is possible that participants were 
assigned in the progression cohort because they had symptomatic knee osteoarthritis in 
one knee, but that the meniscus surgery took place in the contralateral knee. We 
Figure 2   Hazard ratios [95%CI] with knee replacement surgery as the dependent  
variable demonstrating the increased risk for knee replacement surgery for 
participants who underwent arthroscopic meniscectomy compared to those 
participants who did not undergo arthroscopic meniscectomy.
Results are provided for the primary analysis and sensitivity analyses.
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performed an analysis in which we stratified the results of the progression and the 
incidence subcohorts, which demonstrated that the effect was robust.
Clinical implications
In this study we observed that for patients with, or at risk for, symptomatic knee 
osteoarthritis knee arthroscopic surgery with meniscectomy is associated with a 3 fold 
increase in the risk for knee replacement surgery. This increased risk for knee replacement 
surgery can be interpreted as a consequence of an increased progression of osteoarthritis. 
This increased progression of osteoarthritis is caused by the removal of the meniscus, 
and its cartilage protecting effect, in the knee that is already susceptible to osteoarthritic 
changes. 
 Both for patients and medical doctors, this increased risk for knee replacement 
surgery after arthroscopic meniscectomy should be taken into account while weighing 
both beneficial and harmful effects in the choice of treatment. Moreover, informing the 
individual patient on this increased risk is vital in order to achieve valid informed consent. 
Conclusion
In patients with, or at risk for, symptomatic knee osteoarthritis arthroscopic knee surgery 
with meniscectomy is associated with a 3 fold increase in the risk (hazard ratio 3.0, 95%CI 
1.7 to 5.3) for knee replacement surgery. 
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Abstract 
Objectives: It is disputed whether arthroscopic meniscectomy is an (cost-) effective 
treatment for (degenerative) meniscus tears. The objective of this study was to assess 
the cost-effectiveness of arthroscopic meniscectomy in subjects with knee osteo - 
arthritis, while taking into account the increased risk for future knee replacement surgery. 
We compared cost-effectiveness of surgery compared to no surgery.
Design: We used a state transition (Markov) cost-effectiveness simulation model to evaluate 
the cost-effectiveness of arthroscopic meniscectomy compared to no surgery in subjects 
with knee osteoarthritis (age range 45– 79 years). Data used in the preparation of the 
current study were obtained from the Osteoarthritis Initiative database. We applied a 
9 years’ time horizon (which is equal to the current OAI study follow up period), and 
evaluated cost-effectiveness from a societal perspective. The main outcome measure was 
the incremental cost-effectiveness ratio (Euros per quality adjusted life-year (QALY) 
gained)
Results: Arthroscopic surgery was associated with 8.09 (SD ±0.07) QALYs at a cost of 
€ 21,031 (SD ±865), whereas the no surgery was associated with 8.05 (SD ±0.07) QALYs at a 
cost of € 16,304 (SD ±926). For arthroscopic surgery, the incremental cost per QALY gained 
was € 131,306. Sensitivity analysis, in which we ran the model over a lifetime perspective, 
showed no surgery dominant over performing surgery. 
Conclusions: In a routine clinical practice, arthroscopic meniscectomy in subjects with 
knee osteoarthritis is associated with € 131,306 per QALY gained, which exceeds the 
generally accepted willingness to pay (range € 20,000 - € 80,000).
Introduction
Arthroscopic knee surgery with meniscectomy is a well established surgical procedure to 
treat symptoms attributed to degenerative meniscus tears.1-4 Degenerative meniscus tears 
are typically seen in middle aged and older subjects, accompanied by knee osteoarthritis, 
and are caused by chronic degenerative processes.5-8 Common rationalization for the 
treatment of degenerative meniscus tears is that the symptoms (such as locking, catching 
and/or knee pain) are attributable to a mechanical problem and that the degenerative 
meniscus tear is the cause of this mechanical problem.9 
 However, it has been demonstrated that this rationalization falls short. The sensitivity 
and specificity of the symptoms attributed to the injured meniscus in the osteoarthritic 
knee are low 10-13, and asymptomatic meniscal tears are highly prevalent among people 
with knee osteoarthritis.14 
 In line with the concerns about the rationalization for surgery, evidence from 
randomized controlled trials (RCTs) has accumulated that questions the efficacy of 
arthroscopic meniscectomy for degenerative meniscus tears.15-18 
 Despite the associated surgical harms and RCTs questioning its efficacy, orthopedic 
surgeons remain convinced that arthroscopic meniscectomy is an effective treatment for 
degenerative meniscus in the routine clinical practice (i.e. normal health care setting).9 
Primarily, orthopedic surgeons have concerns about the generalizability of the trial results 
and point out that the study populations are not representative to the subjects they 
themselves select for surgery in their clinical practice. 19-23 
 Regarding the skepticism of orthopedic surgeons to results from RCTs, data from 
observational studies, where surgeons themselves selected patients, would provide 
highly valuable information in order to evaluate outcomes in routine clinical practice. 
Moreover, for a thorough assessment of the procedure, the evaluation of the short term 
outcomes should take into account the (long term) consequence as well as the additional 
costs associated with the procedure. We recently showed that in subjects with knee 
osteoarthritis arthroscopic meniscectomy is associated with a threefold increase in risk 
for future knee replacement surgery.24 
 The objective of this study was therefore to assess the cost-effectiveness of 
arthroscopic meniscectomy compared to no surgery in subjects with knee osteoarthritis 
in a normal health care setting, while taking into account the increased risk for future knee 
replacement surgery. The results of this assessment can be used to inform health care 
resource allocation decisions. Moreover, it can be used in shared decision making by 
informing both patients and surgeons about the weighed value of the procedure.
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Methods
Data used in the preparation of the current study were obtained from the Osteoarthritis 
Initiative (OAI) database, which is available for public access at http://www.oai.ucsf.edu/. 
Where the data of the OAI was limited, we used data from other population based studies. 
The OAI cohort study is a multi-center, longitudinal, observational study focusing primarily 
on knee osteoarthritis. In this ongoing cohort study we used data up to and including 9 
year follow-up contact. 
General and analytic overview 
We developed a state-transition (Markov) simulation model for subjects with, or at risk for, 
symptomatic knee osteoarthritis in specialized software (TreeAge Pro Suite 2014, 
Williamstown, Massachusetts). The model was used to evaluate the cost-effectiveness of 
arthroscopic knee surgery with (partial) meniscectomy compared to no surgery, in a 
routine health care setting (i.e. routine clinical practice where surgeons themselves 
selected patients in their routine clinical practice), by the possible improvement in quality 
of life. We applied one year transition cycles, and the time frame was 9 years (which is 
equal to the current OAI study follow up period).
Model structure
The conceptual organization of the model health states that individuals can transition 
between is depicted in Figure 1. The model takes into consideration the transition to 
(revision) knee arthroplasty surgery and the increased risk herein for those subjects who 
underwent arthroscopic meniscectomy compared to subjects who did not undergo 
arthroscopic surgery.24 After each evaluation cycle, subjects may either transition to 
another state or remain in the same state for another year. Subjects may transition from 
any health state to the absorbing death state.
Populations under consideration
We applied the Markov decision model to subjects with, or at risk for, symptomatic knee 
osteoarthritis who underwent arthroscopic meniscectomy during follow up, and 
propensity score matched subjects who did not undergo arthroscopic meniscectomy 
during follow up.
 Due to the observational nature of the data, arthroscopic procedures were not 
randomly assigned to subjects, creating the possibility of confounding by indication (i.e. 
the subjects that underwent arthroscopic surgery may have been different with respect 
to knee symptoms compared to those subject who did not undergo surgery).
 Arthroscopic meniscectomy is normally performed in the treatment of symptoms 
(such as knee pain and mechanical symptoms) that are routinely attributed to the 
degenerative meniscus tears. However, the common conception that these symptoms 
are attributable to degenerative meniscus tears has been refuted, and instead the 
symptoms should be attributed to knee osteoarthritis. 10-13 17 18 Therefore, to control for 
potential confounding by indication, subjects were matched based on characteristics 
related to knee osteoarthritis. Actual matching of subjects was based on propensity 
scores; defined to be the probability of undergoing arthroscopic meniscectomy during 
follow up conditional on a subject’s observed baseline characteristics (i.a. related to knee 
osteoarthritis).25 Propensity scores were calculated on imputed baseline characteristics to 
increase precision and to avoid bias.26 We used a 1:1 matching algorithm without 
replacement to match exposed (surgery) and nonexposed (no surgery) individuals on 
propensity score within a caliper of 0.2 standard deviation of the logit of the propensity 
Figure 1   Conceptual organization of the cost-effective model.
The health state diagram demonstrating the clinical pathway of subjects within the decision model. Subjects may 
transition from any health state to the absorbing death state.
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score.27 28 Standardized differences (difference in means divided by the pooled standard 
deviation) of the baseline characteristics are provided in table 1, a standard difference 
less than 0.1 is often considered negligible.29 Further information on the statistical methods 
on how subjects were matched based on propensity scores is discussed in appendix 1.
 Following the example of the OAI initiative, two subgroups were defined, a progression 
subgroup (subjects with prevalent symptomatic knee osteoarthritis) and an incidence 
subgroup (subjects without symptomatic knee osteoarthritis, but having  characteristics 
that placed them at increased risk for developing symptomatic knee osteoarthritis during 
the study period)
 The OAI enrolled 4,674 subjects, of which 1,390 and 3,284 were recruited for the 
progression and incidence cohort, respectively. Of the 4,674 subjects, 335 subjects (7.2%) 
reported to have undergone arthroscopic meniscectomy during follow up: 308 subjects 
reported to have undergone arthroscopic meniscectomy in either their left or right knee, 
and 27 subjects in both knees. Of the subjects who underwent surgery, 55.2% were female 
and the average age was 59.0 years (range 45– 79 years). Baseline characteristics of subjects 
who underwent arthroscopic surgery and the characteristics of the propensity score 
matched subjects are provided in Table 1.
Clinical data
Of the 335 propensity score matched subjects who did not undergo arthroscopic knee 
surgery, 38 (11.3%) underwent knee replacement (arthroplasty) surgery during the 9 year 
study follow up. For subjects who underwent arthroscopic meniscectomy, the hazard 
ratio for knee replacement surgery was 3.0 (95%CI 1.7 to 5.3).24 Survivorship of knee 
arthroplasty implants was set at 91% (95%CI 90% to 91%) at ten years.30 One-year event 
probabilities were calculated assuming a fixed rate with respect to time.31 Mortality rates 
were obtained from the latest available US life tables.32 We followed the example of Losina 
et al.33 by assuming that 50% of the patients with a failed knee replacement would elect 
revision.33
Quality of life estimates
The value assigned to the different health states related to quality of life and was 
formulated in terms of utility. The utility is the score attributed to a given health state, 
varying from perfect health (utility value = 1) to death (utility value=0). The OAI did not 
implement questionnaires that measured preference-based health-related quality-of-life. 
Therefore, EQ-5D index scores were mapped from the available SF-12 scores to obtain 
preference-based health-related quality-of-life utility scores.34 From the fourth annual visit 
onwards, SF-12 questionnaires were assessed biennially instead of annually. The mean 
EQ-5D of all subjects at the start of the OAI study was set as the baseline utility value for all 
subjects. 
Table 1   Baseline characteristic of subjects in the propensity matched datasets 
stratified for whether subjects underwent arthroscopic meniscectomy 
during follow up.
MATCHED COHORT†
Arthroscopic meniscectomy
no
(n=335)
yes
(n=335)
Standardized 
difference
Baseline age (years) 58.8 (±12.1) 59.0 (±8.4) 0.00
Gender, female (%) 55.2 55.2 0.00
Baseline weight (kg) 84.7 (±23.6) 85.2 (±16.5) 0.00
Baseline Physical Activity Scale for 
the Elderly (PASE) [0-400]
178.8 (±113.0) 178.8 (±88.7) 0.00
Have any kind of health care 
coverage (%)
98.8 98.8 0.00
Highest grade or year of school 
completed [≥ college graduate]‡
65.4 65.5 0.00
Family history of knee 
replacement surgery (% )
20.9 21.7 -0.02
Baseline occupational kneeling 
activities (%)††
72.5 73.3 -0.01
Baseline hand OA (%)§ 20.9 19.9 0.02
Baseline SF12 physical [0-100] 48.7 (±11.8) 48.9 (±9.3) 0.00
Baseline SF12 mental [0-100] 53.3 (±10.1) 53.5 (±8.2) 0.00
Baseline History of medication for 
knee symptoms (%)‡‡
67.8 68.4 -0.01
Baseline Knee replacement 
surgery in either knee (%)
1.8 1.8 0.00
Baseline Radiographic 
osteoarthritis (%)||
Left 49.6 51.3 -0.03
Right 52.5 51.6 0.01
Baseline History of knee 
symptoms (%)*
Left 55.2 55.5 0.00
Right 55.8 56.6 -0.01
Baseline history of serious knee 
injury (%)§§
Left 32.8 32.8 0.00
Right 38.2 38.4 -0.01
Baseline history of knee  
surgery (%)**
Left 19.7 19.4 0.01
Right 20.3 20.9 -0.01
Baseline WOMAC Pain [0-20] Left 2.4 (±4.6) 2.5 (±3.4) -0.01
Right 2.7 (±4.9) 2.7 (±3.1) -0.01
Baseline WOMAC Stiffness[0-8] Left 1.5 (±2.1) 1.5 (±1.6) -0.01
Right 1.7 (± 2.3) 1.8 (±1.6) -0.01
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 An increment was added to this baseline utility value which differed between 
subjects who did, and propensity score matched subjects who did not undergo surgery. 
For subjects undergoing surgery the increment in utility represented the effect of the 
surgery on the quality of life, and for propensity score matched subjects who did not 
undergo surgery this increment represented the natural course of changes in quality of 
life. The difference in increment between the two populations represents the possible 
added value of the surgery on quality of life. The increment in utility value was assessed 
over a two year period, which was defined as the period ranging from the first visit 
preceding arthroscopic surgery to the second annual visit after the arthroscopic surgery. 
For propensity score matched subjects who did not undergo surgery, the increment in 
utility value was assessed over the same two year period as their matched subjects who 
did undergo surgery. 
 The utility value after knee replacement surgery was set as the EQ-5D at the 9 year 
follow up visit for those subjects which had previously undergone knee replacement 
surgery during follow up.
 We followed the example of Losina et al.33 by assuming that a failed knee replacement 
would result in a 25% reduction in quality of life.33
Costs
Costs were calculated from a societal perspective, using the costs accrued to society 
rather than to an individual hospital or practice. For subjects with, or at risk for, symptomatic 
knee osteoarthritis costs related to health care consumption were derived from Hermans 
et al.35 Costs associated with productivity loss were derived from the OAI database taking 
into account the usual working hours per week, and days work missed (absenteeism) 
because of knee symptoms  for those subjects who had paid employment (taking into 
account an average hourly wage of 35 Euros36). 
 Costs related to health care consumption for arthroscopic partial meniscectomy, 
knee replacement surgery, and revision knee replacement surgery were obtained by 
taking the average hospital reimbursement costs from the Dutch health care authority.37 
Next, costs related to productivity loss and physical therapy visits were added to get a final 
cost estimate per health state. Costs associated with productivity loss were derived from 
the OAI database, though data on absenteeism after the surgical procedures were derived 
from the Work & Loss Data Institute and were 14 and 40 days after arthroscopic partial 
meniscectomy and knee replacement surgery respectively 38 Physical therapy was only 
indicated after (revision) knee replacement surgery (25 sessions over a one year period, 36 
Euros per session36).
 We followed the example of Losina et al. 33 by assuming that a failed knee replacement 
would result in a 50% increase in costs compared with (symptomatic) knee osteoarthritis.33
Base case analysis
We applied a probabilistic Monte Carlo simulation, repeated over a large numbers of 
samples (n = 100,000) taking into account the relevant (2nd-order) uncertainty related to 
the sampling distribution of all the parameters. Outcome measures were assessed from 
societal perspective using a 4.0 % and 1.5 % discount rate for costs and effects, respectively.36 39 
Discounting the health effects at a lower rate than the costs takes into account the 
increase in the future value of health effects. Treatment effectiveness was expressed as 
 quality-adjusted life years (QALYs) and costs were estimated in Euros. We expressed 
comparative value in Euros per QALY gained (i.e. incremental cost-effectiveness ratio = ICER). 
 For a better understanding of the treatment effect of arthroscopic surgery and to be 
able to explain changes in quality of life, we also assessed the changes in scores on 
questionnaires specifically related to knee osteoarthritis (the Western Ontario and 
McMasters Osteoarthritis index (WOMAC), and Knee injury and Osteoarthritis Outcome 
Table 1   Continued.
MATCHED COHORT†
Arthroscopic meniscectomy
no
(n=335)
yes
(n=335)
Standardized 
difference
Baseline WOMAC Disability [0-68] Left 8.3 (±15.5) 8.4 (±10.4) 0.00
Right 8.4 (±13.8) 8.6 (±10.5) 0.00
Baseline KOOS FSR [0-100] 65.0 (±35.0) 64.4 (±26.6) 0.00
Baseline KOOS QOL [0-100] 60.5 (±29.1) 60.6 (±21.9) 0.00
Baseline KOOS pain [0-100] Left 83.9 (±23.2) 83.6 (±17.9) 0.00
Right 82.4 (±26.1) 82.0 (±17.2) 0.00
Baseline KOOS symptoms [0-100] Left 85.5 (±17.9) 85.4 (±15.7) 0.00
Right 84.9 (±21.6) 84.4 (±14.6) 0.00
† Pooled estimates of the 10 independently imputed and matched datasets; ‡Highest grade of education 
higher or equal to college graduate (i.e. College graduate, Some graduate school, Graduate degree); 
§Herberden’s nodes was defined as self reported bony enlargement of 1+ DIP joint in both hands; || Baseline 
radiographic osteoarthritis (OARSI atlas grades 1-3, equivalent to Kellgren and Lawrence grade ≥ 2, on fixed 
flexion radiographs; †† Occupational kneeling activities or repetitive knee bending was defined as current 
daily activities at work or outside work requiring frequent climbing, stooping, bending, lifting, squatting, or 
kneeling; ‡‡ Frequent use of medications for treatment of knee symptoms was defined as use of medications 
(all types) on most days of a month in the past 12 months; §§History of serious knee injury was defined as a 
history of knee injury causing difficulty walking for at least a week; ** History of knee surgery was defined as 
a history of any knee surgery; * History of knee symptoms was defined as pain, aching or stiffness in or around 
the knee on most days for at least one month during the past 12 months); 
Data is presented as means ±SD, a standardized difference less than 0.1 is often considered negligible. 
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Score (KOOS)). Although these scores were not taken into consideration in the analytic 
model directly, changes in these scores may form the basis for the possible changes in 
quality of life, providing valuable information for the interpretation of changes in quality 
of life.
Sensitivity analysis
To assess the robustness of the obtained increments in EQ-5D we performed sensitivity 
analyses in which we: stratified the results of the progression and the incidence subgroups; 
imputed missing outcome values of quality of life during follow up; evaluated increments 
in quality of life over a three year period, ranging from the first visit preceding arthroscopic 
surgery to the third visit after arthroscopic surgery; and used the complete dataset without 
imputation of missing values and without matching subjects based on propensity scores.
 We used deterministic 1-way probabilistic sensitivity analysis (systematically,  deter - 
ministically, varying parameters across intervals of interest) to illustrate the relative impact 
of each individual assumption on the cost-effectiveness of the procedure. Moreover, 
we ran the model over a lifetime period (for both subgroups separately), and while applying 
equal discounting of effects and costs at a rate of 3%. 
Results
Changes in quality of life and scores on knee osteoarthritis related questionnaires were 
small. Subjects who underwent surgery had an increment of 0.01 [95C% -0.01 to 0.02] in 
EQ-5D over the two year period, compared to an increment of -0.01 [95%CI -0.02 to 0.01] 
for propensity score matched subjects who did not undergo surgery. (Table 2) With 
respect to knee osteoarthritis specific questionnaires, there was a benefit in WOMAC 
and KOOS questionnaire subscores related to pain for subjects who underwent surgery 
compared to propensity score matched subjects who did not undergo surgery. (Table 2) 
The sensitivity analyses for changes in quality of life demonstrated, apart from a difference 
between subgroups, that the obtained results were robust. (Table 2) 
 Study parameters used in the analytic model are provided in Table 3. Over the 9 year 
study period, arthroscopic surgery was associated with 8.09 (SD ±0.07) QALYs at a cost of 
€ 21,031 (SD ±865), whereas the natural course of knee osteoarthritis was associated with 
8.05 (SD ±0.07) QALYs at a cost of € 16,304 (SD ±926). For arthroscopic meniscectomy, 
the incremental cost per QALY gained was € 131,306. (Table 4) The uncertainty surrounding 
this estimate due to uncertainty in parameter estimates is illustrated in Figure 2. 
 The sensitivity analyses for results from the model demonstrated a lower ICER for the 
incidence subgroup compared to the progression subgroup, and the natural course of 
knee osteoarthritis becoming dominant (less costs and more effectiveness) compared to 
surgery if we ran the model over a lifetime perspective. (Table 4) The results were not 
affected by the assumptions in the model. (Table 4)
Table 2   Changes in quality of life and on questionnaire scores related  
to knee osteoarthritis.
Variable Propensity score  
matched controls
Arthroscopic 
meniscectomy
Difference in  
change
Mean change  
± SE
Mean change  
± SE
Mean [95CI]
EQ-5D [0-1] -0.01 ± 0.01 0.006 ± 0.006 0.01 [-0.01 to 0.03]
- progression subgroup -0.00 ± 0.02 -0.006 ± 0.010 -0.003 [-0.04 to 0.04]
- incidence subgroup -0.00 ± 0.01 0.014 ± 0.007 0.018 [-0.01 to 0.04]
Sensitivity analysis†
- imputed outcomes -0.01 ± 0.01 0.01 ± 0.01 0.01 [-0.00 to 0.03]
- extended follow up -0.01 ± 0.01 0.01 ± 0.01 0.01 [-0.01 to 0.04]
- no PSmatching -0.01 ± 0.00 0.01 ± 0.00 0.01 [0.00 to 0.02]
WOMAC pain [0-20] ‡,|| -0.00 ±0.22 -1.07 ± 0.26 -1.07 [-1.75 to -0.39]
WOMAC stiffness [0-8]‡,|| -0.05 ± 0.14 -0.32 ± 0.12 -0.28 [-0.65 to 0.10]
WOMAC disability [0-68]‡,|| 0.04 ± 0.82 -1.83 ± 0.76 -1.87 [-4.09 to 0.37]
KOOS pain [0-100]§,|| 0.16 ± 1.20 5.48 ± 1.34 5.32 [1.72 to 8.92]
KOOS QOL [0-100]§,|| 1.26 ±1.90 3.74 ± 1.39 2.47 [-2.28 to 7.23]
KOOS FSR [0-100]§ -0.04 ± 2.34 4.37 ± 2.34 4.41 [-2.04 to 10.86]
KOOS SYM [0-100]§ 0.13 ± 0.99 2.19 ± 1.20 2.06 [-1.04 to 5.17]
†To assess the robustness of the obtained increments in EQ-5D we performed sensitivity analyses in which 
we; imputed missing values of EQ-5D during follow up; evaluated increments over a three year period, 
ranging from the first visit preceding arthroscopic surgery to the third visit after arthroscopic surgery; and 
used the complete dataset without matching subjects based on propensity scores; ‡ Higher scores on the 
WOMAC indicate worse performance; § Higher scores on the KOOS & EQ-5D indicate better performance; 
|| Both KOOS and WOMAC questionnaires had subscales that were administered for the left and right knee 
separately. Bilateral observations within one subject cannot be considered as being independent. Therefore, 
in case of bilateral meniscectomies, and for those subjects who did not undergo arthroscopic surgery we 
randomly selected the scores of the left or the right knee.
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Table 3   Parameter inputs used in the base case analysis of cost-effectiveness  
of arthroscopic meniscectomy compared to the natural course of knee 
osteoarthritis.
Parameter Base Value Distribution Source
Health state utilities, in QALYs 
(mean ± S.E.)
  Baseline utility 0.90 ± 0.02 Normal OAI database
   Change in utility after arthroscopic 
meniscectomy
0.01 ± 0.06 Normal OAI database
   Change in utility for matched controls -0.01 ± 0.01 Normal OAI database
   Utility after knee replacement surgery 0.85 ± 0.013 Normal OAI database
Transition probabilities in percentages
(mean ± S.E)
   Knee replacement surgery after 
standard care 
0.02 ± 0.01 beta OAI database,  
Rongen et al.
   Increased risk for knee replacement after 
arthroscopic meniscectomy  
(log scale)
1.11 ± 0.29 lognormal OAI database,  
Rongen et al. 
   Late failure of knee replacement 0.01 ± 0.00 beta Rand et al. 30
   Revision for failed knee replacement 0.500 fixed Losina et al.33
Costs in Euros 
  Arthroscopic meniscectomy € 4,204 gamma RadboudUMC,  
OAI database
  Symptomatic OA (incremental) € 2,155 gamma Hermans et al. 35,  
OAI database
  knee replacement surgery € 15,055 gamma RadboudUMC,  
OAI database
   Revision knee replacement surgery € 18,980 gamma RadboudUMC ,  
OAI database
Miscellaneous 
  Cost discount rate, per yr 4.0% Fixed Hakkaart-  
van Roijen et al.36 39
  Effect discount rate, per yr 1.5% Fixed Hakkaart-  
van Roijen et al.36 39
Table 4   Results of base case analysis and sensitivity analyses of cost-effectiveness  
of arthroscopic meniscectomy compared to the natural course of knee 
osteoarthritis.
Base case analysis
Treatment Costs (SD) /utilities (SD) ICER
Arthroscopic meniscectomy € 21,031 (±865) /  
8.09 (±0.07)
€ 131,306
No surgery € 16,304 (±926) /  
8.05 (±0.07)
Subgroup analyses
Progression subgroup no surgery dominant
Incidence subgroup € 55,624
Sensitivity analyses
Assumption Variation ICER
We ran the model for 9 years, according to the follow up of the OAI study
Lifetime perspective no surgery dominant
Lifetime progression 
subgroup
no surgery dominant
Lifetime incidence  
subgroup
€ 139,400
A failed knee replacement would result in a 25% reduction in quality of life
10% reduction € 127,757
40% reduction € 143,212
A failed knee replacement results in a 50% increase in costs compared with symptomatic knee 
osteoarthritis
0% increase € 134,714
100% increase € 135,286
50% of the patients with a failed knee replacement would elect revision
25% € 131,139
100% € 139,147
We used a 4.0 % and 1.5 % discount rate for costs and effects respectively
3.0 % and 3.0 % € 134,429
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Using open access data from a multi-center, longitudinal, observational study, we 
evaluated the costs and effectiveness of arthroscopic surgery with meniscectomy for 
subjects with, or at risk for, symptomatic knee osteoarthritis in a routine clinical practice, 
and we compared the cost-effectiveness of arthroscopic meniscectomy to no surgery (i.e. 
natural course of symptoms). Although a (small) benefit was observed in scores related to 
knee pain for subjects who underwent surgery compared to those subjects who did not 
undergo surgery, this difference did not result in an improvement in quality of life large 
enough to outweigh the additional costs and increased risk for future knee replacement 
surgery. The reduction in knee pain associated with arthroscopic meniscectomy is in line 
with the common conception of surgeons that arthroscopic surgery with meniscectomy 
is an effective treatment in a routine clinical practice.
 Results from the cost-effectiveness analysis demonstrated that the incremental costs 
of arthroscopic meniscectomy in patients with, or at risk for, knee osteoarthritis was 
€ 131,306 per QALY gained. The willingness to pay per QALY gained differs between health 
care systems and may also be dependent on the burden of the disease of interest (diseases 
with a higher burden may justify a higher willingness to pay), and the degree of uncertainty 
surrounding the calculation of the ICER. Generally, the willingness to pay ranges between 
€20,000 and € 80,000 per QALY gained. Independent of the burden of disease and the 
uncertainty surrounding the calculation of the ICER, the incremental costs per QALY 
gained for the surgical treatment of degenerative meniscus tears exceeds the general 
accepted willingness to pay.
 Although within a time frame of 9 years the ICER of arthroscopic surgery may fall 
within the range of  willingness to pay for the incidence subgroup (subjects at risk for 
developing symptomatic knee osteoarthritis, ICER € 55,624), extending the model horizon 
to a life time perspective resulted in an ICER that exceeds the generally adopted willingness 
to pay. Increasing the time frame of the model puts more emphasis on the negative 
consequences of arthroscopic meniscectomy with respect to the increased risk for knee 
replacement surgery. 
The major strength of our study is that the model input parameters were derived from a 
routine health care setting (instead of a clinical trial with limited generalizability) where 
surgeons themselves selected patients. Moreover, the increased risk for knee replacement 
surgery after arthroscopic meniscectomy was also taken into consideration while 
evaluating the incremental costs and effects of arthroscopic treatment of degenerative 
meniscus tears.
 Some potential limitations should also be discussed. First, due to the observational 
nature (i.e. the lack of randomization of subjects over different treatment regimes) 
confounding by indication cannot be precluded. We compared the cost-effectiveness of 
surgical treatment with no surgery, which can be considered as the natural course of the 
symptoms. Due to selection bias, a difference in health effects over the period of interest 
between subjects who did and subjects who did not undergo arthroscopic meniscectomy 
could be biased by confounding characteristics (i.e. an expected difference in the course 
of knee osteoarthritis based on baseline characteristics). To control for this potential 
confounding by indication, we matched subjects based on propensity scores. Although 
matching of subjects was successfully performed based on a considerable subset of 
baseline characteristics, differences could theoretically still exist in unmeasured character-
istics. However, our sensitivity analysis in which we evaluated the effect of propensity 
score matching demonstrated that the observed changes were quite robust.
 Second, again due to the observational nature, it was not possible to control for 
confounding placebo effects. The overall outcome of the surgical treatment is a cumulative 
effect of three main elements: true treatment effects of the surgical procedure, placebo 
effects, and non-specific effects. The true treatment effect of the specific surgical 
procedure is the effect realized by the component of the surgical procedure believed to 
Figure 2   A scatterplot of incremental costs and effects of arthroscopic meniscectomy.
Taking into account the 2nd-order uncertainty in the sampling distribution of all parameters, the scatter plot 
includes a single set of points representing pairs of incremental cost and effectiveness values from the first 10,000 
of the 100,000 simulation results relative to the costs and effectiveness values of the natural course of knee 
osteoarthritis. The white diamond represents the overall estimate of the ICER. WTP = willingness to pay per QALY 
gained; The willingness to pay per QALY gained differs between health care systems and generally ranges between 
€20,000 and € 80,000 per QALY gained. 20k = wtp of € 20,000; 50k = wtp of € 50,000; 80k = wtp of € 80,000.
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provide the therapeutic effect (here meniscectomy). The placebo effects are related to the 
patients’ expectation and the “meaning of surgery” (i.e. receiving the treatment may 
improve a patient’s condition simply because the person has the expectation that it will 
be helpful, i.e. expectation bias).40 It is likely that the arthroscopic meniscectomy is 
associated with a placebo effect, since invasive procedures and a confident diagnosis and 
decisive approach to treatment (both typical for arthroscopic surgery) usually results in 
strong placebo effects.40-44 For example, in arthroscopic surgery with meniscectomy for 
degenerative meniscal tears, surgery may provide no significant benefit over sham surgery 
at all.45 Non-specific effects are caused by fluctuations in symptoms, the clinical course of 
the disease, regression to the mean, report bias, interaction with the surgeons, etc. Still, 
even without taking a placebo effect (i.e. expectation bias) into consideration, the ICER of 
arthroscopic meniscectomy exceeded the generally adopted willingness to pay.
 A third limitation is the imprecision of the two year period over which changes in 
quality of life were assessed. During each annual follow up visit subjects answered the 
question on whether they had undergone arthroscopic meniscectomy in the time since 
their last visit. By taking the first follow up visit preceding arthroscopic surgery as baseline, 
we did not take into account any acute changes in symptoms that may have occurred and 
which may have been a cause for referral to the orthopedic surgeon. However, the 
degenerative meniscal tears which are typically seen in middle aged or older subjects are 
caused by chronic degenerative processes, and most commonly have a gradual onset of 
symptoms.45 By taking the first visit after the visit where subjects mentioned to have 
undergone arthroscopic surgery we had follow up times of at least one, and a maximum 
of two years. Previous studies suggested that benefits from arthroscopy may be absent at 
1-2 years after surgery, this was not accounted for in our model.15 16 Our sensitivity analysis 
demonstrated that the observed results did not change if we extended the follow up 
period for another year. This justified the initial time perspective in the cost effectiveness 
model of 9 years. However, running the model with a lifetime perspective assumed that 
the observed benefits of surgery remained stable and did not take into account the 
possibility of diminished effects over time, potentially overestimating the surgical treatment 
effect. Still, on a life time perspective, surgery was demonstrated not to be the preferred 
treatment.
 Fourth, we primarily analyzed the data by using subjects from the full OAI cohort, 
ignoring the subdivision into a progression and incidence subcohort. This may result in an 
imprecise estimate if applied to either a patient with, or a patient at risk for knee 
osteoarthritis. However, we chose not to separate both cohorts in the primary analysis 
because this would have been somewhat arbitrary. First, the development of knee 
osteoarthritis is a chronic process, and there is a continuum of pathology between 
incident and progressive osteoarthritis. Second, it is possible that subjects were assigned 
in the progression cohort because they had symptomatic knee osteoarthritis in one knee, 
but that the meniscus surgery took place in the contralateral knee. The subgroups analysis 
demonstrated a difference between subgroups, but on a lifetime perspective, these 
differences did not influence the interpretation of the results.
Clinical implications
In a routine health care setting (i.e. normal clinical practice), arthroscopic meniscectomy in 
subjects with, or at risk for, knee osteoarthritis is associated with a (small) reduction in knee 
pain. Though, this reduction in knee pain does not result into an improvement in quality 
of life large enough to outweigh the increased risk for future knee arthroplasty surgery 
and the increased costs associated with the surgical procedure. These results should be 
used in shared decision making by informing both patients and surgeons about the 
(limited) added value of the surgery.
 Moreover, these results can be used to inform health care resource allocation 
decisions in order to improve the efficiency of the health care system. By limiting the 
amount of arthroscopic meniscectomies in subjects with, or at risk for, knee osteoarthritis 
costs can be controlled without cutting the quality of care.
Conclusion
In the normal clinical practice, where surgeons themselves select patients for surgery, 
arthroscopic meniscectomy in patients with, or at risk for, knee osteoarthritis is not cost-
effective.
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Appendix: Statistical methods
To adjust for confounding baseline characteristics we matched participants based on 
their propensity scores.28-30 The propensity score was defined to be the probability of 
undergoing arthroscopic meniscectomy during follow up conditional on a subject’s 
observed baseline characteristics.31
First, missing values in baseline variables were imputed to increase precision and to avoid 
bias. KOOS Function in Sport and Recreation had 25.8% missing values at baseline whereas 
other variables had less than 1.5% missing values. (appendix Table 1) Multiple imputations 
were used for missing values using logistic and linear regression methods with a random 
component, conditionally being missing at random. Ten independent imputed datasets 
were generated. 
Subsequently, propensity scores were estimated, independently for each imputed dataset, 
using a logistic regression model with arthroscopic meniscectomy during follow up as the 
dependent binary variable in relation to the following baseline characteristics: treatment 
center, age, gender, weight, Physical Activity Scale for the Elderly (PASE) score, having any 
kind of health care coverage, having any kind of health care coverage, knee replacement 
in either knee at baseline, presence of Herberden’s nodes in both hands, engaging in 
frequent knee bending activities, radiographic composite grade of osteoarthritis, history 
of serious knee injury, baseline knee symptoms, history of medication used for knee 
symptoms, history of knee surgery, family history on knee replacement surgery, WOMAC 
subscale scores, KOOS subscale scores, and SF-12 subscale scores.
We used a 1:1 matching algorithm without replacement to match exposed and non - 
exposed individuals on propensity score within a caliper of 0.2 standard deviation of the 
logit of the propensity score.25, 26 Balance after matching was checked graphically and 
descriptively.
Both KOOS and WOMAC questionnaires had subscales that were administered for the left 
and right knee separately. Next, over time, participants could have undergone arthroscopic 
surgery in both knees. Bilateral observations within one subject cannot be considered as 
being independent.34 Therefore, in case of bilateral meniscectomies, and for those 
participants who did not undergo arthroscopic surgery we randomly selected scores 
corresponding to the left or the right knee .
Changes in quality of life (EQ-5D) and knee osteoarthritis symptoms (KOOS and WOMAC 
subscales) were assessed over a two year period. This period was defined as the period 
ranging from the first visit preceding arthroscopic surgery to the second annual visit after 
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To assess the robustness of the obtained results we performed sensitivity analyses in 
which we: imputed missing values of outcome data on quality of life and knee osteoarthritis 
symptoms; evaluated differences in changes over a three year period, ranging from the 
first visit preceding arthroscopic surgery to the third visit after arthroscopic surgery; 
stratified the results of the progression and the incidence subcohorts; and used the data- 
set without propensity score matching of participants. (appendix Table 2)
All analyses were performed in IBM SPSS statistics version 22.0.
the arthroscopic surgery. For participants who did not undergo arthroscopic surgery, 
changes in quality of life and knee osteoarthritis symptoms were assessed over the same 
period as their matched participants who did undergo arthroscopic surgery.
We used an independent Student’s t-test to test for differences in changes in quality of life 
(EQ-5D) and knee osteoarthritis symptoms (WOMAC & KOOS) between participants who 
underwent arthroscopic meniscectomy and their matched control participants who did 
not undergo arthroscopic surgery. The resulting estimates on the ten independent 
imputed and propensity matched datasets were pooled to obtain final estimates.35
Appendix 3. Table 2   Results of sensitivity analyses of differences in changes in  
knee symptoms and quality of life.
Variable PRIMARY ANALYSIS Imputed outcomes Longer follow up Variable progression cohort Incidence cohort No PS matching
Difference [95CI] Difference [95CI] Difference [95CI] Difference [95CI] Difference [95CI] Difference [95CI]
EQ-5D [0-1] 0.011 [-0.007 to 0.031] 0.013 [-0.003 to 0.030] 0.012 [-0.013 to 0.038] EQ-5D [0-1] -0.003 [-0.043 to0.037] 0.018 [-0.007 to 0.043] 0.012 [0.002 to 0.022]
WOMAC pain [0-20] -1.07 [-1.75 to -0.39] -1.16 [-1.88 to -0.44] -1.08 [-1.80 to -0.36] WOMAC pain [0-20] -1.20 [-2.63 to 0.23] -0.93 [ -1.81 to -0.05] -0.99 [-1.35 to -0.64]
WOMAC stiffness [0-8] -0.28 [-0.65 to 0.10] -0.27 [-0.63 to 0.10] -0.28 [-0.67 to 0.12] WOMAC stiffness [0-8] -0.17 [-0.74 to 0.41] -0.19 [ -0.60 to 0.21] -0.31 [-0.48 to -0.13]
WOMAC disability [0-68] -1.87 [-4.09 to 0.37] -2.08 [-4.08 to -0.08] -2.88 [-5.53 to -0.24] WOMAC disability [0-68] -2.62 [-6.91 to 1.68] -1.02 [ -3.03 to 1.26] -1.81 [-2.88 to -0.74]
KOOS pain [0-100] 5.32 [1.72 to 8.92] 5.58 [2.04 to 9.13] 5.85 [2.02 to 9.67] KOOS pain [0-100] 5.23 [-2.06 to 15.51] 4.82 [ 0.11 to 9.54] 5.14 [3.35 to 6.93]
KOOS QOL [0-100] 2.47 [-2.28 to 7.23] 2.36 [-1.87 to 6.59] 4.02 [-0.93 to 8.98] KOOS QOL [0-100] 0.12 [-6.24 to 6.49] 3.69 [-1.25 to 8.63] 3.69 [1.57 to 5.81]
KOOS FSR [0-100] 4.41 [-2.04 to 10.86] 3.68 [-1.22 to 8.57] 5.31 [-2.12 to 12.73] KOOS FSR [0-100] 3.66 [-9.31 to 16.63] 4.56 [-2.84 to 11.96] 5.51 [ 2.23 to 8.78]
KOOS SYM [0-100] 2.06 [-1.04 to 5.17] 1.95 [-1.38 to 5.28] 3.82 [0.48 to 7.16] KOOS SYM [0-100] 1.68 [-4.24 to 7.60] 1.46 [-2.35 to 5.27] 2.30 [-0.78 to 3.83]
Reported are the differences in changes between participants who underwent surgery relative to participants 
who did not undergo surgery [mean 95%CI], stratified for the different sensitivity analyses. Higher scores on the 
WOMAC scales indicate worse performance, whereas higher scores on the KOOS & EQ-5D scales indicate 
better performance over the course of arthroscopic surgery with meniscectomy compared to propensity 
score matched participants who did not undergo arthroscopic surgery.
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Introduction
The menisci fulfill an important biomechanical function in the knee by distributing load 
evenly over two incongruent surfaces, preventing the accumulation of pathological peak 
stresses.1 Meniscus tears are one of the most frequent diagnoses made by orthopedic 
surgeons.2-4 Based on the underlying etiology and clinical presentation it is possible to 
distinguish two different entities of meniscal tears, traumatic and degenerative tears.5 
 Traumatic meniscal tears occur in younger active patients and are caused by a 
traumatic injury. Symptoms of traumatic meniscus tears are routinely treated by a partial 
meniscectomy, removing only as little meniscus tissue necessary and to preserve the 
peripheral rim of the meniscus wherever possible.6 Although providing satisfactory 
short term improvement in symptoms, the disadvantage of partial meniscectomy is 
the consequential development of degenerative changes in the knee joint, increasing 
the likelihood to develop symptomatic knee osteoarthritis.7, 8 Currently, much effort is 
put into the development of novel procedures that focus on these adverse effects of 
partial meniscectomy. Two different approaches can be distinguished. The first approach 
focuses on the prevention of knee osteoarthritis after partial meniscectomy by retaining 
or substituting the damaged meniscus tissue. The secondly  approach focuses on the 
alleviation of symptoms in the previously partially meniscectomized knee by substituting 
lost meniscus tissue. Both approaches will be discussed in the first part of this general 
discussion.
 Degenerative meniscal tears are typically seen in middle aged and older patients, are 
accompanied by knee osteoarthritis, and are caused by chronic degenerative processes.5, 9 
Routinely, these tears are treated arthroscopically by the resection of the degenerative 
meniscus tear. However, the indication for surgical treatment of degenerative meniscus 
tears is currently subject of debate, and will be discussed in the second part of this general 
discussion. 
 Following on the discussion of the treatments for traumatic and degenerative meniscus 
tears, recommendations for future research will be provided in order to increase the quality 
and effectiveness of care related to meniscus pathology.
PART 1 traumatic meniscus tears
Prevention of knee osteoarthritis
Much effort is put into the development of procedures that treat traumatic meniscus tears 
by repairing or substituting the damaged meniscus tissue, theoretically preventing the 
development of knee osteoarthritis otherwise encountered after resection of damaged 
meniscus tissue.10-12 
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 We will discuss on meniscus repairs as well as meniscus substitutes. However, before 
discussing these procedures in more detail, one important aspect should already be 
considered, and that is that, even with these treatments retaining or reconstructing 
meniscus tissue, the development of knee osteoarthritis may not be completely avoidable. 
First, irrespective of the traumatic meniscus tear, the natural predisposition to develop 
knee osteoarthritis should be considered. Second, the initial trauma responsible for the 
meniscus to tear is on itself also a risk factor for the development of symptomatic knee 
osteoarthritis.13 The initial trauma, large enough to damage the meniscus, may well also 
have damaged the articular cartilage, either directly or indirectly via a subsequent 
inflammatory response. 
Meniscus repair
Meniscus repair procedures assume that preservation of meniscus tissue prevents or 
reduces the development of knee osteoarthritis otherwise encountered after partial 
meniscectomy. Although meniscus repairs are performed increasingly14, it still remains an 
evolving  procedure, and not all tears have been demonstrated to be amendable for 
repair.15 Due to the continuously evolving nature of meniscus repair procedures, strict 
indications are lacking. However, successful healing of the repaired traumatic meniscus 
has been demonstrated to depend on several factors.15 Firstly, the location of the tear. 
Tears should be in the vascularized zone because vascular supply is the most important 
factor in healing. Secondly, the tear size. Tears should not be more than 4 cm in length 
because larger tears are unstable to the point that repairs often fail. Thirdly, the tear shape. 
Vertical tears are suitable for repair since they are amendable to suture fixation. Fourthly, 
patients age. Repairs are preferred in younger patients (age < 40 years) since they are 
believed to have a more effective healing response. Moreover, a correct knee alignment 
and a stable knee is recommended for successful repair.15 
 The repair procedure is followed by a prolonged rehabilitation program. This rehabilitation 
program includes restrictions in allowed weight bearing and in range of motion. This 
extensive rehabilitation program is designed to prevent undesired stresses on the repair 
in the early stages of healing.15 
 Although promising in concept, the efficacy of meniscus repairs in the prevention of 
knee osteoarthritis has not yet been demonstrated. Moreover, it is unclear how the 
postoperative outcomes after meniscus repairs measure up to the satisfactory outcomes 
after partial meniscectomy. This lack of knowledge is the result of an absence of 
randomized controlled clinical studies evaluating the efficacy of meniscus repairs (in 
treating symptoms and in preventing knee osteoarthritis) compared to the standard 
partial meniscectomy. Although case series demonstrate feasibility and satisfactory 
postoperative outcomes, they also demonstrate considerable failure rates of meniscus 
repairs, requiring reoperations (re-repair or yet partial meniscectomy) in up to 30% over 
a 10 year period.16 
 Considering the pros and cons of the treatment makes it legitimate to question 
whether the prolonged rehabilitation program, the considerable risk of requiring a 
reoperation, and the additional costs warrant the general adoption of novel procedures 
for meniscus repair without evidence of its clinical efficacy. 
 Moreover, one could even go as far as speculating whether there is any added value 
of surgical repair for some of these tears at all. Formerly, traumatic meniscus tears were 
routinely treated by total meniscectomy, and as a result, outcomes of conservative 
approaches have been less well documented. On the other hand, it is accepted that 
meniscus tears have the ability to heal15, 17, 18, especially in the well vascularized peripheral 
zone, and it is this healing potential that forms the basis of meniscus repairs. Therefore, 
it is interesting to speculate whether precisely these tears, qualifying for repair since they 
have the potential to heal, would also heal after following the extensive rehabilitation 
protocol as provided with meniscus repairs only. Here, preventing undesired stresses on 
the tear may well allow natural healing of some tears.
Meniscus replacement
Despite its promising concept, meniscus repairs have been demonstrated not to be suited 
for all traumatic meniscus tears. Hence, other alternatives procedures to treat irreparable 
meniscus tears are being developed that aim to prevent knee osteoarthritis by substituting 
the damaged and resected meniscus tissue.
 The concept of replacing damaged and resected meniscus tissue became reality 
with the application of meniscus allograft transplantations. As from the late 80s, meniscus 
allograft transplantation procedures were developed to offer a solution for the many 
patients who had underwent a total meniscectomy previously.19 Treating meniscus tears 
with total meniscectomy was considered routine practice until the late 80s. It was only 
after appreciating the development of knee osteoarthritis subsequent to the total 
meniscectomy that made surgeons switch to partial meniscectomies. Meniscus allografts 
were supposed to treat and prevent the development of knee osteoarthritis in the knee 
joint after meniscectomy.19, 20 However, the limited availability of (size matched) donor 
menisci, concerns of disease transmission and graft longevity, and challenges in tissue 
processing led to a pragmatic approach to selectively use meniscus allografts in the 
treatment of patients who had developed symptoms of in their previously meniscecto-
mized knee compartment.19, 21 Despite the shift in indication from prevention to 
treatment, the experience with meniscus allograft transplantations had demonstrated 
the feasibility of replacing the meniscus. This encouraged the development of meniscus 
implants, intended for the treatment of meniscus tears that would otherwise be treated 
by the nowadays routinely performed partial meniscectomies.11 Meniscus implants can 
broadly be categorized in permanent implants (e.g. NUsurface®) and degradable implants 
(e.g. the Collagen Meniscus Implant (CMI®) and the Actifit® implant). Permanent implants 
are designed to take over the function of the damaged and resected meniscus tissue 
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while degradable implants are scaffolds designed to promote the formation of new 
functional meniscus tissue in a self-healing process. For correct implantation, the currently 
available permanent and degradable meniscus implants require an intact peripheral rim 
of the meniscus. Besides, to guarantee successful tissue ingrowth, degradable implants 
are also dependent on blood supply and a stable fixation. 
 Although it has been demonstrated that meniscus allografts have the ability to 
reduce the development of osteoarthritic changes compared to meniscectomy in animals 22, 
a similar effect has not been robustly demonstrated for meniscus implants.11, 23-27 
On the other hand, pre clinical animal studies did demonstrate the feasibility of meniscus 
implant procedures. This feasibility may be regarded as a proof of concept and  ratio - 
nalization to consider proceeding to human implementation. However, at the same time, 
the limited evidence on efficacy points out the importance of the evaluation of the 
implants’ effectiveness in preventing knee osteoarthritis s in a clinical setting.
 In the clinical setting, meniscus implants are currently evaluated for those (traumatic) 
meniscus tears that are not suitable for repair procedures. Generally, other prerequisites 
are that a stable peripheral meniscus rim is present, and that the knee joint is correctly 
aligned and stable. Due to the continuously evolving nature of meniscus repairs, there is 
no strict definition of an irreparable meniscus tear, and thus a clearly defined indication 
for meniscus implant procedures in the treatment of traumatic meniscus tears is lacking. 
Tears considered not suitable for repair and thus eligible for meniscus implant procedures 
would include large (>4cm) unstable vertical tears in the vascularized zone, and tears in 
the non vascularized zones that would otherwise be treated by partial meniscectomy.15 
Partial meniscectomy of tears in non vascularized zones would lead to relative limited 
meniscus tissue being resected. In addition, the application of a meniscus implant in these 
cases may require additional resection of meniscus tissue (on top of the tissue resected 
during partial meniscectomy) to allow for correct meniscus implant positioning. For the 
degradable CMI® and Actifit® implants a defect site should be prepared that extends into 
the vascularized zone, wherein defects sites that only extend to the border of vascular 
supply require additional puncture holes into the fully vascularized zone. For the 
permanent NUsurface® implant a subtotal meniscectomy has to be performed, leaving 
only the peripheral rim of the meniscus, to allow correct implant positioning. The 
assumption that for smaller tears in non vascularized zones, meniscus implant procedures 
offer a solution to prevent knee osteoarthritis relies heavily on their yet undemonstrated 
cartilage protecting effect.
 Large traumatic tears in the vascularized zone of the meniscus, due to their lack of 
intrinsic stability not suited for repair, would lead to considerable loss of meniscus tissue if 
excised during partial meniscectomy. Here, meniscus implant procedures may offer a 
more promising solution to prevent the development of knee osteoarthritis. Though, 
this assumption also relies on the yet undemonstrated cartilage protecting effect.
 In general, for degradable meniscus implants, the concern can be raised as to whether 
there is an indication in the treatment of irreparable meniscus tears at all. Since, just as 
meniscus repairs, degradable meniscus implants require blood supply and a stable 
fixation in order to guarantee tissue ingrowth and successful healing. This suggests a 
possible overlap in indication of meniscus repairs and degradable implants in the 
treatment of traumatic meniscus tears, leaving to wonder what the added value of 
degradable implants would be over repairs. Moreover, it is unclear whether there is an 
indication for degradable implants for tears that have been demonstrated to be not 
suitable for repair.
 To date, clinical studies evaluating meniscus implants rely on uncontrolled case series 
evaluating initial safety and feasibility of implant procedures. However, (randomized) 
controlled trials will be necessary to demonstrate a cartilage protecting effect of meniscus 
implant procedures compared to partial meniscectomy. 
Treatment of symptoms post meniscectomy
To prevent the development of knee osteoarthritis, meniscus implants should ideally 
be implanted at the same time as which the partial meniscectomy would have been 
indicated. However, clinical studies have broadened the indication of meniscus implant 
procedures by also evaluating their application in the treatment of localized pain in the 
previously partial meniscectomized knee, seemingly subordinating the prevention of 
knee osteoarthritis to pain reduction. This intended application follows the example of 
meniscus allograft transplantation in the treatment of knee pain after a previous total 
meniscectomy (as illustrated in the previous section), but focuses on previous partial 
meniscectomies.
 Pursuing the indication of treating localized pain in the previously partial meni-
scectomized knee with meniscus implants is based on the presumption that meniscus 
allograft transplantation is an effective treatment for symptoms post total meniscectomy. 
Although supporters of the procedure plead that the results of meniscus allograft 
 transplantation in the treatment of pain in the meniscectomized knee are promising, and 
that the application of these allografts should no longer be considered experimental28, 29, 
some critical reflection is required. Case series may demonstrate feasibility and safety of 
these transplantations, though evidence in favor of efficacy over any reference treatment is 
lacking. Results presented in case series originated from patients aged 14 through 69 years. 
Typically, the time between the initial meniscectomy and transplant implantation was 
more than 10 years, and the knees in these patients were typically already in an early stage 
of osteoarthritis.28, 30 Also, patients generally had a history of multiple previous surgical 
procedures in the same knee, and concomitantly underwent other surgical procedures in 
the same knee during the meniscus allograft transplantation. Moreover, postoperatively 
patients had to adhere to a prolonged and intensive rehabilitation program.28 These 
factors hinder an unbiased interpretation of any clear effect of meniscus allografts in 
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the treatment of localized knee pain post meniscectomy. Even more so, inherent to the 
study designs, any true treatment effect cannot be unraveled from placebo or nonspecific 
effects. Thus, a randomized controlled trial that evaluates the efficacy over a reference or 
placebo intervention is needed in order to appreciate the true effectiveness of the 
treatment.
 Questioning the extent of a true treatment effect of meniscus allograft transplantation 
concomitantly questions the pursued indication of meniscus implant procedures to treat 
pain localized in the previous partially meniscectomized knee. Moreover, in this setting 
the remaining degenerative meniscectomized meniscus tissue has a very poor or no 
healing capability, questioning the regenerative potential necessary for procedures with 
degradable implants. 
 Next to putting emphasis on the need for high quality randomized controlled trials 
both for meniscus allografts as for meniscus implants, the question may be posted here 
what it is that is actually being treated? Rather than the symptoms originating from the 
deficiency of meniscus tissue and the subsequent increased peak pressures on the 
cartilage, it is more likely that symptoms are a part of early onset knee osteoarthritis. 
The localized symptoms may well arise from multi-factorial osteoarthritic processes 
caused by both the initial trauma as well as the sustained and prolonged increased 
pathological peak pressures after loss of meniscus tissue. 
 For symptoms related to knee osteoarthritis a rigorous conservative non surgical 
treatment is the preferred first line treatment.31 If conservative treatment fails, other 
surgical options may be considered, such as a (unicompartmental) knee arthroplasty.31 
A dilemma that may be encountered is that patients with symptomatic knee osteoarthritis 
after a previous (partial) meniscectomy are relatively young. It is questionable, however, 
whether meniscus implant procedures have the potential to offer a cost-effective solution 
to this dilemma in comparison to other alternative treatments.32 
PART 2 Treatment of degenerative meniscus tears
In addition to the treatment of acute traumatic meniscus tears and symptoms post 
meniscectomy, the continuum of meniscus related treatments also includes the treatment 
of symptoms attributed to degenerative meniscus tears.
 Degenerative meniscal tears are typically seen in middle aged and older patients, are 
accompanied by knee osteoarthritis, and are caused by chronic degenerative processes.5, 9 
Clinical symptoms attributed to the degenerative meniscus tear generally have a gradual 
onset  and may encompass localized pain and mechanical obstructions (occasional 
catching or locking).33-35 According to the national guidelines by the Netherlands 
Orthopedics Association, conservative, non surgical, treatment should be the preferred 
option, though degenerative tears associated with persistent pain and mechanical 
symptoms may be treated arthroscopically.6 
 However, the expanding knowledge about degenerative meniscus tears questions 
the indication of surgical treatment. Firstly, the common conception that symptoms such 
as pain and mechanical obstructions are attributable to degenerative meniscus tears has 
been refuted.36-39 Secondly, accumulating evidence from randomized controlled trials 
has demonstrated that the treatment effect, if present at all, is inconsequential and does 
not outweigh the short term surgical harms.35, 40, 41 Thirdly, the procedure is associated 
with an increased risk for future knee replacement surgery.42 Fourth and finally, also in a 
normal health care setting where surgeons individually select patients for surgery,  the 
small beneficial treatment effect does not translate into an improvement in quality of life 
large enough to outweigh the additional costs and the increased risk for future knee 
replacement associated with the procedure.43
 Unfortunately, studies have demonstrated a delay in dissemination, acceptance and 
implementation of this growing clinical evidence into orthopedic practice.44-47 Also in 
the Netherlands, meniscus surgery is still performed disproportionately often in the 
treatment of degenerative meniscus tears.48
 Supporters of the procedure may apparently still consider the current evidence 
insufficient to reconsider their practice. Orthopedic surgeons have expressed their 
concerns about the generalizability of the trial results and point out that the study 
populations are not representative to the patients they select for surgery in routine clinical 
practice.49-53 However, results from observational studies draw similar conclusions as 
the trials criticized by orthopedic surgeons. 
 In view of all evidence pointing in the same direction, it can be disputed whether 
holding on to current practice is ethically justified. All the information that questions the 
indication of the treatment cannot be waved aside while informing the patient of the pros 
and cons in the choice of treatment in order to obtain valid informed consent and to allow 
for shared decision making. It would be more appropriate to consider these patients as 
having (early stage) osteoarthritis and to treat them accordingly and in line with clinical 
guidelines for knee osteoarthritis, starting with information, exercise and weight loss.31
 Additionally, it is unlikely that the meniscus repair and implant procedures can offer 
any added value in the treatment of symptoms attributed to degenerative meniscus tears. 
Not only because the symptoms that are intended to be treated cannot be attributed to 
the degenerative meniscus tear, but also because the torn and degraded meniscus has 
very poor or no healing potential.
Recommendations for future research
In view of the reporting on novel treatments related to the meniscus demonstrates that it 
is has been rather a practice of trial and error. Formal and comparative assessments of 
the procedures played only a marginal role, and there has been hardly any attention to 
patients and societal inconvenience or costs. In order to demonstrate effectiveness, high 
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quality randomized controlled trials are highly needed, and these trials should include 
both patient-relevant outcome measures and modern MRI outcomes to detect early 
changes in cartilage status. Further accumulation of (retrospective) case series that 
demonstrate feasibility and short term outcomes without providing evidence on efficacy 
can be considered redundant.
 The data from the already reported case series can be used to allow power 
calculations, strictly clarify the definition and indications of the interventions, and develop 
quality measures. For those interventions where experience with the procedure may still 
be limited, data should be monitored systematically by means of registered prospective 
research databases. By systematically monitoring every patient that is subjected to the 
novel procedure, full documentation of the adverse outcomes is also warranted
Traditionally, orthopedic research is focused on retrospective cohort studies, and 
orthopedic surgeons (like other surgeons) have often been blamed for not adhering to 
scientific standards and for ignoring randomized controlled trials as the best methodology 
for evaluating treatment effectiveness.54-58 The general conception is that randomized 
controlled trials are more complicated, difficult to carry out with sufficient numbers of 
subjects or duration of follow-up, and are irrelevant to their clinical practice because of 
concerns about generalizability. However, few, if any, of these challenges apply only to 
surgical procedures, and despite its challenges, randomized controlled trials remain the 
best possible study design for the assessment of therapeutic interventions. 
 Formal assessment of novel surgical procedures, although considered complex, is 
necessary so that introduction and adoption of surgical procedures can derive from 
evidence based principles (the promotion of unbiased, reliable types of evidence) rather 
than trial and error. 
A regulatory framework 
The limited success of the implementation of evidence based principles in the (orthopedic) 
surgical community is in part attributable to the absence of a framework that regulates 
the development of novel surgical procedures (as available for drug development). Such 
a framework is highly desirable in order to protect patients against potential harms of any 
novel surgical procedure and to prevent the adoption of those procedures with no proven 
benefit.
 In order to overcome this lack of a regulatory framework, a collection of methodologists 
and clinicians (i.e. the Balliol collaboration) proposed a framework, referred to as the IDEAL 
recommendations (the acronym IDEAL stands for the different stages of surgical 
innovation; Idea, Development, Exploration, Assessment, and Long term study).55, 58, 59 
The recommendations consist of (a) a framework that described the various developmental 
stages of surgical (interventional) innovations and (b) guidelines on (how to improve) 
the methodology and reporting of research at each of these stages. The IDEAL framework 
is based on the belief that surgical innovation and evaluation can and should progress 
jointly in an ordered manner from concept (Idea & Development), through exploration 
(Exploration), to validation by randomized controlled trials (Assessment) and surveillance 
(Long term study). For each stage, guidelines on the research methodology and reporting 
are provided, encouraging widespread replacement of case series by registered 
prospective development studies, using prospective databases and registries, and the 
use of randomized controlled trials whenever possible to investigate efficacy.
 Adhering to IDEAL recommendations will result in the adoption (or refusal) of surgical 
innovations based on unbiased, reliable types of evidence, and consequently protect 
patients against the potential harms of any novel procedure. To be of success, the 
implementation of these improved standards will require widespread changes and full 
involvement of publishers, payers/funders, regulatory bodies, and surgical societies.
 It is crucial that these recommendations are also adhered to in the evaluation of novel 
meniscus treatment strategies. An encouraging development is that already some of 
the IDEAL recommendations have been adopted, looking at the timely registration of 
prospective developmental/safety studies of meniscus implants.(60, 61)
Cost-effectiveness 
Although the IDEAL recommendations propose a valuable framework for the evaluation 
of the safety and efficacy of novel surgical procedures, they do not take into account the 
additional costs and therapeutic consequences of new treatment procedures. This 
weighing of the additional costs and consequences against its potential treatment effect 
is becoming increasingly important since health care budgets are constrained, and the 
current policy by health authorities tends towards only reimbursing novel procedures 
that are cost-effective. 
 With respect to novel procedures, evaluating and weighing additional costs against 
the possible treatment effectiveness of the procedures is preferably performed in an early 
(developmental) phase. The situation should be prevented that these cost-effectiveness 
analyses are only performed when the procedure is already adopted or implemented in 
health care practice. These late evaluations are undesired because procedures embedded 
in the health care system are not likely to be abandoned after it has been demonstrated 
that the procedure provides too limited health benefit relative to the additional costs.62, 63 
Therefore, the preferred strategy is to demonstrate the (potential) added value and 
cost-effectiveness of novel proceudres prior to implementation in health care practice, 
preferably in an early (developmental) phase of an innovation. Such an early evaluation 
of novel procedures with regard to whether they have the potential to offer added value 
are also known as early health technology assessments. These early health technology 
assessments can guide investment and design decisions in product development, and 
allocation of funds for applied/translational research programs, in order maximize 
monetary value.64, 65 
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Reasoning from the patients’ perspective, it may be considered redundant to take into 
account the costs of a treatment if there is an expected health benefit from the treatment. 
While this is true in the setting of infinite health care resources, it is not realistic not to 
consider costs of care in the normal health care setting where budgets are constrained. 
Moreover, it should be taken into account that the health care costs are ultimately passed 
on to the society, including the patients themselves (i.e. via taxes or other national 
reimbursement regulations). Thus, it seems in the society’s best interest that the given 
resources should be used for those treatments or activities that maximize health gain 
and monetary value. 
 Regarding this need for efficient use of resources, there is a general agreement 
that the stretched health services budgets should not be used for low value services. 
By limiting the support of treatments with no or low added value, costs can be controlled 
without cutting the quality of care. Based on the current available data questioning the 
indication of surgical treatment for degenerative meniscus tears, disinvestment (either 
totally or partially) in these surgical procedures could contribute in controlling health care 
costs, without reducing the quality of care. Moreover, this would allow reallocation of 
funds towards interventions that are more cost-effective, maximizing health gain (and 
maximize monetary value). 
In conclusion, also in the treatment for meniscus tears there is a moral obligation to strive 
for appropriate, high quality and effective care (ensuring that patients receive the right 
care at the right time in the right way) for the population, served at affordable costs. 
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Background
The overall objective of this thesis was to provide an evidence based evaluation of the 
added value of treatment strategies for meniscus tears, in which treatment strategies for 
traumatic and degenerative tears were assessed separately. In part 1 of this thesis, the 
treatment of traumatic meniscus tears was evaluated. The treatment of degenerative 
meniscus tears was evaluated in part 2 of this thesis.
PART 1 Traumatic meniscus tears 
Traumatic meniscus tears occur in younger active patients and are caused by a traumatic 
injury of the meniscus in a previously healthy knee. Depending on the extent of the tear, 
symptoms encompass pain, joint effusions, and mechanical symptoms such as catching 
or locking. Surgical management of symptomatic traumatic tears is traditionally based on 
the resection of damaged meniscus tissue (i.e. partial or complete meniscectomy). 
Although providing satisfactory short term improvement in symptoms, the disadvantage 
of partial meniscectomy is the development of degenerative changes (i.a. damage to the 
articular cartilage) in the knee joint due to loss of meniscus tissue. These degenerative 
changes can lead to the development of symptomatic knee osteoarthritis. Currently, 
much effort is put in the development of treatment strategies for traumatic meniscus 
tears that do not lead to the development of knee osteoarthritis.
After acknowledging the deleterious effects of total meniscectomy on the knee joint, and 
in order to provide a solution for those patients who had underwent total meniscectomy, 
surgeons explored the possibility of donor meniscus transplantation. The goal of trans-
plantation was to treat, prevent, and possibly even reverse the development of knee 
osteoarthritis that followed total meniscectomy. Early promising results of meniscus 
allograft transplantation encouraged the development of meniscus implants, intended 
for the treatment of meniscus tears that would otherwise be treated by partial 
meniscectomy. Unfortunately, despite the widespread reporting on clinical results that 
demonstrate the feasibility of meniscus allograft transplantation, it is still unknown 
whether meniscus allografts have the ability to prevent the development of knee 
osteoarthritis associated with meniscectomy. 
 Chapter 2 describes a study in which the available literature was systematically 
reviewed on the effect of meniscus allograft transplantation on articular cartilage. This 
study focused on animal studies because controlled clinical studies that evaluated the 
effects of meniscus allograft transplantation on articular cartilage were not available. The 
systematic review and meta-analyses demonstrated that although meniscus allograft 
transplantation does not completely protect articular cartilage from damage, it reduces 
the extent of it when compared with total meniscectomy. Consistent results across 
different species and models provide reassurance that this observed effect is reliable, and 
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that humans might respond in a similar manner. Regarding the meniscus allograft as a 
reference standard for meniscus implant procedures, this cartilage protecting effect 
provides a solid foundation for the development of meniscus implants that aim to prevent 
the development of knee osteoarthritis associated with partial meniscectomy.
 On the other hand, some limitations should also be addressed. First, it was demonstrated 
that both meniscectomy as well as meniscus allograft transplantation cause damage to 
articular cartilage. This implies that complete prevention of knee osteoarthritis by treatment 
with allografts or implants is not possible. Second, results from animal studies did not take 
into account the initial trauma responsible for the meniscus to tear. This trauma may, 
either directly and/or indirectly, also have damaged the articular cartilage, increasing the 
likelihood to develop knee osteoarthritis. These limitations raise the question as to 
whether the theoretically reduced damage to articular cartilage by applying meniscus 
replacement procedures will lead to clinically meaningful benefit. Especially since short 
term results after partial meniscectomy are satisfactory, and not all subjects who undergo 
partial meniscectomy will develop symptomatic knee osteoarthritis. Moreover, these 
novel procedures come with additional therapeutic consequences and increased costs 
accrued to society compared to the standard (partial) meniscectomy, in a health care 
system that already has to manage with the challenge on how to deal with constrained 
budgets. Thus, although promising in concept, the potential effectiveness of meniscus 
implants should outweigh additional therapeutic and financial consequences. 
 Chapter 3 describes an early health technology assessment in which the (potential) 
cost-effectiveness of treating a meniscus tear with a degradable meniscus implant was 
evaluated. In striving to prevent symptomatic knee osteoarthritis, based on the currently 
available efficacy data, the Collagen Meniscus Implant (CMI®) was not cost-effective in the 
treatment of acute meniscus tears compared to partial meniscectomy. Thus, although 
promising in concept, the CMI® is yet of unproven benefit and therefore its implementation 
in health care should be delayed until critical parameters are addressed (i.e. demonstrating 
efficacy, providing more insight in health related resource consumption). To be considered 
cost-effective, the treatment of traumatic meniscus tears with meniscus implants should 
prevent at least 30% of the patients that would develop symptomatic knee osteoarthritis 
after partial meniscectomy. The cost-effectiveness may be improved by, for example, 
treating those patients who have a high risk of symptomatic knee osteoarthritis after 
partial meniscectomy, and/or adapting the implants’ design to increase the robustness of 
the implant and the speed of tissue regeneration in order to allow a faster rehabilitation 
regime.
 Besides striving to prevent osteoarthritis, clinical studies have broadened the 
indication of the CMI® to also treat localized pain in the previous partial meniscectomized 
knee. The cost-effectiveness of this treatment strategy was also assessed and compared to 
standard arthroscopic surgery. Results demonstrated that the treatment of pain after a 
previous partial meniscectomy with a CMI® is not cost-effective over standard arthroscopic 
surgery with partial meniscectomy, nor does it hold any promise that it will become 
cost-effective in the near future. 
 The results of this early health technology assessment rely on the limited available 
data on efficacy of the CMI®. Subsequently, the strength of the assessment can be 
improved as additional clinical data on meniscus implant procedures become available. 
However, transparent reporting on trial results of these implants has been demonstrated 
to be a thorny issue. So far, there has been only one randomized controlled trial that 
reported results on safety and efficacy of a meniscus implant. This study was initiated and 
sponsored by ReGen Biologics, which is also responsible for the development, fabricating 
and marketing of the CMI®. Comparing the published manuscript and the original study 
design revealed that results had been reported selectively (in favor of meniscus implant) 
in the published article. The original protocol stated that the primary objective of the 
multicenter randomized controlled study was to assess the safety and clinical benefit of 
the CMI®. According to the protocol, safety was to be assessed by serum markers (immune 
response to the implant) and adverse events (significant adverse events attributable to 
the implant). Effectiveness was primarily to be assessed in terms of functional parameters. 
An individual patient’s success outcome was to be determined using three primary clinical 
endpoints (pain, knee function, and patient self-assessment) assessed at 24 months after 
the intervention. A clinically significant improvement (according to pre-defined criteria) in 
any two of these three endpoints would be considered a success.
 The results presented in the published manuscript did not report on serum markers 
related to safety, nor did it report on the primary composite endpoints related to effectiveness. 
Moreover, outcomes were assessed at widely different time-points, disregarding the time 
frame of 24 months after the intervention to evaluate the outcomes. 
 Instead, the published manuscript introduced two (new) statistically significant 
positive clinical endpoints related to effectiveness and safety: a benefit in a Tegner index 
(p = 0.02) and significantly fewer reoperations (p = 0.04) for subjects that received the 
collagen implant. The Tegner index was a newly introduced and unprecedented method 
of analyzing scores of the Tegner activity scale. With respect to safety and reoperations, 
the published manuscript omitted to report on 5 reoperations in the control group and 17 
in the collagen implant group due to subjective use of in- and exclusion criteria on what 
to consider a reoperation (e.g. in contrast to the control group, the implant group received 
a standard second-look arthroscopy after 1 year, concomitant surgical procedures 
conducted during this arthroscopy were not included as reoperations).
 The course of events outlined above is an example of selectively reporting a subset 
of the available outcomes based on their outcomes, which is a potential threat for the 
validity of evidence based medicine. It can lead to situations in which ineffective or 
harmful interventions are promoted, and/or that expensive therapies, that are thought to 
be better than cheaper alternatives, are not truly superior.
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 In order to prevent selective outcome reporting and to achieve full transparency with 
respect to performance and reporting of clinical trials, the International Committee of 
Medical Journal Editors (ICMJE) initiated the policy, as of 2005, that required investigators 
to register their trial (including filling out a 20-item trial registration dataset) in a public 
trials registry before the onset of patient enrollment. 
 These guidelines should have resulted in the ability, as a reader, to rely on the 
unbiased nature of reported results while evaluating the presented evidence, for example 
on new treatment strategies for traumatic meniscus tears. However, it is questionable 
whether this assumption can be taken for granted. Randomized controlled trials on 
treatments for traumatic meniscus tears are scarce. Therefore, an assessment of trial 
registration in the general orthopedic surgical community may provide useful information 
for the evaluation of upcoming trial reports on novel treatments for traumatic meniscus 
treatments.
 Chapter 4 reports on a study that evaluated trial registration in the general orthopedic 
surgical community. It was demonstrated that trial registration is reported in only few 
(24.8%) published manuscript of orthopedic surgical randomized controlled trials. 
Moreover, of those trials that had been registered (i.e. trial registration mentioned in the 
published manuscript), only few (37.8%) had been registered adequately. Inconsistencies 
between registered primary outcomes with those reported in the published articles, as 
well as selective outcome reporting favoring significant outcomes was highly prevalent. 
Apparently, although trial registration is now the rule, trial registration in orthopedic 
surgical randomized controlled trials is currently far from optimal and selective outcome 
reporting is still prevalent. Selective outcome reporting limits the validity of evidence 
based medicine in the orthopedic community. Moreover it impedes thorough and 
unbiased evaluations of new orthopedic surgical procedures. Full involvement of authors, 
editors, and reviewers is necessary to ensure publication of quality, unbiased results in 
order to allow thorough evaluation of new technologies, such as meniscus implants.
PART 2 Degenerative tears
Degenerative meniscus tears are a very different entity compared to traumatic tears. 
Degenerative meniscus tears are typically seen in middle aged and older patients, are 
accompanied by knee osteoarthritis, and are caused by chronic degenerative processes. 
Degenerative meniscus tears may be accompanied with knee pain and mechanical 
symptoms (i.e. catching or occasional locking) and are commonly treated by arthroscopic 
knee surgery with removal of the degenerated meniscus tissue. Common rationalization 
for arthroscopic surgery for the degenerative meniscus tear is that the symptoms are 
attributable to a mechanical problem, and that the degenerative meniscus tear is the 
cause of this mechanical problem. However, it has been demonstrated that this rational-
ization falls short. The sensitivity and specificity of the symptoms attributed to the 
degenerative meniscus tear in the osteoarthritic knee are low, and asymptomatic 
meniscus tears are highly prevalent among people with knee osteoarthritis. Next to the 
conception that the degenerative meniscus tear may not be the (prime) cause responsible 
for the symptoms, evidence has accumulated that questions the effectiveness of 
arthroscopic surgery with meniscectomy for degenerative meniscus tears. 
 In contrast to the emerging evidence that questions its efficacy, the incidence of 
arthroscopic meniscectomies for degenerative meniscus tears is seemingly rising, at least 
in the United States, the United Kingdom and Denmark. The guidelines by the Netherlands 
Orthopaedic Association advises to be reluctant with surgical treatment for degenerative 
meniscus tears, and indicate that non surgical treatment is preferred for degenerative 
meniscus tears without symptoms of mechanical obstruction. On the other hand, the 
guidelines state that, in suspected degenerative meniscus tears accompanied by 
mechanical obstructions, and/or after insufficient benefit from non surgical treatment, 
surgical treatment with (partial) meniscectomy is indicated.
 Chapter 5 reports on a study that evaluated the incidences of surgical meniscal 
procedures from 2005 up to and including 2014 in the Netherlands. This study used 
registry based data from the nationwide Dutch National Hospital Care Basic registrations. 
It was demonstrated that the incidence of meniscus surgery was highest in patients aged 
40-65, accounting for half of the total number of meniscal surgeries. These are patients 
who are known to have degenerative meniscus tears. The total incidence of meniscus 
procedures decreased by 25% from 2005 to 2014. However, this decrease was attributable 
to a decline in procedures over all age groups, and not the result of a disproportional 
reduction of meniscal procedures performed on patients with degenerative meniscus 
tears. Despite accumulating evidence questioning the rationalization and effectiveness of 
the treatment, meniscus surgery is still performed disproportionately often in the 
treatment of degenerative meniscus tears in the Netherlands.
The weighing of both beneficial and harmful effects is paramount in the choice of 
treatment, and informing the patient of both beneficial and harmful effects is vital in order 
to obtain valid informed consent. Surgery related risks of knee arthroscopy include 
thrombosis, infection, and anesthesia-related complications. Moreover, retrospective 
studies have raised the concern that arthroscopic meniscectomy may have a detrimental 
effect on articular cartilage. Despite this concern, it is unclear what the effect is of 
arthroscopic meniscectomy for degenerative meniscus tears on already prevalent 
osteoarthritis. This information is needed in order to appropriately weigh, and inform 
patients of, harms and benefits of the procedure.
 Chapter 6 describes a study that uses open access data from the Osteoarthritis 
Initiative to evaluate the effect of (partial) meniscectomy on prevalent knee osteoarthritis. 
The study demonstrated that arthroscopic meniscectomy in patients with, or at risk for, 
knee osteoarthritis was associated with a 3 fold increase in the risk of future knee 
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replacement surgery compared to matched subjects who did not undergo arthroscopic 
meniscectomy. This is a considerable risk that should be taken into consideration while 
weighing both pros and cons in the choice of treatment.
 Despite the associated harms, and randomized controlled trials that demonstrated 
small or inconsequential benefits of the procedure, orthopedic surgeons remain 
convinced that arthroscopic surgery is an effective treatment for degenerative meniscus 
tears. Primarily, orthopedic surgeons have concerns about the generalizability of 
randomized controlled trials and point out that the study populations are not 
representative to the patients they themselves individually select for surgery in the normal 
health care setting. Indeed, although the strength of the randomized controlled trial rests 
on its internal validity, the generalizability (or external validity) of randomized controlled 
trials may be limited. 
 Regarding the skepticism of orthopedic surgeons to results from RCTs, data from 
observational studies, where surgeons themselves selected patients, would provide 
highly valuable information in order to evaluate outcomes in routine clinical practice. 
Moreover, for a thorough assessment of the procedure, the evaluation of the short term 
outcomes should take into account the (long term) consequences as well as the additional 
costs associated with the procedure. In the previous chapter it was demonstrated that, in 
patients with knee osteoarthritis, arthroscopic meniscectomy is associated with an 
increased risk for future knee replacement surgery. 
 Chapter 7 reports on a study, again using open access data from the Osteoarthritis 
Initiative, in which the cost-effectiveness of arthroscopic meniscectomy for degenerative 
meniscus tears was evaluated and compared to no surgery. This cost-effectiveness analysis 
took into account the increased risk for future knee replacement surgery after arthroscopic 
meniscectomy. Moreover, results on effectiveness of the procedure were obtained from 
observational data from a normal health care setting (routine clinical practice) where 
surgeons themselves selected patients for surgery. Results demonstrated that in a routine 
health care setting (i.e. normal clinical practice), arthroscopic meniscectomy in subjects 
with, or at risk for, knee osteoarthritis is associated with a (small) reduction in knee pain. 
Though, this reduction in knee pain does not result into an improvement in quality of life 
large enough to outweigh the increased risk for future knee arthroplasty surgery and the 
increased costs associated with the surgical procedure. This evidence contributes to the 
conception that arthroscopic meniscectomy should not be performed in middle aged 
patients with meniscal tears. 
General discussion
In Chapter 8 the treatment of meniscus tears is discussed from a broader perspective. 
 For traumatic meniscus tears it is concluded that, so far, there is no evidence that 
novel treatments for traumatic meniscus tears have the ability to prevent the development 
of knee osteoarthritis. Beside the prevention of osteoarthritis there is increasing interest to 
use meniscus implants in the treatment of knee pain post meniscectomy. There is however 
no evidence that meniscus implants have the ability to effectively treat these symptoms 
post meniscectomy. Moreover, it can even be disputed whether there is an rationale to 
treat patients with symptoms post meniscectomy with an meniscus implant at all.
In view of the reporting on novel treatments of meniscus tears demonstrates that it is has 
been rather a practice of trial and error. Formal and comparative assessments of the 
procedures played only a marginal role, and there has been hardly any attention to 
patients and societal inconvenience or costs. 
 The limited success of the implementation of evidence based principles in the 
orthopedic surgical community is in part attributable to the absence of a framework that 
regulates the development of novel surgical procedures. The IDEAL recommendations 
overcome this lack of a regulatory framework. The IDEAL framework is based on the belief 
that surgical innovation and evaluation can and should progress jointly in an ordered 
manner from concept (Idea & Development), through exploration (Exploration), to 
validation by randomized controlled trials (Assessment) and surveillance (Long term 
study). For each stage, guidelines on the research methodology and reporting are 
provided, encouraging widespread replacement of case series by registered prospective 
development studies, using prospective databases and registries, and the use of 
randomized controlled trials whenever possible to investigate efficacy.
 Adhering to IDEAL recommendations will result in the adoption (or refusal) of surgical 
innovations based on unbiased, reliable types of evidence, and consequently protect 
patients against the potential harms of any novel procedure.
 The IDEAL  recommendations do not take into account the weighing of additional 
costs and therapeutic consequences of novel treatment procedures. This weighing of the 
additional costs and consequences against its potential treatment effect is becoming 
increasingly important since health care budgets are constrained, and the current policy 
by health authorities tends towards only reimbursing novel procedures that are cost-
effective. 
 The preferred strategy is to demonstrate the (potential) added value and cost- 
effectiveness of novel procedures prior to their implementation in health care practice, 
most preferably in an early (developmental) phase of a novel procedure. These early 
health technology assessments can guide investment and design decisions in product 
development, and guide allocation of funds for applied/translational research programs 
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in order maximize monetary value. Moreover early health technology assessments  have 
the potential to prevent the need for disinvesting in novel procedures after they have 
been implemented in clinical practice.
Health care budgets are stretched. Regarding the need for efficient use of resources, there 
is a general agreement that the stretched health services budgets should not be used for 
low value services. By limiting the support of treatments with no or low added value, costs 
can be controlled without cutting the quality of care. Based on the current available data 
questioning the indication of surgical treatment for degenerative meniscus tears, 
disinvestment (either totally or partially) in these surgical procedures could contribute in 
controlling health care costs, without reducing the quality of care. Moreover, this would 
allow reallocation of funds towards interventions that are more cost-effective, maximizing 
health gain (and maximize monetary value). 
Summarizing, also in the treatment of meniscus tears there is a moral obligation to strive 
for appropriate, high quality and effective care (ensuring that patients receive the right 
care at the right time in the right way) for the population, served at affordable costs.
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Achtergrond
Het doel van dit proefschrift was om de toegevoegde waarde van nieuwe en bestaande 
behandelingen voor meniscusscheuren te onderzoeken. Het proefschrift bestaat uit twee 
delen. In het eerste deel werd de behandeling van traumatische meniscusscheuren 
geëvalueerd en in het tweede deel de behandeling van degeneratieve scheuren.
DEEL 1 Traumatische meniscusscheuren
Traumatische meniscusscheuren komen voor bij relatief jonge actieve personen 
(doorgaans jonger dan 40 jaar) en worden vaak veroorzaakt door een sportongeval. 
Klachten die hierbij acuut ontstaan zijn pijn, zwelling in het kniegewricht en slotklachten 
(onvermogen om de knie volledig te strekken). Traumatische meniscusscheuren die veel 
klachten veroorzaken worden behandeld tijdens een kijkoperatie (artroscopie). Tijdens 
deze artroscopie wordt doorgaans het deel van de meniscus tot aan de scheur verwijderd 
(partiële artroscopische meniscectomie).
 Een partiële artroscopische meniscectomie geeft op korte termijn goede verlichting 
van de klachten. Het nadeel van de procedure is echter dat het verwijderen van een deel 
van de meniscus aanleiding geeft tot gewrichtsslijtage en artrose van de knie.
Momenteel wordt er veel onderzoek gedaan naar nieuwe behandelmethoden voor 
menis cusscheuren die knieartrose kunnen voorkomen. Zo wordt er, na het onderkennen 
van de nadelige effecten van totale meniscectomie op het kraakbeen van het kniegewricht 
en om een oplossing te kunnen bieden voor die patiënten die eerder reeds een totale 
meniscectomie hadden ondergaan en daar klachten van kregen, al vanaf midden jaren 80 
onderzoek gedaan naar het transplanteren van donormenisci. Het doel van de meniscus-
transplantatie was het voorkomen en het behandelen van de knieartrose dat volgde op 
het verwijderen van de meniscus. Hoopgevende eerste resultaten met het transplanteren van 
donormenisci hebben geleid tot de ontwikkeling van meniscusimplantaten die ingezet kunnen 
worden bij de behandeling van meniscusscheuren die momenteel worden behandeld 
met een partiële meniscectomie.
 Echter, ondanks de vele klinische studies die beschrijven dat het mogelijk is om 
donormenisci te transplanteren is het nog steeds niet duidelijk of een meniscustrans-
plantatie de ontwikkeling van knieartrose na een meniscectomie kan voorkomen.
Hoofdstuk 2 van dit proefschrift beschrijft een literatuuronderzoek waarin systematisch 
werd geëvalueerd wat het effect is van het transplanteren van een donormeniscus op 
gewrichtsslijtage. Omdat er geen geschikte onderzoeken met mensen bleken te zijn 
uitgevoerd om dit effect te kunnen beoordelen, is er in het literatuuronderzoek gekeken 
naar de resultaten uit alle beschikbare dierstudies. De resultaten van het literatuur-
onderzoek tonen aan dat het transplanteren van een donormeniscus gewrichtsslijtage 
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niet voorkomt. Echter, het transplanteren van een donormeniscus geeft minder gewrichts-
slijtage in vergelijking tot het compleet verwijderen van de meniscus. De resultaten laten 
zien dat dit relatief beschermend effect robuust is en dat dit effect waarschijnlijk ook bij 
mensen aanwezig zal zijn. Dit beschermend effect kan gezien worden als een rechtvaar-
diging voor de ontwikkeling van meniscusimplantaten om knieartrose te voorkomen. 
 Aan de andere kant zijn er ook beperkingen aan de resultaten uit het literatuuronder-
zoek. Allereerst blijkt dat het niet mogelijk is om gewrichtsslijtage compleet te voorkomen. 
Ten tweede, de resultaten in het onderzoek beschrijven het effect van het verwijderen 
van de meniscus en het vervolgens transplanteren van een donormeniscus. Het beschreven 
resultaat neemt niet mee in overweging dat er bij mensen een ongeval aan de scheur 
voorafgaat. Dit ongeval, dat groot genoeg is geweest om het meniscusweefsel te doen 
scheuren, kan ook zelf aanleiding zijn tot het ontstaan van knieartrose. 
 Deze begrenzing aan de resultaten doen de vraag rijzen of het theoretische 
beschermend effect wel aanleiding zal geven tot een klinisch relevant voordeel voor de 
patiënt. Daarnaast is het goed om te benadrukken dat de meeste patiënten na het 
verwijderen van (een deel van) de meniscus tevreden zijn en dat niet alle patiënten last 
zullen krijgen van de gewrichtsslijtage. Het is dus niet vanzelfsprekend dat een behandeling 
van een meniscusscheur met een meniscusimplantaat zal zorgen voor een betere uitkomst 
voor alle patiënten. Anderzijds brengt het gebruik van meniscusimplantaten additionele 
kosten met zich mee. Deze extra kosten moeten opwegen tegen de voordelen van het 
gebruik van implantaten bij de behandeling van patiënten met meniscusscheuren.
 Hoofdstuk 3 beschrijft een vroege health technology assessment waarin de 
(potentiële) kosteneffectiviteit van de behandeling van meniscusscheuren met een  meniscus - 
implantaat werd geëvalueerd. Health technology assessment is een verzamelnaam voor 
evaluatieonderzoek in de gezondheidszorg, en dient als instrument ter onderbouwing 
van het wel of niet toelaten, bevorderen of daadwerkelijk gebruiken van een medische 
technologie.
 Met als doel om knieartrose te voorkomen en uitgaande van de huidig beschikbare 
gegevens over de werkzaamheid, bleek het Collagene Meniscus Implantaat (CMI®), 
een van de twee meniscusimplantaten die nu klinisch beschikbaar zijn, niet kosten-
effectief te zijn in vergelijking tot een partiële meniscectomie bij de behandeling van 
acute meniscusscheuren. Dus, hoewel het gezien kan worden als een veelbelovend 
concept, is de toegevoegde waarde van de CMI® nog niet aangetoond en is het advies 
om de implementatie ervan in de gezondheidszorg uit te stellen totdat deze is aangetoond. 
Om kosteneffectief te worden moet een dergelijk implantaat er voor zorgen dat het aantal 
patiënten met symptomatische knieartrose met 30% afneemt ten opzichte van de huidige 
behandeling. Daarnaast kan de kosteneffectiviteit worden verbeterd door bijvoorbeeld 
patiënten te selecteren die een hoge kans hebben op het ontwikkelen van symptomatische 
knieartrose na een partiële meniscectomie, en/of het ontwerp van het implantaat zodanig 
aan te passen dat het revalidatieproces sneller verloopt.
 Naast het doel om knieartrose te voorkomen wordt er ook onderzoek gedaan of 
 meniscusimplantaten ingezet kunnen worden bij de behandeling van patiënten met 
knieklachten na een eerdere partiële meniscectomie. Het doel van deze behandeling is 
hier dus het behandelen van de knieklachten in plaats van het voorkomen van knieartrose. 
Ook de toegevoegde waarde van deze toepassing van het CMI® werd onderzocht in een 
health technology assessment. Uit deze assessment bleek dat het implantaat niet koste-
neffectief is bij de behandeling van knieklachten na een eerdere partiële meniscectomie. 
Daarnaast toont de analyse dat de toepassing van het implantaat voor deze klachten 
weinig potentie heeft om kosteneffectief te worden.
 De resultaten van de health technology assessment zijn voor een deel afhankelijk van 
de slechts beperkt beschikbare informatie over de werkzaamheid van de CMI®. Meer en 
beter inzicht in de werkzaamheid van het implantaat zal het mogelijk maken de 
behandeling beter en nauwkeuriger te evalueren. 
 Echter, het transparant beschrijven en publiceren van onderzoeksresultaten over 
de werkzaamheid van meniscusimplantaten blijkt een lastige kwestie te zijn. Tot nu toe is 
er slechts één gerandomiseerd gecontroleerde studie gepubliceerd die de uitkomsten 
beschrijft van de werkzaamheid en veiligheid van een meniscusimplantaat. Dit onderzoek 
werd geïnitieerd en gefinancierd door ReGen Biologics, een commercieel bedrijf dat ook 
verantwoordelijk is voor het in de handel brengen van het meniscusimplantaat. Bij het 
vergelijken van de uitkomsten in het gepubliceerde artikel met de uitkomsten in het oor-
spronkelijke studieprotocol, blijkt er dat in het gepubliceerde artikel resultaten selectief 
worden beschreven (in het voordeel van het implantaat). 
 Volgens het oorspronkelijke studieprotocol was het hoofddoel van de gerandomiseerd 
gecontroleerde studie het beoordelen van de veiligheid en de klinische voordelen van de CMI®. 
De veiligheid zou worden beoordeeld door middel van serum markers (immuun respons op het 
implantaat) en registratie van adverse events (significante bijwerkingen toe te schrijven aan het 
implantaat). De effectiviteit zou worden beoordeeld in termen van functionele parameters. Een 
succesvolle uitkomst van een individuele patiënt zou worden bepaald aan de hand van drie 
primaire klinische eindpunten (pijn, kniefunctie, en de patiënt self-assessment) beoordeeld op 
24 maanden na de ingreep. Een klinisch significante verbetering (op basis van vooraf 
gedefinieerde criteria) in twee van de drie eindpunten zou worden beschouwd als een succes.
 In het gepubliceerde manuscript wordt echter niet gesproken over serum markers in 
verband met de veiligheid, noch wordt er verslag gedaan van de primaire samengestelde 
eindpunten gerelateerd aan effectiviteit. Daarnaast werden de beschreven uitkomsten 
beoordeeld op zeer verschillende tijdstippen, ongeacht de oorspronkelijke termijn van 
24 maanden na de interventie om de resultaten te evalueren. In plaats van de oorspronkelijke 
primaire uitkomsten worden er in het gepubliceerde artikel twee nieuwe uitkomsten met 
betrekking tot effectiviteit en veiligheid gepresenteerd: een voordeel in een Tegner index 
(p = 0,02) en een significant minder aantal heroperaties (p = 0,04) bij patiënten die het 
CMI® ontvingen. 
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 De gepresenteerde Tegner index is een ongebruikelijke maat die wordt verkregen uit 
de scores van de Tegner activiteiten schaal. Met betrekking tot de veiligheid en 
heroperaties blijkt dat er in het gepubliceerde artikel wordt nagelaten om 5 heroperaties 
in de controlegroep en 17 heroperaties in het CMI groep te rapporteren, door gebruik te 
maken van subjectieve in- en exclusie criteria bij het definiëren van heroperaties (in 
tegenstelling tot de controlegroep, kreeg de CMI® groep een standaard second-look 
artroscopie na 1 jaar en werden gelijktijdig uitgevoerde chirurgische ingrepen niet 
meegenomen als heroperaties ongeacht de aard van de extra ingreep).
 De manier van het rapporteren van resultaten zoals hierboven beschreven is een 
voorbeeld van het selectief rapporteren van een deel van de beschikbare uitkomsten op 
basis van de richting en grootte van het effect. Het selectief rapporteren van uitkomsten 
is een potentieel gevaar voor de validiteit van evidence-based medicine (geneeskunde 
op basis van bewijs). Het kan leiden tot situaties waarin ineffectieve en/of schadelijke 
interventies worden gepromoot, en/of waarin dure therapieën, die beter lijken te zijn dan 
goedkopere alternatieven, niet echt beter zijn.
 Om selectieve rapportage van uitkomsten te beperken en te streven naar volledige 
transparantie omtrent de uitvoering en rapportage van klinische trials werd in 2005 door 
het International Committee of Medical Journal Editors (ICMJE) het beleid ingevoerd dat 
onderzoekers verplicht hun trial moeten registreren (met inbegrip van het invullen van 
een 20-items tellende registratie vragenlijst) in een openbaar register voordat er wordt 
gestart met de inclusie van proefpersonen. Dit beleid moet er voor zorgen dat men als 
lezer er van uit mag gaan dat de resultaten in een wetenschappelijk artikel niet selectief 
worden gerapporteerd, bijvoorbeeld bij het evalueren van de effectiviteit van nieuwe 
strategieën voor de behandeling van traumatische meniscusscheuren. Het is echter maar 
de vraag of het registreren van trials naar behandelingen van meniscusscheuren (goed) 
gebeurt. Omdat trials naar behandelingen voor traumatische meniscusscheuren schaars 
zijn, kan een evaluatie van het registratieproces binnen de orthopedische gemeenschap 
belangrijke informatie verschaffen. Deze informatie kan gebruikt worden bij het evalueren 
van aankomende trials met nieuwe behandelingen voor traumatische meniscusscheuren.
 Hoofdstuk 4 doet verslag van een onderzoek naar het registreren van trials binnen 
de orthopedie. Er werd aangetoond dat slechts enkele gepubliceerde studies (24.8%) 
rapporteren dat de trial die ze beschrijven geregistreerd was. Bovendien, van die trials die 
aangaven geregistreerd te zijn bleek slechts de minderheid (37,8%) adequaat geregistreerd. 
Binnen deze adequaat geregistreerde studies bleken inconsistenties tussen geregistreerde 
primaire uitkomstmaten en de primaire uitkomstmaten in het gepubliceerde artikel, 
evenals het selectief rapporteren van uitkomsten op basis van richting en grootte van het 
effect, veelvuldig voor te komen.
 Hoewel het registreren van trials nu de regel is, blijkt het registreren van trials binnen 
de orthopedie verre van optimaal te zijn en komt het selectief rapporteren van uitkomsten 
nog veel voor. Het slecht registreren van studies en het selectief rapporteren van 
uitkomsten ondermijnt de betrouwbaarheid van de bewijsvoering van orthopedische 
studies. Daarnaast beperkt het de mogelijkheid tot het doen van grondige evaluaties van 
nieuwe orthopedische behandelingen, waaronder nieuwe behandelingen voor 
traumatische meniscusscheuren. Betrokkenheid van auteurs, onderzoekers, reviewers en 
redactieleden van tijdschriften is nodig om er voor te zorgen dat dit probleem wordt 
aangepakt.
DEEL 2 Degeneratieve meniscusscheuren
Degeneratieve meniscusscheuren zijn geheel iets anders dan traumatische meniscus-
scheuren. Degeneratieve meniscusscheuren komen voor bij mensen van middelbare en 
oudere leeftijd, in een knie waarin al tekenen van gewrichtsslijtage aanwezig zijn. 
Degeneratieve scheuren ontstaan veelal geleidelijk en worden veroorzaakt door chronisch 
degeneratieve processen in de knie. Symptomen die vaak worden toegeschreven aan 
degeneratieve meniscusscheuren zijn kniepijn en mechanische obstructies (klikken en 
kortdurend blokkeren van de strekbeweging van de knie). Aanhoudende pijnklachten en/
of mechanische klachten bij een degeneratieve meniscusscheur worden vaak operatief 
behandeld door het verwijderen van een deel van de meniscus tot aan de scheur 
(artroscopische partiële meniscectomie).
 De argumentatie om over te gaan tot een operatie is de veronderstelling dat de door 
de patiënt ervaren knieklachten worden veroorzaakt door een mechanisch probleem en 
dat de meniscusscheur aan dit mechanisch probleem ten grondslag ligt. Het is echter 
aangetoond dat deze veronderstelling niet zondermeer juist is. De sensitiviteit en 
specificiteit van symptomen die worden toegeschreven aan degeneratieve meniscus-
scheuren in de artrotische knie zijn laag en asymptomatische degeneratieve meniscus-
scheuren komen veel voor bij oudere mensen met gewrichtsslijtage. 
 Naast het inzicht dat de degeneratieve meniscusscheur niet zonder meer verant-
woordelijk is voor de toegeschreven symptomen, laten verschillende trials zien dat een 
operatie aan een degeneratieve meniscusscheur niet of nauwelijks effectief is in de 
behandeling van de symptomen. In tegenstelling tot dit toenemend bewijs dat de 
effectiviteit van een operatie in twijfel trekt, worden er in verschillende landen (Amerika, 
Groot Brittannië, en Denemarken) juist steeds meer operaties uitgevoerd aan degeneratieve 
meniscusscheuren. De richtlijn van de Nederlandse Orthopaedische Vereniging (NOV) 
adviseert terughoudend te zijn met chirurgische behandeling van degeneratieve menis-
cusscheuren, en geeft aan dat niet-chirurgische behandeling de voorkeur geniet bij 
degeneratieve meniscusscheuren zonder mechanische obstructie. Anderzijds indiceert 
de richtlijn chirurgische behandeling bij de verdenking van een degeneratieve meniscus-
scheur gepaard met mechanische obstructies en / of na onvoldoende effect van niet- 
chirurgische behandeling.
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 Hoofdstuk 5 beschrijft een studie waarin is gekeken naar de aantallen meniscus-
operaties die in Nederland werden uitgevoerd van 2005 tot en met 2014. De studie maakt 
gebruik van gegevens uit de Landelijke Basisregistratie Ziekenhuiszorg en toont aan dat 
de incidentie van ingrepen aan de meniscus het hoogst was voor patiënten in de leeftijd 
van 40-65 jaar, samen goed voor de helft van het totaal aantal meniscusoperaties in 
Nederland. Van de patiënten in deze leeftijdsgroep weten we dat ze degeneratieve me-
niscusscheuren hebben. De aantallen meniscusoperaties zijn in 2014 met 25% afgenomen 
ten opzichte van 2005. Deze afname is het gevolg van een daling van het aantal ingrepen 
bij zowel jongere als oudere patiënten. Gezien het toenemend bewijs dat de zin van een 
dergelijke ingreep bij degeneratieve meniscusscheuren in twijfel trekt, werd een grotere 
afname verwacht in het aantal ingrepen bij oudere mensen. Het gegeven dat deze 
afname niet werd waargenomen laat zien dat er een vertraging is in de acceptatie en 
implementatie van bewijs uit klinische studies naar de daadwerkelijke behandeling van 
patiënten met meniscusscheuren in de Nederlandse praktijk.
 Bij het maken van een weloverwogen keuze voor een behandeling is het belangrijk 
dat de voor- en nadelen tegen elkaar worden afgewogen en dat de patiënt hierover 
adequaat wordt geïnformeerd. Met behulp van deze informatie kan de patiënt samen 
met de behandelend arts beslissen om een behandeling wel of niet te ondergaan. De 
risico’s die verbonden zijn aan een artroscopische meniscectomie behelzen onder andere 
trombose, infectie en complicaties gerelateerd aan de (lokale) verdoving. Naast deze 
risico’s zijn er zorgen dat een partiële meniscectomie een nadelig effect heeft op het 
kraakbeen. Maar ondanks deze zorgen is het onduidelijk wat het effect is van artroscopische 
meniscectomie van degeneratieve meniscusscheuren op reeds bestaande artrose van de 
knie.
 Hoofdstuk 6 beschrijft een studie waarin is onderzocht wat het effect is van een 
(partiële) meniscectomie van een degeneratieve meniscusscheur op reeds bestaande 
knieartrose. Deze studie maakt gebruik van vrij toegankelijke onderzoeksgegevens van 
het Osteoarthritis Initiative (OAI). De resultaten van het onderzoek demonstreren dat 
patiënten met knieartrose die een meniscusoperatie hadden ondergaan een 3 keer zo 
hoog risico hadden op het krijgen van een knieprothese in vergelijking tot soortgelijke 
patiënten die geen meniscusoperatie hadden ondergaan. Dit verhoogd risico op een 
toekomstige knieprothese is aanzienlijk en moet mee worden genomen in de afweging 
van voor- en nadelen om tot een keuze te komen tot een behandeling voor een 
degeneratieve meniscusscheur.
 Ondanks de nadelen van de operatie en de verschillende trials die laten zien dat er 
niet of nauwelijks voordelen voor de patiënt zijn, blijven orthopedisch chirurgen ervan 
overtuigd dat de operatieve behandeling van degeneratieve scheuren een effectieve 
behandeling is. Orthopedisch chirurgen hebben hun bedenkingen bij de generaliseer-
baarheid van de resultaten uit gerandomiseerd gecontroleerde studies en wijzen erop dat 
de deelnemers aan deze studies niet representatief zijn voor de patiënten die zij zelf 
individueel selecteren voor een operatie. Inderdaad, hoewel de kracht van gerandomiseerd 
gecontroleerde trials berust op de interne validiteit, kan de generaliseerbaarheid (of 
externe validiteit) van gerandomiseerd gecontroleerde studies beperkt zijn.
 Ten aanzien van de scepsis van orthopedisch chirurgen omtrent de resultaten uit 
gerandomiseerd gecontroleerde studies, zouden gegevens uit observationele studies, 
waar de chirurgen zelf patiënten selecteren, waardevolle informatie kunnen verstrekken 
over de effectiviteit van een dergelijk ingreep in de dagelijkse klinische praktijk. Voor een 
grondige evaluatie van de behandeling moet er echter, naast de resultaten op korte 
termijn, ook rekening gehouden worden met de gevolgen op langere termijn en de extra 
kosten van de procedure zelf. Het in het vorige hoofdstuk aangetoonde verhoogd risico 
op een toekomstige knieprothese moet hier bijvoorbeeld in worden meegewogen.
 Hoofdstuk 7 beschrijft een studie naar de kosteneffectiviteit van een artroscopische 
meniscectomie voor een degeneratieve meniscusscheur bij mensen met knieartrose in 
vergelijking tot het afzien van een operatie. In de studie wordt net als in het voorgaande 
hoofdstuk gebruik gemaakt van de vrij toegankelijke onderzoeksgegevens van het OAI. 
De analyse hield rekening met het verhoogde risico op het krijgen van een knieprothese 
die patiënten met knieartrose hebben na een artroscopische meniscectomie. Daarnaast 
maakte de analyse gebruik van uitkomsten na de operatie afkomstig uit de normale 
praktijk waar patiënten door chirurgen zelf werden geselecteerd voor de behandeling. 
 Het onderzoek toonde aan dat de operatie aan de degeneratieve meniscusscheur 
gepaard ging met een (kleine) verlichting van kniepijn. Maar deze verlaging in kniepijn 
resulteerde niet in een verbetering van kwaliteit van leven die groot genoeg was om op 
te wegen tegen het hoger risico op een knieprothese en de extra kosten van de operatie. 
Dit bewijs draagt bij aan de opvatting dat men terughoudend moet zijn met een operatie 
voor degeneratieve meniscusscheuren. 
Discussie
In hoofdstuk 8 wordt vanuit een breder perspectief een algemene discussie gevoerd over 
de behandeling van meniscusscheuren. Voor de behandeling van traumatische menis-
cusscheuren kan er worden geconcludeerd dat er tot nu toe geen bewijs is dat de nieuwe 
behandelingen voor meniscusscheuren ook daadwerkelijk knieartrose voorkomen. Ook is 
er een trend dat implantaten worden ingezet bij de behandeling van patiënten met 
pijnklachten in de knie waar eerder al een gedeelte van de meniscus verwijderd werd. 
Ook hiervoor geldt dat er geen bewijs is dat implantaten verlichting van de klachten 
kunnen geven. Daarnaast kan het in twijfel worden getrokken of er überhaupt wel een 
gegronde reden is om deze patiënten met een implantaat te behandelen. 
 Wat duidelijk wordt als het onderzoek naar nieuwe behandelmethoden voor menis-
cusscheuren wordt geëvalueerd, is dat het onderzoek met name berust op trial en error. 
Gecontroleerd vergelijkende studies van nieuwe behandelmethoden worden slechts bij 
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uitzondering uitgevoerd en er wordt nauwelijks rekening gehouden met de wensen van 
patiënten en kosten voor de maatschappij.
 Het achterwege blijven van kwalitatief gedegen studies komt mede doordat er geen 
regelgeving is voor de invoering van nieuwe chirurgische behandelmethoden. Een dergelijke 
regelgeving is er wel voor de invoering van nieuwe medicijnen. Dergelijke regelgeving 
beschermt de patiënten tegen de gevaren van nieuwe behandelingen en is dan ook zeer 
gewenst om invoering van nieuwe chirurgische behandelmethoden, zoals meniscusim-
plantaten, te reguleren. Om aan dit gebrek van regelgeving tegemoet te komen zijn de 
IDEAL aanbevelingen opgesteld. Deze aanbevelingen bestaan uit (a) een kader dat de 
verschillende ontwikkelingsstadia van nieuwe chirurgische behandelingen beschrijft en 
(b) richtlijnen over wat voor een soort onderzoek in elk van deze stadia gedaan moet 
worden. De IDEAL richtlijn dringt er op aan om geen retrospectieve patiëntenseries meer 
te beschrijven. Daarvoor in de plaats moet er gebruik worden gemaakt van prospectieve 
en geregistreerde patiëntenseries voor nieuwe behandelingen. Dit soort studies zorgen 
er voor dat ook de adverse events van de nieuwe behandelingen goed worden geregistreerd. 
Daarnaast geeft de richtlijn aan dat het nodig is om gecontroleerd vergelijkende studies uit 
te voeren om te beoordelen of nieuwe behandelingen ook daadwerkelijk beter zijn dat 
de standaardbehandeling. Hoewel de invoering van deze regelgeving een investering 
vraagt van alle betrokkenen zal het de patiëntenzorg ten goed komen.
De IDEAL aanbevelingen houden geen rekening met de extra kosten die nieuwe 
behandelingen met zich mee brengen. Een afweging van de bijkomende kosten en gevolgen 
tegen het potentiële effect van de behandeling wordt steeds belangrijker omdat het 
budget voor gezondheidszorg beperkt is en het huidige beleid door de gezondheids-
autoriteiten er naar neigt om alleen die procedures te vergoeden die kosteneffectief zijn.
 De aanbevolen strategie is om de (potentiële) toegevoegde waarde en de kosten-
effectiviteit van nieuwe behandelingen aan te tonen voorafgaand aan de invoering 
van deze nieuwe behandelingen in de gezondheidszorg, bij voorkeur al in een vroege 
ontwikkelingsfase. De uitkomsten van deze vroege health technology assessments kunnen 
sturing geven aan investeringen en ontwerpbeslissingen in de productontwikkeling en 
kunnen gebruikt worden bij de toewijzing van subsidies voor onderzoeksprogramma’s 
om zo de monetaire waarde te maximaliseren. Bovendien heeft het uitvoeren van health 
technology assessments de potentie om moeilijke situaties te voorkomen waarin er 
 gedesinvesteerd moet worden in reeds geïmplementeerde behandelmethoden.
 De budgetten in de gezondheidszorg staan onder druk. Dit roept op om efficiënt om 
te gaan met de beschikbare middelen. Beschikbare middelen moeten derhalve niet 
worden ingezet voor die behandelmethoden die geen toegevoegde waarde bieden. 
Door het terugdringen van niet effectieve behandelingen kunnen de kosten in de zorg 
gecontroleerd worden zonder dat daarbij de kwaliteit van de geleverde zorg in het geding 
komt. 
 Op basis van de huidige beschikbare gegevens die de effectiviteit van chirurgische 
behandeling voor degeneratieve meniscusscheuren in twijfel trekt, kan een desinvestering 
(geheel of gedeeltelijk) in deze procedure bijdragen aan het beheersen van de kosten 
voor gezondheidszorg, zonder dat de kwaliteit van de zorg aangetast wordt. Bovendien 
zouden de vrijgekomen middelen herverdeeld kunnen worden in de richting van wel 
kosteneffectieve interventies en zo de gezondheidswinst en de monetaire waarde 
maximaliseren. 
Concluderend, bij de behandeling van meniscusscheuren, moeten we streven naar de 
juiste, kwalitatieve en effectieve zorg (de juiste zorg op het juiste moment op de juiste 
manier) voor patiënten tegen betaalbare kosten.
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 Dr. van Tienen, beste Tony, hoewel je betrokkenheid binnen mijn promotietraject 
langzaam maar zeker naar de achtergrond is verschoven blijft je klinische input je van 
onmisbare waarde voor het onderzoek. Je loopt over van ideeën, en ik vind het 
 bewonderenswaardig om te zien hoe je jezelf inzet voor je eigen meniscus project. 
Naast vakinhoudelijke ondersteuning ben ik je minstens zo dankbaar voor al je adviezen 
met betrekking tot mijn eigen carrière ontwikkeling.
 Prof. Ir. Dr. Verdonschot, beste Nico, je enthousiasme, gedrevenheid, kennis, en je 
positieve instelling maken dat het ORL zich geen beter afdelingshoofd kan wensen. Ik wil 
je graag bedanken voor al je inspanningen die je voor mij gedaan hebt.
 All the colleagues of the ORL, I want to thank you all for the great atmosphere that 
made that I enjoyed working here so much.
 Dr. Govers en Drs. Tax, paranimfen, beste Tim en Casper, bedankt dat jullie mij bij 
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bij jij het wel. Jij zorgt voor evenwicht in mijn leven en steunt me in alles wat ik doe. Ik zie 
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2013-2016
2013-2016
2013-2016
2013-2015
0.50
0.10
0.30
1.00
c) (Inter)national Symposia & congresses
- RIMLS New Frontiers symposium 2013, 2014
- RIMLS PhD retreat *
-  NBTE symposium (Nederlandse Vereniging voor 
Biomaterialen en Tissue Engineering)
-  STW annual congress (Stichting Toegepaste 
Wetenschappen)
- Laboratory Animal Science 2.0 *
- NOV congress (Nederlandse Orthopedie Verenging)
- The meniscus congress (Porto, Portugal)
2013, 2014
2013
2013
2014, 2015
2015
2015
2015
2.00
0.75
0.50
0.50
0.50
0.50
0.75
d) Other
- RadboudUMC Career advice trajectory
- Journal club orthopaedic research lab
2015
2013-2015
1.75
2.00
TEACHING ACTIVITIES
e) Lecturing
- BSc / MSc course Clinical human movement sciences 2014-2016 0.30
f ) Other
- Supervisor Oriënterende onderzoeksstage (OMB2)
- Peer review scientific papers
2014
2013-2016
1.00
0.40
TOTAL 21.6
* indicates a poster presentation during the activity

